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Abstract 
Mitochondria house a variety of cellular functions, including catabolic and anabolic 
pathways, apoptosis and Ca2+ handling. These functions critically depend on nuclear-encoded 
proteins given that mitochondrial DNA only encodes for 13 proteins, which are incorporated 
into the respiratory chain. While mitochondria differ in morphology and functions among 
tissues in vivo, mitochondrial diversity among cell types is less well understood – especially in 
heterogeneous tissues such as the nervous system. 
Here, I present an in vivo tool for the characterization of cell type-specific mitochondria in 
mouse. Via the MitoTag mouse model, mitochondria from the cell type of interest are tagged 
in a Cre recombinase-dependent manner with GFP, which is localized to the outer 
mitochondrial membrane (GFP-OMM). This tagging allows for the immunocapture of 
organelles and their subsequent investigation through functional assays and omics-based 
screenings. 
We applied the MitoTag approach to the cerebellum and profiled the mitochondrial proteome 
of Purkinje cells, granule cells and astrocytes. Among these cell types, we found 196 proteins 
differentially enriched, of which 19 candidates were independently confirmed as cell type-
enriched mitochondrial ‘markers’. Further analysis revealed functional specializations that we 
corroborated in independent assays using immunocaptured mitochondria. Specifically, 
astrocytic mitochondria superiorly oxidized long-chain fatty acids, while neuronal 
mitochondria demonstrated enhanced Ca2+ uptake via the mitochondrial calcium uniporter in 
granule cells and enhanced contact sites with the endoplasmic reticulum via regulator of 
microtubule dynamics protein 3 in Purkinje cells. In studies across species, I confirmed that 
neural mitochondrial diversity is conserved in the nervous system of mammals, aves and 
amphibian. Hence, we used neuronal and astrocytic mitochondrial ‘markers’ to show 
mitochondrial pathology in mouse models and human cases of Alzheimer’s disease and 
amyotrophic lateral sclerosis. 
The MitoTag approach enables mitochondrial research in a defined cellular context in vivo. 
Future applications will reveal the cell type-specific fine-tuning of mitochondria in many 
contexts, such as development, aging and diseases, as well as their contribution to the 
selective vulnerability of certain cell types. 
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Chapter 1: Introduction 
In Tasic et al. (2016) the authors state: “The mammalian brain is likely the most complex 
animal organ, given the variety and scope of functions it controls, the diversity of cells it 
comprises, and the number of genes it expresses […]”. For example, Herculano-Houzel et al. 
(2006) quantified approximately 109 million cells including 71 million neurons in mouse brain. 
In the history of neuroscience, cells of the brain were first simply defined as neuronal and non-
neuronal ('Neuron doctrine' reviewed in Shepherd, 2015; 'Nervenkitt' reviewed in Somjen, 
1988). In contrast nowadays, scientists aim to define cells by their molecular, morphological 
and physiological properties (reviewed in Zeng and Sanes, 2017). These systematic efforts 
have let us to an approximate number of 100 cell types per brain area resulting in ∼1,000 cell 
types for the total brain (Hodge et al., 2019; Koch, 2019). 
Despite our acknowledgement of the cellular diversity in mammalian brain, our image of their 
mitochondria – the powerhouse of the cell – has remained uniform. In fact, the most 
acknowledged discrimination of neural mitochondria by neuroscientists is their dependency 
on oxidative phosphorylation to generate ATP. However, mitochondria are dynamic 
organelles and so are their proteome and functions that are adapting to the cellular 
physiology. Therefore, in principle, mitochondria should differ among neural cell types; 
however, a systematic approach to test this hypothesis is currently unavailable and motivated 
this thesis. 
1.1. Mitochondria – a short curriculum vitae 
The mitochondrion (from Greek ‘mitos’ for thread and ‘chondrion’ for granule or grain-like) is 
a double membrane-bound subcellular organelle (Figure 1a). It is present in most eukaryotic 
cells with the exception of red blood cells (Gronowicz et al., 1984). Mitochondria are 
composed of: (i) outer mitochondrial membrane, which is permeable for uncharged        
molecules ≤5 kDa (Benz, 1985); (ii) intermembrane space; (iii) inner mitochondrial membrane, 
which is impermeant and forms invagination into the matrix, termed cristae; and (iv) matrix 
(Figure 1b). In contrast to other organelles, mitochondria contain their own DNA (mtDNA; 
Nass and Nass, 1963), which is maternally inherited (Giles et al., 1980). In mammals, mtDNA 
encodes for 13 proteins, 2 ribosomal RNAs and 22 transfer RNAs, is organized as circular 
plasmid and lacks introns. The DNA is packed in higher-order structures, termed nucleoids, via 
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TFAM and other proteins (Bogenhagen et al., 2008). Mitochondria were first discovered by 
Albert von Kolliker in 1857 and later coined as ‘mitochondrion’ by Carl Benda in 1898. 
According to the endosymbiont theory of mitochondrial origin, the organelle derives from 
ancestral oxidative proteobacteria that were engulfed by a glycolytic host cell (Sagan, 1967; 
Martijn et al., 2018). Instead of their degradation, the organelles were retained in the cell and 
integrated creating an evolutionary benefit by oxygen scavenging. The integration entailed 
several adaptations from the incorporation of novel host proteins, like the ADP/ATP 
translocase, to the transfer of most of the proteobacterium’s genes to the nucleus (Thorsness 
and Fox, 1990), as well as the establishment of the protein import machinery (reviewed in 
Kurland and Andersson, 2000). Interestingly, the remaining protein-coding genes (n=13) 
cannot be transferred to the nucleus because such gene transfer would result in their 
mislocalization to the endoplasmic reticulum (von Heijne, 1986; Roger et al., 2017). 
Mitochondrial form and dynamics vary between cell types, cells of different physiological 
states and among mitochondria of a single cell. Mitochondrial morphology is frequently linked 
to mitochondrial function (Benard et al., 2007) and analyzed in disease models and pathology 
(reviewed in Eisner et al., 2018). Through cycles of organelle fission and fusion mediated by 
distinct proteins (Drp1, Mfn1, Mfn2, Opa1; reviewed in Wai and Langer, 2016), mitochondrial 
content is exchanged – especially mtDNA (reviewed in Tilokani et al., 2018). For example in 
Saccharomyces cerevisiae, mitochondrial networks differ in complexity and surface area 
dependent on fermentable or non-fermentable growth conditions (Visser et al., 1995; Egner 
et al., 2002). Additionally, mitochondria are actively transported throughout the cell via 
Figure 1│Structural organization of the mitochondrion. (a) Electron micrograph of an isolated 
mitochondrion from this study. Scale bar: 100 nm. (b) Schema from electron micrograph 
shown in (a) illustrating the different compartments of this organelle. From outside to inside: 
outer mitochondrial membrane (black line), mitochondrial intermembrane space (white), 
inner mitochondrial membrane (blue line) forming cristae into the matrix (gray). 
 
5 
 
cytoskeleton tracts and motor proteins (reviewed in Lin and Sheng, 2015). Adaptation of the 
mitochondrial network provides critical advantages for mitochondrial respiration and 
membrane potential, as well as organelle stress responses (Hoitzing et al., 2015; Zamponi et 
al., 2018). 
1.2. Mitochondrial function 
Mitochondria harbor a number of cellular functions, such as oxidative phosphorylation; 
assembly of iron-sulphur clusters (Lill et al., 2012); phospholipid, nucleotide, heme and amino 
acid synthesis; Ca2+ homeostasis and buffering; and apoptosis (Zamzami et al., 1996; Susin et 
al., 1999). From these, the most essential function to life is the assembly of iron-sulphur 
cluster, which is the only function preserved in mitosomes of microsporidia. Mitosomes are 
evolutionary reduced mitochondria-related structures with a simplified protein import 
machinery, no genome and no ATP production; however, they possess the machinery for iron-
sulphur clusters synthesis (reviewed in Santos et al., 2018). 
1.2.1.  Mitochondrial bioenergetics 
In mitochondria, metabolites of sugar, lipids and proteins are oxidized to CO2 and energy in 
the form of ATP. For this, substrates are metabolized to acetyl-coenzyme A (acetyl-CoA) or 
other intermediates, which enter the tricarboxylic acid cycle (TCA or Krebs cycle; Figure 2a; 
Krebs, 1970). Glucose is first converted to pyruvate, which is imported into mitochondria and 
converted mainly to acetyl-CoA via pyruvate dehydrogenase (PDH); but also to oxaloacetate 
via pyruvate carboxylase (PC; Utter and Keech, 1960) to replenish TCA cycle intermediates 
(termed anaplerosis; Owen et al., 2002). Fatty acids are metabolized to acetyl-CoA via beta-
oxidation and amino acids are converted by multiple, individual enzymes to either pyruvate, 
acetyl-CoA or other TCA cycle intermediates (section 23.5; Berg et al., 2002). The two-carbon 
acetyl group of acetyl-CoA is initially transferred to oxaloacetate creating citrate, the first 
intermediate of the TCA cycle. Citrate is then metabolized to oxaloacetate in seven enzymatic 
reactions that release two-carbon units as CO2 and transfer the free electrons to the reduction 
equivalents, nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2). Only one reaction – succinyl-CoA to succinate plus ATP via succinyl-CoA ligase – 
generates nucleoside triphosphate in the TCA cycle, termed substrate level phosphorylation 
(Johnson et al., 1998). Interestingly, dependent on the subunits of succinyl-CoA ligase, either 
ATP  (Sucla2)  or  GTP  (Suclg2)  are  generated.  While   ATP  is  transported  via  the  ADP/ATP 
6 
 
  
Figure 2│ Tricarboxylic acid cycle and electron transport chain. (a) Schema of TCA cycle depicting 
major entry routes for glucose, fatty acids and amino acids. TCA intermediates are indicated by 
their carbon chain length (blue) and enzymes (orange). NADH, FADH2, ATP and GTP are green. 
Depending on Sucl subunits, substrate phosphorylation can generate ATP or GTP. PDH, pyruvate 
dehydrogenase; PC, pyruvate carboxylase; CS, citrate synthase; Aco2, aconitase 2; Idh, isocitrate 
dehydrogenase; α-Kgdh, α-ketoglutarate dehydrogenase; Sucl, succinyl-CoA ligase; Sdh, succinate 
dehydrogenase; Fh, fumarase; Mdh, malate dehydrogenase. (b) Schema of ETC depicting complex 
I-IV and complex V. Electrons (orange) are provided by NADH or Sdh complex via FADH2, and travel 
via coenzyme Q (CoQ) and cytochrome c (CyC) in the inner mitochondrial membrane. Protons are 
pumped via complex I, III and IV into the intermembrane space (ΔpH) and thereby create the 
membrane potential over the inner mitochondrial membrane ΔΨm. At complex V, the proton 
gradient is used to generate ATP. 
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translocase complex (ANT1/2), no mitochondrial transporter for GTP exists. Therefore, the 
energy from GTP needs to be transferred to ATP or ADP (via nucleoside diphosphate kinase or 
adenylate kinases) or be used within mitochondria, e.g. by phosphoenolpyruvate 
carboxykinase (Pck2). The TCA cycle is regulated via substrate availability, ATP and NADH 
inhibition and allosteric inhibition of intermediates with three rate-limiting enzymes: citrate 
synthetase, isocitrate dehydrogenase and α-ketoglutarate dehydrogenase. Furthermore, Ca2+ 
stimulates the TCA cycle by activating isocitrate dehydrogenase, α-ketoglutarate 
dehydrogenase and pyruvate dehydrogenase phosphatase, which activates PDH (Wan et al., 
1989). 
NADH and FADH2 are transferring the free energy in form of electrons to the electron 
transport chain (ETC) that consists of five multisubunit protein complexes (Figure 2b). All are 
localized in the inner mitochondrial membrane and collectively use the free energy to pump 
protons from the matrix into the intermembrane space thereby creating an electrochemical 
gradient and the membrane potential ΔΨm. This potential is finally used in complex V to 
generate ATP by chemiosmosis.  
First, NADH diffuses to complex I and donates two electrons to the complex, which allows the 
translocation of four protons into the intermembrane space. The electrons are passed down 
to coenzyme Q (CoQ) that freely diffuses thought the inner mitochondrial membrane. In 
contrast, FADH2 is directly formed on complex II (succinate dehydrogenase) and donates its 
electrons to CoQ. Complex II does not translocate protons over the inner mitochondrial 
membrane. Next on complex III, CoQ is oxidized passing two protons to the intermembrane 
space and its electrons to cytochrome c. The reaction enables an additional two protons to 
cross the inner membrane. Finally, at complex IV, electrons are transferred from cytochrome 
c to the complex that pumps four protons across the membrane and generated two H2O from 
oxygen. 
At complex V, the F0F1ATPase, the chemiosmotic gradient is used to phosphorylate adenosine 
diphosphate to ATP (Mitchell, 1961). Paul D. Boyer and John E. Walker received the Novel 
Prize in Chemistry in 1997 (Walker, 1998) for discovering the rotation mechanism of 
F0F1ATPase. Not all translocated protons participate in the production of ATP. Protons can leak 
across the mitochondrial membranes, e.g. via mitochondrial uncouplers, and generate heat 
(Nedergaard et al., 1977; reviewed in Kadenbach, 2003). It is estimated that a molecule NADH 
and a molecule FADH generate three and two molecules ATP, respectively (Watt et al., 2010). 
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1.2.1.1. Beta-oxidation 
Mitochondria and peroxisomes metabolically cooperate in beta-oxidation of fatty acid (FA). 
While peroxisomes metabolize very long-chain (>C22) and branched-chain FA, mitochondria 
oxidize long, medium and short-chain FA (reviewed in Demarquoy and Le Borgne, 2015). In 
peroxisomes, FAs are shortened to acyl-CoA (C2, C3, C11), which is exported in the form of 
acylcarnitine and imported into mitochondria for full oxidation (Verhoeven et al., 1998; 
Ferdinandusse et al., 1999). 
Mitochondrial beta-oxidation can be split into two steps: FA import and FA degradation to 
acetyl-CoA (reviewed in Eaton, 2002). For mitochondrial FA import, long-chain FA are 
imported via the carnitine shuttle system (reviewed in Qu et al., 2016) composed of carnitine 
o-palmitoyltransferase 1, liver isoform (Cpt1a) in the outer mitochondrial membrane (van der 
Leij et al., 1999) and carnitine/acylcarnitine translocase (Slc25a20) in and Cpt2 associated to 
the inner mitochondrial membrane (Console et al., 2014). In brief, FAs are conjugated to 
carnitine via Cpt1a (Yates and Garland, 1970), transported over the inner mitochondrial 
membrane via Slc25a20 (Iacobazzi et al., 2004) and conjugated to CoA via Cpt2 (Bonnefont et 
al., 2004). In contrast, medium and short-chain FA (<C12) can freely enter mitochondria. For 
FA catabolism, FAs are activated by conjugation to CoA that is catalyzed by acyl-CoA 
synthetases (Acs; reviewed in Watkins, 2008). This family is composed of several members 
with substrate chain length specificity (Watkins et al., 2007). FA (<C12) are activated via Acsm 
and Acss in the mitochondrial matrix (Williamson et al., 1968). In contrast, long-chain fatty 
acids are conjugated to CoA via Acsl and Acsbg in the cytosol and imported via the carnitine 
shuttle system with CoA conjugation via Cpt2. The mitochondrial membrane is impermeable 
for acyl-CoA and therefore conjugates are trapped for degradation. 
For FA degradation, acyl-CoA is shortened to acetyl-CoA in repeated rounds of four reactions, 
namely oxidation-hydration-oxidation-thiolysis. These reactions are performed by chain-
specific acyl-CoA dehydrogenases (Acad) and the trifunctional protein (Uchida et al., 1992; 
and reviewed in Houten and Wanders, 2010). The products of mitochondrial beta-oxidation 
are acetyl-CoA, which enters the TCA cycle, FADH2 and NADH, which both transfer electrons 
to the ETC.  
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1.2.2. Anabolic role of mitochondria 
Mitochondria are also biosynthetic hubs and participate for example in the anabolism of 
amino acids, fatty acids, glucose, heme and nucleotides. Several intermediates of the TCA 
cycle are precursors for the biosynthesis of macromolecules apart from their catabolic role in 
the Krebs cycle. For example in the adaptive immune system, naïve T cells are quiescent, have 
a catabolic metabolism and relay on oxidative phosphorylation. Upon activation, T cells 
become proliferative, shift to an anabolic metabolism and rely on glycolysis and glutaminolysis 
despite oxygen availability (reviewed in van der Windt and Pearce, 2012). In both physiological 
states mitochondrial metabolism and the TCA cycle are active; however, ATP is generated 
differently. Later on as memory T cells, metabolism is switched back to catabolism with 
enhanced beta-oxidation and mitochondrial biogenesis. 
The biosynthesis of amino acids uses carbon backbones from intermediates of glycolysis, the 
pentose phosphate pathway and the TCA cycle. Specifically, the amino acids glutamate 
(Glud1), glutamine (Gs, Gls), proline (Oat, Pycr) and arginine (Ass) are derived from                          
α-ketoglutarate; aspartate (Got2) and asparagine (Asns) from oxaloacetate; and alanine 
(Gpt2) from pyruvate. All other amino acids derive from intermediates of glycolysis and the 
pentose phosphate pathway with the exception of essential amino acids (phenylalanine, 
valine, threonine, tryptophan, methionine, leucine, isoleucine, lysine and histidine). 
Gluconeogenesis is primarily a cytosolic process; still, its starting point originates in 
mitochondria, where oxaloacetate is converted to malate or aspartate for mitochondrial 
export. In the cytosol, phosphoenolpyruvate carboxykinase (Pck1) continuous by generating 
phosphoenolpyruvate that is converted to glucose-6P. This substrate can enter the pentose 
phosphate pathway or glycogenesis (mostly active in astrocytes; Vilchez et al., 2007). 
Alternatively, oxaloacetate can be converted by mitochondrial phosphoenolpyruvate 
carboxykinase (Pck2) to phosphoenolpyruvate and exported over the mitochondrial 
membrane (Drahota et al., 1983). Pck2 is GTP-dependent and uses GTP produced via substrate 
level phosphorylation in the TCA cycle (see Chapter 1.2.1). Interestingly, in the absence of 
glucose, Pck2 fuels the TCA cycle with phosphoenolpyruvate via glutamine utilization (Vincent 
et al., 2015).  
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Fatty acid synthesis is performed by two cellular systems: a cytosolic system providing 
triglycerides for phospholipids and a mitochondrial system (mtFAS) generating lipoic acid via 
octanoyl-ACP (Brody et al., 1997) and long-chain acyl carrier proteins (ACP). As such both 
systems have distinct roles – with mtFAS providing control over the TCA cycle and the 
respiratory chain dependent on acetyl-CoA availability (reviewed in Nowinski et al., 2018). 
Specifically, lipoic acid, which is generated from octanoyl-ACP, is an important cofactor for 
pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain dehydrogenase 
and the glycine cleavage system (Perham, 2000). However, apart from octanoyl-ACP, longer 
ACPs were found in mitochondria with unknown function. Recently, Van Vranken et al. (2018) 
demonstrated their interaction with the LYR protein family, which contains proteins important 
for respiratory chain assembly and iron-sulphur cluster biogenesis (Runswick et al., 1991; Van 
Vranken et al., 2016; reviewed in Angerer, 2015). LYR proteins are present in complex I-III and 
allosterically activated by acyl-ACP in a length-specific manner.  
The synthesis of heme (porphyrin synthesis) is unique in the sense that its biosynthesis is 
coordinated between cytosol and mitochondria, and requires compartmentalization. Heme is 
incorporated in many metalloproteins, like cytochromes and catalase (Smith et al., 2011). In 
the mitochondrial matrix, aminolevulinate is generated from succinyl-CoA and glycine via 
aminolevulinate synthetase and exported via Slc25a38. In the cytosol, aminolevulinate is 
modified to coproporphyrinogen III that is actively imported into the intermembrane space 
via Abcb6. Here, it is first converted to protophyrinogen via coproporphyrinogen oxidase and 
then imported into the matrix, where ferrochelatase inserts ferrous iron. H2O2 is generated 
during this synthesis; hence, the confinement to a membrane-bound organelle. 
1.2.3. Mitochondrial Ca2+ buffering 
Ca2+ is a tightly regulated signaling molecule in cells. Its cytosolic levels are low, while the 
endoplasmic reticulum functions as intracellular Ca2+ store. Mitochondria participate in 
cellular Ca2+ homeostasis by Ca2+ buffering at privileged contact sites with the endoplasmic 
reticulum and the plasma membrane (Szymanski et al., 2017). The outer mitochondrial 
membrane is permeant for Ca2+ and therefore, cytosolic and mitochondrial intermembrane 
space concentrations are at equilibrium (Rizzuto et al., 1998). Free Ca2+ is driven into 
mitochondria through the negative membrane potential ΔΨm and enters mainly via the 
mitochondrial calcium uniporter (Mcu); still, two additional Ca2+ currents have been measured 
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in mitoplasts (Bondarenko et al., 2013). In the mitochondrial matrix, Ca2+ has been shown to 
stimulate key enzymes of the TCA cycle and the F0F1ATPase, but can also be buffered via a 
system with inorganic phosphate (Rossi and Lehninger, 1964; Lehninger, 1974). Here, free Ca2+ 
forms a calcium-phosphate complex (Chalmers and Nicholls, 2003). In addition, Ca2+ can be 
extruded from mitochondria via the electroneutral H+/Ca2+ exchanger or the electrogenic 
Na+/Ca2+ antiporter (NCLX; reviewed in De Stefani et al., 2016). 
The ability of mitochondria to uptake Ca2+ was known for a long time (Deluca and Engstrom, 
1961); still, its underlying molecular identity was only reported in the last decade: first with 
the identification of the mitochondrial calcium uptake protein 1 (Micu1; Perocchi et al., 2010), 
followed by Mcu (Baughman et al., 2011; De Stefani et al., 2011) and later its other complex 
components. The Mcu complex is localized to the inner mitochondrial membrane and consists 
of the pore-forming proteins: Mcu, McuB (Raffaello et al., 2013) and essential MCU regulator 
(Emre; Sancak et al., 2013). While Mcu is the Ca2+ permeant pore and can be reconstituted 
alone into lipid bilayers (De Stefani et al., 2011), its function in cells requires co-expression of 
Emre (Kovacs-Bogdan et al., 2014). Mcu forms homodimers and heterodimers with McuB and 
their distribution is heterogeneous across tissue (Fieni et al., 2012). Raffaello et al. (2013) 
showed that Ca2+ flux through McuB is impaired. In fact, McuB acts as dominant-negative Mcu 
homolog and its presence is proposed as regulatory mechanism for mitochondrial Ca2+ 
regulation across tissues and during stress conditions (reviewed in De Stefani et al., 2016; 
Lambert et al., 2019). 
The Mcu complex further consists of Micu 1-3 that regulate the sigmoid opening of the 
channel and are localized to the intermembrane space. Both Micu1 and Micu2 (Plovanich et 
al., 2013) have gatekeeper function for Mcu with Micu1 controlling the Ca2+ threshold and 
opening of the channel at high Ca2+ concentrations (Mallilankaraman et al., 2012b; Csordas et 
al., 2013) and Micu2 controlling the channel closure at low Ca2+ concentrations (Patron et al., 
2014). Additionally, Tomar et al. (2019b) identified MIC60 and CHCHD2 as novel                          
Ca2+-independent interactors of Micu1 – thus, indicating Micu1 function in cristae 
organization. Micu3 is predominantly expressed in the central nervous system (Plovanich et 
al., 2013), where it interacts with Micu1 to regulate Mcu opening. In contrast to Micu2, Micu3 
increases Ca2+ uptake of the Mcu complex and is an activator of the channel (Patron et al., 
2019). 
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Finally, Mallilankaraman et al. (2012a) identified another interactor of the Mcu complex, 
McuR1. Its function in the complex is currently still controversial (reviewed in Paupe et al., 
2015; Raffaello et al., 2016). 
Regulation of the Mcu complex has been shown at multiple levels: (i) via expression levels of 
Mcu/McuB (Fieni et al., 2012); (ii) via expression levels of Micu1/Mcu (Paillard et al., 2017); 
and (iii) via posttranslational modification of Micu1 (Madreiter-Sokolowski et al., 2016; Marchi 
et al., 2019). Interestingly, mice on a mixed CD1-C57BL/6 background can compensate Mcu 
deletion (Pan et al., 2013), while Mcuko mice are embryonal lethal on a C57BL/6 inbreed strain 
(Murphy et al., 2014). The underlying cause is currently under investigation. Furthermore, 
deletion of Mcu is not detrimental in multiple cell types apart from their metabolic adaptation 
(Luongo et al., 2015; Nichols et al., 2018; Gherardi et al., 2019; Tomar et al., 2019a).                          
In contrast, Micu1 deletion in mouse leads to a high perinatal lethality and surviving animals 
develop severe neurological defects and myopathy (Liu et al., 2016; Antony et al., 2016).  
1.2.4. Contact sites – mitochondrial association with other organelles 
Mitochondria are not simply ‘rocks in the sea of cytoplasm’ – but are tightly interconnected 
with other organelles (Valm et al., 2017). Classically a contact site between organelles is the 
close apposition of their membranes. Such sites of interaction allow for the exchange of 
molecules for shared biochemical pathways and signaling. An increasing number of molecules 
that establish these contact sites have been identified between most organelles (Eisenberg-
Bord et al., 2016). These molecules can be categorized into tether and spacer (Fernandez-
Busnadiego et al., 2015) depending on the phenotype of their loss/enhancement. As defined 
in Scorrano et al. (2019), contact sites are mediated by a protein-protein or protein-lipid 
interaction, can range from 10 – 80 nm in distance (but also might span >300 nm; Klecker et 
al., 2013), should convey a function and can be static or dynamic (Raiborg et al., 2015).  
In the case of mitochondria, a number of organelle-specific tethers have been described.                   
For example, mitochondria form contact sites with: the endoplasmic reticulum via Mfn2 (de 
Brito and Scorrano, 2008) or VAPB-Rmdn3 (De Vos et al., 2012); lipid droplets via Plin5 (Wang 
et al., 2011a); the plasma membrane via Num1 (Ping et al., 2016); lysosomes via Rab7 (Wong 
et al., 2018); and with peroxisomes via Pex34 (Shai et al., 2018). 
Amongst them, the contact to the endoplasmic reticulum (ER) is best studied in the context 
of Ca2+ homeostasis (Rizzuto et al., 1998), phospholipid synthesis (Vance, 1990) and its role in 
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mitochondrial fission (Friedman et al., 2011).  
Peroxisomes and mitochondria share an intimate relationship via their functional interplay in 
beta-oxidation (reviewed in Wanders et al., 2016), reactive oxygen species handling (reviewed 
in Lismont et al., 2015) and anti-viral signaling (Dixit et al., 2010). While the molecular identity 
of their contact sites is less clear than with the ER, a frequent placing of peroxisomes at sites 
of ER-mitochondria contacts was reported by Cohen et al. (2014).  
1.3. Mitochondrial proteome 
The mitochondrial proteome is estimated to contain ∼1,200 – 1,500 proteins. Of these,                       
13 proteins are encoded by mtDNA in mammals, while >99% of mitochondrial proteins are 
transcript from genes in the nucleus. Consequently, mitochondria are shaped by the cellular 
translatome. Related to the endosymbiont origin of mitochondria, the engulfed 
proteobacteria had to adapt to their host cell on different levels and this process has shaped 
the current mitochondrial proteome by: (i) incorporation of host proteins; (ii) transfer of genes 
to the less mutagenesis-prone nucleus; (iii) loss of proteobacterial proteins or their relocation 
to other subcellular compartments; and (iv) adaption of an import machinery for novel and 
own proteins. Gabaldon and Huynen (2007) calculated that ∼15% of mitochondrial proteins 
have orthologs in α-proteobacteria with an additional 28% originating from other 
proteobacteria and the rest deriving from prokaryotes (∼16%) and eukaryotes (~40%; 
reviewed in Szklarczyk and Huynen, 2010).  
As >99% of proteins are encoded by nuclear DNA, an essential element of mitochondrial 
adaptation was the targeting of proteins to the organelle and their selective import. 
Currently, at least six mechanisms are known that target proteins for the import into 
mitochondria (reviewed in Chacinska et al., 2009). They can be divided into cleavable and non-
cleavable target sequences, and present as: (i) positively charged amphipathic α-helix;                          
(ii) β signal for β-barrel proteins; (iii) α-helical transmembrane segment for the outer 
mitochondrial membrane (via signal anchor, tail anchor or internal signal); (iv) multiple 
internal transmembrane signals; (v) an internal presequence-like signal; or (vi) as cysteine-
containing signal. Via these motives, proteins are directed to the mitochondrial matrix, inner 
and outer mitochondrial membrane or the intermembrane space. Signal recognition is 
mediated through several complexes that sort proteins, namely the translocase of the outer 
membrane   (TOM complex; van Wilpe et al., 1999; Abe et al., 2000)   with   the   sorting   and  
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Table 1. Experimental studies defining the mitochondrial proteome. 
Mitochondrial proteome 
Study Species Sample Isolation method Proteins 
Rabilloud et al. (1998) Hu Placenta CMF 46
Taylor et al. (2003) Hu Heart Sucrose density centrifugation 615
Mootha et al. (2003) Ms Heart, kidney, liver, brain Percoll density centrifugation 399 
Kislinger et al. (2006) Ms Heart, kidney, liver, brain, lung, placenta CMF 2,533 
Forner et al. (2006) Ms Heart, liver, muscle Sucrose density centrifugation, 689
Foster et al. (2006) Ms Liver Density gradient centrifugation, protein correlation profiling 297 
Adachi et al. (2007) Ms 3T3-L1 adipocytes Sucrose density centrifugation 1,130
Johnson et al. (2007) Rat Heart, kidney, liver, brain CMF 1,162 
Pagliarini et al. (2008) Ms 14 tissues CMF vs Percoll density centrifugation 1,098 
Lotz et al. (2014) 
Hu Heart 
CMF 419 Ms Heart, liver 
Dmel total 
Calvo et al. (2016) Hu Ms 
update from 
Pagliarini et al. 
(2008) 
CMF vs Percoll density 
centrifugation 1,158 
Itzhak et al. (2016) Hu 
HeLa endocervical 
adenocarcinoma 
cells 
Density gradient centrifugation 
with SILAC 658 
Morgenstern et al. 
(2017) Yeast total 
CMF vs Percoll density 
centrifugation, subcompartments 901 
 
Mitochondrial subcompartment proteome 
Study Species Sample Isolation method Proteins 
Rhee et al. (2013) Hu HEK 293T embryonic kidney cells APEX-labeling, matrix 495 
Hung et al. (2014) Hu HEK 293T embryonic kidney cells 
APEX-labeling, intermembrane 
space with SILAC 127 
Hung et al. (2017) Hu HEK 293T embryonic kidney cells 
APEX-labeling, outer mitochondrial 
membrane with SILAC 137 
 
Mitochondrial proteomes in the central nervous system 
Study Species Sample Isolation method Proteins 
Stauch et al. (2014) Ms Brain, synaptosomes 
Percoll gradient for synaptosomal 
and non-syn. mitochondria then IC 
Tom22; SILAC mix from cell culture 
1,629 
(2,260) 
Graham et al. (2017) Rat Sheep 
Forebrain, 
synaptosomes 
Fiscoll-sucrose density 
centrifugation for synaptosomal 
and non-syn. mitochondria 
1,511 
Stauch et al. (2019) Ms Forebrain, midbrain, synaptosomes 
Percoll gradient for synaptosomal 
mitochondria then IC Tom22; SILAC 
mix from cell culture 
750 
(1,293) 
Hu, human; Ms, mouse; Dmel, Drosophila melanogaster; CMF, crude mitochondrial fraction. X (Y), 
mitochondrial annotated proteins (total proteins). 
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assembly machinery (SAM) for the outer mitochondrial membrane, the mitochondrial import 
1 (Mim1) also for the outer mitochondrial membrane, the mitochondrial intermembrane 
space assembly (MIA), the presequence translocase of the inner membrane (TIM23 complex; 
Yamamoto et al., 2002) with presequence translocase-associated motor (PAM) for the matrix 
and insertase/export machinery of the inner membrane (OXA) for the inner mitochondrial 
membrane, and the carrier translocase of the inner membrane (TIM22 complex) for carrier 
proteins of the inner mitochondrial membrane. In the mitochondrial matrix, target sequences 
are cleaved off via the mitochondrial processing peptidase and proteins can be further 
modified via other peptidases in matrix and intermembrane space (Vogtle et al., 2009; 
reviewed in Schmidt et al., 2010). 
Targeting sequences have been used by Calvo et al. (2017) and others to define the 
mitochondrial proteome using experimental data, genomic sequencing data and 
bioinformatics tools (reviewed in Gaston et al., 2009). Still, targeting sequences alone are not 
powerful in detecting the mitochondrial proteome as a whole due to our limitation in 
sequence knowledge and a high false-positive rate from prediction studies (reviewed in Calvo 
and Mootha, 2010). In addition, proteomics of purified mitochondrial fractions via tandem 
mass spectrometry has been successful in identifying the core mitochondrial proteome                
(see Table 1).  
The most conclusive study today – the MitoCarta – combined the experimental evidence of 
mitochondrial proteins across 14 mouse tissues by mass spectrometry with six other data 
sources, including yeast homology, Pfam domains and N-terminal targeting signals, and 
integrated them via Bayesian integration (Figure 3a; Pagliarini et al., 2008; Calvo et al., 2016). 
The initial mass spectrometry discovery phase included Percoll gradient isolated mitochondria 
from cerebrum, cerebellum, brainstem, spinal cord, kidney, liver, heart, skeletal muscle, white 
adipose tissue stomach, small intestine, large intestine, testis, and placenta, and identified 
3,881 proteins by LS-MS/MS. In a second phase, crude mitochondria and Percoll gradient 
isolated mitochondria from ten tissues were analyzed and 2,565 proteins were identified with 
1,022 and 709 enriched in the crude and pure fractions, respectively. Based on subtractive 
proteomics and protein abundance, the authors calculated a likelihood ratio for each protein 
taking into account several other data sources via a Maestro naïve Bayes framework 
integration (Calvo et al., 2006). This predicted 951 proteins under a corrected false discovery 
rate of 10%. Further complementation by microscopy and literature search defined a total of 
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1,098 proteins in mouse and 1,013 in human as mitochondrial. In 2016, the study was updated 
to MitoCarta 2.0 – now containing 1,158 proteins in mouse and human. Interestingly, the 
authors noticed several features of mitochondria across tissues: (i) mitochondrial abundance 
can vary up to 30 times between tissues (Figure 3b); (ii) ∼one-third of proteins represent a 
common core across tissue proteomes; and (iii) pairs of tissues share 63 – 88% of their 
mitochondrial proteome (Figure 3c). 
The MitoCarta is currently the ‘gold standard’ for defining mitochondrial proteins; still, ∼30% 
of its entries are orphan proteins without functional annotation. Here, advances are made by 
Figure 3│ MitoCarta catalog of 1,098 mitochondrial genes. (a) Building a compendium of 
mitochondrial proteins by an integrated analysis of seven genome-scale data sets (gray circle), 
a large-scale GFP tagging and microscopy study (green circle), and prior experimental support 
from focused studies (red circle). Reprinted from Pagliarini et al. (2008), Figure 1 and figure 
legend. (b-c) Mitochondrial proteins expression across 14 mouse tissues. (b) Mitochondrial 
quantity per tissue, assessed by ELISA measurements of cytochrome c from whole-tissue 
lysates. Error bars represent the range of duplicate measurements. (c) Correlation matrix of 
MitoCarta proteins detected by MS/MS in each tissue, clustered hierarchically. Counts on the 
diagonal indicate number of MitoCarta proteins identified by MS/MS. Reprinted from 
Pagliarini et al. (2008), Figure 4c and 4d, and figure legend. Reprinted from Cell, 134/1, 
Pagliarini et al. (2008), with permission from Elsevier. DOI: 10.1016/j.cell.2008.06.016. 
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the collection of big data sets, their integration via bioinformatics and the deciphering of                  
co-regulated proteins. For example, Stefely et al. (2016a) used multi-omic profiling of 
proteome, lipidome and metabolome in mitochondrial deletion strains in Saccharomyces 
cerevisiae and hereby identified novel members of the CoQ pathway. Recently, Kustatscher et 
al. (2019) generated a co-regulation map of the entire human proteome and thereby, 
identified co-regulation of Pex11β with subunits of the mitochondrial ETC. They further 
showed that Pex11β established contact sites between peroxisomes and mitochondria, likely 
for the exchange of metabolites. Related to the nervous system, Sharma et al. (2015) 
generated a high-resolution proteome of 10 defined brain tissue areas, four FACSorted cell 
types and five primary cell types in culture and identified 12,934 proteins of the ∼20,000 genes 
in mammals. Interestingly, 144 MitoCarta proteins were not identified by this study implying 
their absence in the nervous system or molecular restrictions that prevent their identification 
by mass spectrometry. 
In addition, several databases have been created (Smith and Robinson, 2016; Godin and 
Eichler, 2017; Yim et al., 2020) that collected experimental data from a variety of experiments 
and assays and integrated them for further processing by users. 
Overall, our understanding of the molecular composition of mitochondria has been 
broadened by the identification of estimated >85% of its proteins. Still, as mitochondria are 
made by the translatome of their host cells, not every mitochondrion will be the same, but 
rather is adapted by the cell depending on tissue, cell type and physiological state. As 
proteomes cannot easily be inferred from transcriptomes (Ghazalpour et al., 2011) and the 
profiling from nuclear mRNA does not necessarily reflect local translation – especially in 
complex cells such as neurons, we are still far from understanding the mitochondrial 
proteome in its heterogeneity and complexity in different cells. 
1.4. Mitochondrial diversity 
Through proteomics studies like the MitoCarta (Pagliarini et al., 2008) and many others                 
(see Table 1), it is widely accepted that mitochondrial populations from different tissues 
contain subsets of differential proteins (12-33% of proteins; Figure 3c) and hence are 
specialized in certain mitochondrial functions. In addition, mitochondrial ultrastructure varies 
among tissues linking form to function (reviewed in Zick et al., 2009; Vafai and Mootha, 2012). 
Interestingly, given that all mtDNA-encoded proteins are essential for the respiratory chain, 
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only nuclear-encoded proteins contribute to this heterogeneity. Still, mitochondrial diversity 
is particularly discussed on the level of inter- and intracellular mtDNA heteroplasmy (reviewed 
in Aryaman et al., 2018) – likely due to its context in mitochondrial diseases (see Chapter 1.7). 
While cells contain up to several thousand copies of mtDNA (D'Erchia et al., 2015), mtDNA is 
more prone to mutations than nuclear DNA – particularly for age-related deletions and 
replication errors (Kennedy et al., 2013). Dependent on time of occurrence, mutations might 
propagate along the lineage of a cell type and influence a whole organ system; or accumulate 
over time through the mtDNA life cycle of degradation and biogenesis in even non-
proliferative cells, e.g. neurons (Aryaman et al., 2018; and references herein). However, only 
mutations that cross a certain threshold, result in a phenotype (reviewed in Rossignol et al., 
2003). This threshold is tissue- and cell type-dependent and partially causative for the 
heterogeneity of symptoms in humans with mtDNA mutations and deletions (reviewed in 
Moggio et al., 2014). Morris et al. (2017) analyzed three high-confidence single-nucleotide 
variances in individual mitochondria from neurons and astrocytes and confirmed their 
heteroplasmy across single cells and individuals in mice and humans.  
In contrast to mitochondrial proteome heterogeneity among tissues, the distribution of this 
diversity among its resident cell types is less well known. Similarly, we are limited in our 
knowledge of organelle variation within cells. One reason for this is the limitation to probe for 
such origin-specific organelles in vivo.  
For example, in skeletal muscle fibers, mitochondria are present as distinct intracellular 
populations dependent on localization, namely subsarcolemmal and intermyofibrillar 
mitochondria (reviewed in Hollander et al., 2014). These mitochondrial populations differ in 
ultrastructure and function – particularly respiration and Ca2+ handling (Palmer et al., 1977; 
McMillin-Wood et al., 1980; Shimada et al., 1984; Cogswell et al., 1993). Murgia et al. (2015) 
performed mass spectrometry on single muscle fibers and identified distinct fiber 
specialization in TCA cycle, beta-oxidation and redox metabolism – for example in isocitrate 
dehydrogenase 2 and 3 expression. Further analysis strengthened their conclusion of a                      
fiber-tuned TCA cycle (reviewed in Schiaffino et al., 2015). 
This situation is more complex in neurons, which in some cases can have an axon length of 
∼0.46 m in mouse and ∼100 m in humans (Matsuda et al., 2009; Wu et al., 2014), and face an 
extraordinary challenge in maintaining organelles throughout their entire geometry. While in 
other cells mitochondrial content can be easily exchanged via mitochondrial dynamics and 
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biogenesis, these processes are spatially limited in neurons due to an increasing distance to 
the nucleus and a limited local organelle pool. Specifically, the interplay of selective and 
directional transport, local translation, organelle dynamics and protein degradation as well as 
bulk biogenesis and autophagy form the neuronal “[…] mitostasis […]” (Misgeld and Schwarz, 
2017). Hence, mitochondria differ between dendrites, soma, axon and synapse. For example, 
Lewis et al. (2018) quantified mitochondria in cortical pyramidal neurons of layer 2/3 in vivo 
and observed a length gradient of 1.3 – 13.3 μm in dendrites and 0.5 – 1.1 μm in axons. 
Independent confirmation of these size differences comes from ultrastructure analysis across 
brain regions (Delgado et al., 2019). Furthermore, scientists have particularly focused on 
mitochondria at the synapse. These mitochondrial populations can be enriched via gradient 
density centrifugation (Lai et al., 1977) and are traditionally compared to non-synaptic 
mitochondria. Early studies by Dennis et al. (1977) demonstrated respiratory differences 
between these organelle populations. Further, McKenna et al. (2000) showed enrichment of 
glutamate metabolism at the synapse and recent proteomics studies identified molecular 
differences (Stauch et al., 2014; Graham et al., 2017). Consensus of these studies is that 
oxidative phosphorylation, mitochondrial dynamics and Ca2+ handling are major contributors 
to mitochondrial specialization at the synapse. 
Still, these studies have to face two major criticisms: (i) the contamination of glial 
mitochondria; and (ii) the multisubtype-specific origin of synaptic mitochondria. 
Synaptosomes, which are the starting material for synaptic mitochondria, usually contain 
material from pre-, postsynapse, and glial processes. While glial processes might be removed 
or pre- and postsynapse separated via sophisticated protocols, the presence of glial 
mitochondria within the non-synaptic fraction cannot be denied. Hence, the comparison of 
synaptic vs non-synaptic mitochondria is to a large degree a comparison of neuronal to brain 
mitochondria including all non-neuronal cell types. Secondly, even within the synaptic 
fraction, mitochondria originate from different neuronal subtypes, e.g. excitatory and 
inhibitory neurons (reviewed in Wang and Savas, 2018 with focus on the synapse in general). 
This mixing of mitochondrial origin either in the non-synaptic or synaptic fraction is masking 
the true mitochondrial heterogeneity among neural cell types and their specialization at 
synapses. Thus, novel purification approaches are needed for a cell type-resolved 
interpretation of synaptic mitochondria. 
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Nevertheless, a number of studies have uncovered profound functional specializations of 
neural mitochondria – even within neuronal compartments (see the following Chapters). 
1.4.1. Mitochondrial proteins enriched in neural cell types 
Mitochondrial calcium uptake protein 3 (Micu3) is a paralog to Micu1 and Micu2 and 
microarray data from 21 mouse tissues showed its strong enrichment in the nervous system 
(Plovanich et al., 2013). This was independently confirmed in fly and humans (Tufi et al., 2019; 
Patron et al., 2019). Micu2 and Micu3 are interacting with Micu1 and recently, Xing et al. 
(2019) reported their similarity in structure based on their Ca2+-bound and unbound crystal 
structure. In contrast, Patron et al. (2019) reported that Micu1-Micu3 interaction leads to an 
increased Ca2+ uptake of Mcu and therefore proposed Micu3 as Mcu activator. Thus, Micu2 
and Micu3 seem to have opposing roles in the Mcu complex, while their structural mechanism 
is similar. In agreement with this report, Ashrafi et al. (2020) demonstrated that neuronal 
mitochondria uptake stimulus-evoked Ca2+ in an ER-independent manner in axons and that 
this is possible due to the lower Ca2+ threshold of Micu3-containing Mcu complex.  
Adck3 (Coq8a) and Adck4 (Coq8b) are orthologues of the yeast Coq8 gene. Both have been 
shown to be part of the coenzyme Q10 complex and to stabilize it (Floyd et al., 2016). Their 
function is non-redundant given that Stefely et al. (2016b) demonstrated that Adck3 has 
ATPase activity, while its protein kinase activity is structurally blocked (Stefely et al., 2015).               
In contrast, Adck4 functions as protein kinase (Stefely and Pagliarini, 2017). Strikingly, 
deficiency in Adck3 clinically presents as ataxia and cerebellar atrophy (Lagier-Tourenne et al., 
2008), while Adck4 deficiency leads to nephrotic syndrome (Ashraf et al., 2013). In an Adck3 
deficient mouse model, Stefely et al. (2016b) observed dark and shrunken Purkinje cells with 
∼10% neuronal degeneration and altered peacemaking activity implicating a cell type-specific 
vulnerability in Adck3. 
4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 
(Nipsnap1) is localized to the mitochondrial matrix and Nautiyal et al. (2010) reported its 
exclusive expression in neurons in the nervous system. Functionally, Nipsnap1 was shown to 
interact with components of the branched-chain α-keto acid dehydrogenase enzyme complex 
(Nautiyal et al., 2010) and the amyloid precursor protein (APP) in mitochondria via the                       
C-terminal region of APP (Tummala et al., 2010). Recently, two reports provided evidence for 
Nipsnap1 accumulation on the outer mitochondrial membrane of damaged mitochondria, 
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where it served as an autophagy recruitment signal (Abudu et al., 2019; Princely Abudu et al., 
2019). Interestingly, while Nipsnap1 is also expressed in non-neuronal tissues, like kidney and 
liver, its deletion in zebrafish leads to Parkinsonism and neuronal loss                          
(Princely Abudu et al., 2019). 
Pyruvate can enter the TCA cycle via the pyruvate dehydrogenase complex (PDH) or via 
pyruvate carboxylase (PC), which are both differentially regulated in neuronal and                         
non-neuronal cells.  PDH contains three units, E1, E2 and E3, and complex activity is modulated 
by protein expression levels, phosphorylation by pyruvate dehydrogenase kinases (Pdk1 - 4) 
and dephosphorylation by pyruvate dehydrogenase phosphatases (Pdp1/2), as well as 
acetylation and succinylation (reviewed in Patel and Korotchkina, 2001). Halim et al. (2010) 
showed that all PDH components are expressed in neurons and astrocytes; however, in 
astrocytes PDH is inactivated via phosphorylation through PDK2 and PDK4. Itoh et al. (2003) 
reported that inhibition of PDK4 by dichloroacetate increased pyruvate respiration in 
astrocytes at the cost of lactate production. 
In contrast, PC levels are regulated on the protein level with high expression in astrocytes and 
neglectable levels in neurons (Yu et al., 1983; Shank et al., 1985; Waagepetersen et al., 2001). 
PC converts pyruvate to oxaloacetate to replenish this TCA intermediate. This process is 
termed anaplerosis and in total mediated by four carboxylating enzymes, namely PC, 
phosphoenolpyruvate carboxykinase (Pck2), malic enzymes (Me2, Me3) and propionyl-CoA 
carboxylase (PCC; Hassel, 2000), which can provide oxaloacetate from pyruvate, 
phosphoenolpyruvate from oxaloacetate, pyruvate from malate or methyl-malonyl-CoA from 
propionyl-CoA. 
Carnitine o-palmitoyltransferase 1, liver isoform (Cpt1a) is part of the carnitine shuttle system 
that imports long-chain fatty acids (FA) into mitochondria for their oxidation. While the 
catabolism of FA is debated in the nervous system (reviewed in Schonfeld and Reiser, 2013; 
and answered in Panov et al., 2014), Knobloch et al. (2017) showed that neural 
stem/progenitor cells depend on FA metabolism and remodel its use during proliferation and 
differentiation in the developing and adult brain. Specifically, neural progenitor cells rely on 
FA oxidation during their quiescent state, while their proliferation is dependent on de novo 
lipogenesis and FA oxidation blocked by malonyl-CoA (Knobloch et al., 2013). Repression of 
Cpt1a reduces the pool of neural stem cells by enhancing symmetric differentiating divisions 
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(Xie et al., 2016). Finally, Cpt1a expression is reduced during neurogenesis and FA oxidation 
repressed in differentiated neurons. 
Lopez-Fabuel et al. (2016) observed in neurons and astrocytes in culture that complex I of the 
respiratory chain is preferentially assembled into supercomplexes in neurons. In contrast, 
more free complex I was found in astrocytes correlating with a lower oxygen consumption 
ratio and higher reactive oxygen species (ROS) production (Maranzana et al., 2013; 
Hernansanz-Agustin et al., 2017). The functional purpose of supercomplex assembly of the 
respiratory chain is currently still debated (Blaza et al., 2014), while cristae shape regulates 
supercomplex assembly (Cogliati et al., 2013). However, through analysis of complex I 
subunits in free or supercomplex formation, Lopez-Fabuel et al. (2016) found that the subunit 
Ndufs1 is enriched in neurons – especially in supercomplexes. They further corroborated that 
Ndufs1 stimulates supercomplex assembly of complex I by neuronal knockdown and astrocytic 
overexpression. Hence, the authors concluded that metabolic differences between neurons 
and astrocytes arise in part from structural difference of complex I assembly. 
1.4.2. Mitochondrial proteins enriched in neuronal cell compartments 
Syntaphilin (Snph) was first described as SNAP25 competitor for the interaction with                  
syntaxin-1, and Snph/syntaxin-1 interaction blocks SNARE complex formation (Lao et al., 
2000). In a later study, Kang et al. (2008) demonstrated that Snph localizes to the outer 
mitochondrial membrane via its C-terminal transmembrane domain. In neuronal cultures, 
Snph was enriched in axons and sparse in MAP2-positive dendrites. Specifically, Kang et al. 
(2008) identified an axon-sorting domain in residues 381-469 of Snph and deletion of this 
region abolished axon targeting and distributed Snph equally throughout the cell. 
Functionally, Snph contains a microtubule-binding domain (AA 130-203) and via this domain 
arrests mitochondrial transport. While Snph function seems most relevant in neurons, it is 
also expressed in non-neuronal tissues (Snph via HPA049393 in the Human Protein Atlas; 
Uhlen et al., 2015). 
Mitochondrial fission factor (Mff) is an outer mitochondrial membrane protein that recruits 
– like Fis1 (James et al., 2003; Yoon et al., 2003) - mitochondrial dynamin protein 1 (Drp1) to 
mitochondria and enables mitochondrial fission (Gandre-Babbe and van der Bliek, 2008; Loson 
et al., 2013; Liu and Chan, 2015). Mff and Fis1 are dually localized to mitochondria and 
peroxisomes (Koch and Brocard, 2012). In neurons, Mff is present in dendrites, soma and 
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axon; however, Mff selectively regulates mitochondrial size in axons and prior to axon entry, 
while it does not affect dendritic mitochondria (Lewis et al., 2018). In this study, knockdown 
of Mff increased the length of axon-entering mitochondria by fourfold, while mitochondrial 
flux was reduced by half. In the axon, increased mitochondrial size resulted in enhanced 
mitochondrial Ca2+ uptake without altering axonal transport, membrane potential or ATP 
levels. Still, altered mitochondrial morphology decreased neurotransmitter release and 
resulted in reduced axon branching in cortical pyramidal neurons in vivo. The authors 
hypothesized that compartment-specific regulation of Mff and/or Drp1 underlie the dominant 
axonal effect of Mff function. 
1.5. Tools: Affinity purification of subcellular organelles 
Traditionally, subcellular organelles, like the nucleus, mitochondria or synaptosomes, are 
isolated via centrifugation (reviewed in Satori et al., 2012). Here, separation is achieved via 
differential centrifugation, i.e. sequential centrifugation at different speeds, and density 
gradient centrifugation in different media. While these methods sufficiently enrich organelles 
from cells, current application methods often require purer or faster isolation approaches. 
Some of which are: fluorescence-activated organelle sorting (Luquet et al., 2017), laser 
capture microdissection (Pflugradt et al., 2011) and affinity purification. In particular, affinity 
purification has been applied to enrich peroxisomes (Luers et al., 1998), plasma membrane 
(Lawson et al., 2006), synaptic vesicles (Burre et al., 2007; Morciano et al., 2005), mitochondria 
(Hornig-Do et al., 2009) and lysosomes (Nylandsted et al., 2011) by using endogenous proteins 
as organelle ‘handles’. 
Recently, this approach has been refined by modifying organelle-specific proteins with 
epitope ‘handles’ in cells in culture and transgenic organisms. Importantly, the epitope is 
accessible from the outside of the intact structure, i.e. present on the surface of organelles. 
Truernit and Hibberd (2007) described the isolation of cell type-specific chloroplasts via the 
expression of YFP-labeled chloroplast envelop protein 14. Transgene expression in distinct cell 
types was achieved via enhancer trap lines of Arabidopsis using the Gal4-UAS system and 
organelles purified via magnetic beads with anti-GFP antibody. Chloroplasts were further 
analyzed for their mRNA content depending on cell type. 
Heiman et al. (2008) developed a rapid, affinity purification method to isolate translating 
mRNAs from defined cell types in vivo. This method – termed translating ribosome affinity 
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purification (TRAP) – allowed the cell type-specific expression of the EGFP-tagged 60S 
ribosomal subunit L10a. EGFP-RPL10a incorporates into polysomes and provides an isolation 
‘handle’ on translating ribosomes and their bound mRNA via immunoprecipitation against 
GFP. In vivo profiles were first derived from 24 distinct cell types via 16 transgenic bacTRAP 
mouse lines (Doyle et al., 2008).  Later, Sanz et al. (2009) reported a different mouse                     
model – termed RiboTag mouse. Here, the endogenous Rpl22 gene was targeted, of which 
exon 4 is in-frame tagged with double HA in a Cre recombinase-dependent manner. These 
mice then express endogenous levels of HA-Rpl22 protein after Cre recombination. Similar to 
TRAP, the tagged protein is incorporated in polysomes and enables the isolation of actively 
translated mRNA via immunoprecipitation against HA. 
Chen et al. (2016) reported the rapid isolation of mitochondria – termed HA-MITO IP – from 
cells in culture. Here, the C-terminus of OMP25 is triple HA tagged (3xHA-EGFP-OMP25) and 
introduced into cells. Affinity purification of mitochondria is performed by using magnetic 
beads with anti-HA antibody in as little as 12 minutes and organelle content used for 
metabolomics. 
Abu-Remaileh et al. (2017) presented a rapid isolation method for lysosomes – termed                  
LysoIP – from cells in culture. Here, the authors overexpressed the transmembrane protein 
192 tagged with triple HA. Lysosomes were affinity purified by using magnetic beads with anti-
HA antibody in as little as 10 minutes and profiled for their metabolome. 
Roh et al. (2017) introduced the NuTRAP mouse to isolated cell type-specific nuclei and mRNA 
in vivo. Here, Rosa26 knock-in mice were created with a cassette containing a floxed ‘stop’ 
sequence, a biotin ligase, a dual tagged RanGAP1 protein with biotin ligase recognition peptide 
and mCherry, and EGFP-RPL10a. The transgenes are expressed in a Cre recombinase 
dependent manner and allow the tagging of the nuclear envelop via tagged RanGAP1 protein 
together with the tagging of polysomes via EGFP-RPL10a. The authors chose two tags on the 
RanGAP1 protein to enable isolation by biotin immunocapture and by mCherry fluorescence-
activated sorting. NuTRAP allows for the correlated analysis of transcriptome and epigenome 
in defined cell types. 
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1.6. Cerebellum 
The cerebellum coordinates the planning and execution of motor behavior                           
(Ito and Itō, 1984), but also non-motor functions, such as cognition and emotions via 
polysynaptic circuits between the cerebellum – thalamus – cerebral cortex (Buckner, 2013; 
Sathyanesan et al., 2019). Furthermore, Carta et al. (2019) recently demonstrated cerebellar 
involvement in reward learning and social behavior via cerebello-ventral tegmental area 
projections. 
Structurally, the cerebellum is organized as two hemispheres with the central vermis; each 
hemisphere can be divided into 10 lobules (Figure 4a) and all connection from and to other 
parts of the brain travel through the pons. Cells of the cerebellar cortex are present in three 
layers (Figure 4b): the molecular layer (ML) containing Bergmann glia, basket and stellate cells 
as well as Purkinje cell dendrites and granule cell axons; the Purkinje cell layer (PCL) containing 
Purkinje cell perikarya and candelabrum cells (Laine and Axelrad, 1994); and the granule cell 
layer (GCL) containing granule cells, unipolar brush, Golgi and Lugaro cells, Purkinje cell axons 
and other glial cells. The Purkinje cell axon run in fiber tracts to the four cerebellar nuclei: 
dentate, emboliform, globose and fastigii.  
Figure 4│ Organization of mouse 
cerebellum. (a) Schemata of sagittal 
mouse brain and detail of 
cerebellum with its 10 lobules I – X. 
Fiber tract, black; granule cell layer, 
gray; molecular layer, white. (b) 
Schema depicting the cellular 
architecture of the cerebellum: 
molecular layer (ML, white), 
Purkinje cell layer (PCL, dark gray), 
granule cell layer (GCL, light gray) 
and fiber tract. Shown cell types in 
ML are: A, astrocytes (blue); S, 
stellate cell; B, basket cell. Shown 
cell types in PCL are: P, Purkinje cell 
(magenta); C, candelabrum cell. 
Shown cell types in GCL are: G: 
granule cell (orange); g, Golgi cell; A, 
astrocyte (blue); L, Lugaro cell; u, 
unipolar brush cell. Due to 
complexity, not all cell types are 
depicted. 
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While the cellular architecture of the cerebellum is uniform, additional parasagittal zones 
contribute to its complexity. These zones are based on multiple molecular markers in Purkinje 
cells, namely zebrin II (Hawkes and Leclerc, 1987), EAAT4 (Dehnes et al., 1998), mGluR1β 
(Mateos et al., 2001), PLCβ3/4 (Sarna et al., 2006) and D3 dopamine receptor, dopamine 
transporter and synaptic vesicular monoamine transporter (Kim et al., 2009). This molecular 
diversity further correlated with functional heterogeneity across Purkinje cell populations 
obtained by electrophysiology (reviewed in Gill and Sillitoe, 2019). 
1.7. Mitochondrial dysfunction in human diseases 
Mitochondrial disorders represent a class of genetic diseases that are primarily defined by 
oxidative phosphorylation defects. Mutated genes are encoded either by nuclear DNA or 
mtDNA (15-20% of patients). In the case of mtDNA, it is important to consider that mutations 
can occur as homoplasmy or heteroplasmy and that the age of onset, severity of symptoms 
and involved organ systems depend on mutation load. Amongst nuclear encoded 
mitochondrial proteins, mitochondrial DNA polymerase γ (POLG) mutations are most common 
among mitochondrial diseases. POLG mutations can cause a spectrum of disorders like 
childhood myocerebrohepatopathy spectrum disorders (MCHS), Alpers-Huttenlocher 
syndrome, myoclonic epilepsy myopathy sensory ataxia (MEMSA), ataxia neuropathy 
spectrum (ANS) or progressive external ophthalmoplegia (PEO) with or without sensory ataxic 
neuropathy and dysarthria (SANDO). Affected organ systems are in the majority the 
musculoskeletal, gastrointestinal and central/peripheral nervous systems (Saneto and 
Naviaux, 2010). For example, patients frequently present with cerebellar ataxia with reports 
of Purkinje cell vulnerability, synaptic disorganization and loss (Lax et al., 2012b), profound 
neuronal loss of complex I (Hakonen et al., 2008), microinfarcts in cerebellar cortex (Tzoulis et 
al., 2010) and myelinopathy (Lax et al., 2012a). Mitochondrial disease may also cause severe 
cerebellar atrophy (Scaglia et al., 2005; Inbar-Feigenberg et al., 2018; Finsterer and Zarrouk-
Mahjoub, 2018). Additionally, POLG mutation have been described for recessive Charcot-
Marie Tooth disease (Harrower et al., 2008) and idiopathic Parkinson’s disease (Hsieh et al., 
2019). In fact, mitochondrial disorders frequently present as neuropathy and 
neurodegeneration (reviewed in Lax et al., 2017), which gives reason to the hypothesis that 
the nervous system is more susceptible to mitochondrial dysfunction than other organ 
systems. 
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Vis versa mitochondrial dysfunction is implicated in many neurodegenerative diseases, such 
as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Specifically, 
mitochondrial alterations in ATP production, oxidative stress, Ca2+ homeostasis, mitophagy 
and axonal transport have been reported (reviewed in Cabral-Costa and Kowaltowski, 2020). 
Alzheimer’s disease (AD; Alzheimer, 1907) is a form of dementia with the hallmarks of 
intraneuronal neurofibrillary tangles generated by hyperphosphorylated tau and 
extraneuronal plaques made of amyloid-β (Aβ), the cleavage product of amyloid precursor 
protein (APP; reviewed in Polanco et al., 2018; Hardy and Allsop, 1991; Hardy and Higgins, 
1992). A number of dysfunction have been ascribed to AD pathology, such as synaptic failure, 
oxidative stress, axonal injury, microglia and mitochondria dysfunction (reviewed in 
Swerdlow, 2018; and Cenini and Voos, 2019). Hirai et al. (2001) and Baloyannis (2006) have 
reported ultrastructural alteration in mitochondria from AD patients. Additionally, others 
have reported Aβ-related alterations in mitochondrial enzymes and metabolism (Casley et al., 
2002; Gibson et al., 2010), decreased cytochrome c oxidase activity (Parker et al., 1990; 
Canevari et al., 1999), decrease Ca2+ extrusion via NCLX (Jadiya et al., 2019), as well as altered 
mitochondrial dynamics (Mandelkow et al., 2003; Wang et al., 2008) and mitophagy via tau 
(Cummins et al., 2019). Cardoso et al. (2001) demonstrated Aβ-induced apoptosis in a               
mtDNA-dependent manner. Interestingly, APP and Aβ have been reported to localize to 
mitochondria (reviewed in Pagani and Eckert, 2011) as well as the specific interaction of Aβ 
with mitochondrial proteins: 3-hydroxyacyl-CoA dehydrogenase type 2 (Hsd17b10; Lustbader 
et al., 2004), the TOM complex (Hansson Petersen et al., 2008; Cabodevilla et al., 2013) and 
its clogging via Aβ (Anandatheerthavarada et al., 2003), mitochondrial ATP synthase subunit 
O (Atp5po; Beck et al., 2016) and cyclophilin F (CypD; Du et al., 2008). Additionally, APP 
processing is affected by mitochondrial dysfunction (Gabuzda et al., 1994; Webster et al., 
1998) and mtDNA polymorphism (Scheffler et al., 2012). All this evidence has led to the 
formulation of a ‘mitochondrial cascade hypothesis’ in addition to the leading paradigm, the 
‘amyloid cascade hypothesis’ (Swerdlow and Khan, 2004). 
Amyotrophic lateral sclerosis (ALS; Charcot, 1881) is characterized by the selective loss of 
upper and lower motor neurons in spinal cord, which leads to progressive muscle denervation, 
motor dysfunction, speech problems, paralysis and respiratory failure (reviewed in Chio et al., 
2013). ALS pathology has been linked mechanistically to the aggregation of protein in cytosol, 
increased oxidative stress, axonal transport deficits, deregulation of mRNA metabolism, 
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dysfunction in glial cells and mitochondrial dysfunction (reviewed in Carri et al., 2017). 
Ultrastructural alterations in mitochondria from ALS patients and mouse models have been 
reported for example by Okamoto et al. (1990), Sasaki and Iwata (2007), Xu et al. (2010) and 
Genin et al. (2016). Furthermore, several reports document reduced respiration and complex 
I and IV activity (Wiedemann et al., 1998; Borthwick et al., 1999; Vielhaber et al., 2000; Straub 
et al., 2018) as well as increased mtDNA mutations (Wiedemann et al., 2002) and abnormal 
mitochondrial transport (Magrane et al., 2014; Marinkovic et al., 2012). Specifically, 
cupper/zinc superoxide dismutase 1 (SOD1) is found mutated in one fifth of familiar ALS cases 
(Banci et al., 2008), but is also observed in sporadic cases (Pare et al., 2018). Mouse models of 
mutant SOD1, like SOD1G93A and SOD1G37R, recapitulate features of the disease in mice (Gurney 
et al., 1994; Wong et al., 1995). In SOD1G93A, misfolded protein is found in the inner 
mitochondrial membrane (Ahtoniemi et al., 2008), impairs voltage-dependent anion-selective 
channel (VDAC) function (Israelson et al., 2010), increases oxidative stress (Andrus et al., 1998; 
reviewed in Barber and Shaw, 2010) and leads to apoptosis (Pasinelli et al., 2004; Pedrini et 
al., 2010). 
29 
 
Chapter 2: Aims 
 
A IMS OF THIS  THESIS  
Mitochondrial biology is intimately intertwined with essential cellular functions – as one 
would expect from an organelle that integrated as a proteobacterium into a host cell more 
than 1.5 billion year ago. The transfer of essential genes to the host nucleus as well as the 
incorporation of novel host proteins into mitochondria give current day cells the opportunity 
to equip and fine-tune mitochondria according to their physiological state.  
Hence, mitochondria across tissues, cell types and even within cells differ in their molecular 
composition and function. Surprisingly, our knowledge of most mitochondrial proteins is poor 
(Pagliarini and Rutter, 2013) and particularly the contribution of mitochondrial proteins to the 
physiology of specific cell types, e.g. neuronal subtypes, unknown.  
In the strong believe that such cell type-resolved information will elucidate the function of 
mitochondrial proteins, i.e. the cellular context of an enriched protein can inform about its 
function and help generating related hypotheses, the present thesis aims to: 
1. Introduce a method for the molecular and functional characterization of cell type-
specific mitochondria from mouse tissue (Chapter 4.1). 
 
2. Demonstrate the extant of mitochondrial diversity in the context of mouse cerebellum 
by probing mitochondria from Purkinje cells, granule cells and astrocytes (Chapter 4.2). 
 
3. Follow up on the mitochondrial biology of each probed cell types and thereby 
consolidating the findings of Aim 2 (Chapter 4.3 – 4.5). 
 
4. Provide evidence for the conservation of cerebellar mitochondrial diversity                       
across species and the utilization of cell type-enriched mitochondrial ‘markers’ to 
investigate neurodegeneration (Chapter 4.6). 
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Chapter 3: Materials and Methods 
3.1. Materials 
3.1.1. Plasmids 
Name # Reference 
pMXs-IP GFP-Omp25 Addgene #38249 Yoshii et al. (2011) 
pEx-CAG-stop-bpA - Hitz et al. (2007) 
pDsRed2-Mito 632421 Clontech Laboratories 
pEx-CAG-Stop-GFP-OMM-bpA - This study 
pCMV-GFP-OMM - This study 
 
3.1.2. Buffers 
Gitocher buffer pH 8.8, 10x   
Tris Base 
Ammonium sulfate 
Magnesium chloride hexahydrate 
Gelatin 
670 mM
166 mM
65 mM
0.1%
T1503 
A4418 
630628 
48723 
Sigma 
Sigma 
Sigma 
Sigma 
  
Ringer’s solution, 1x   
Sodium chloride 
Potassium chloride 
Sodium phosphate monobasic dihydrate 
Sodium bicarbonate 
Calcium chloride dihydrate 
Magnesium chloride hexahydrate 
D-(+)-Glucose 
125 mM
2.5 mM
1.25 mM
26 mM
2 mM
1 mM
20 mM
3957.1 
7447-40-7 
71505 
S5761 
C7902 
630628 
G7021 
Roth 
Merck 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
oxygenate with carbogen (95% O2/5% CO2)
   
PBS pH 7.4, 10x   
Sodium phosphate monobasic dihydrate 
Sodium phosphate dibasic 
Sodium chloride 
18.6 mM
84.1 mM
1.75 M
71505 
S5136 
3957.1 
Sigma 
Sigma 
Roth 
  
4% Paraformaldehyde in PBS   
Paraformaldehyde 
PBS, pH 7.4 (10x) 
4%
1x
158127 
- 
Sigma 
- 
heat paraformaldehyde in water to 50°C, add two drops of NaOH until clear;  
filter solution, add PBS and adjust pH 
 
TBSt pH 7.6, 10x   
Tris HCl 
Tris Base 
Sodium chloride 
Tween20 
158 mM
46 mM
1.5 M
10%
T5941 
T1503 
3957.1  
P1379 
Sigma 
Sigma 
Roth  
Sigma 
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Isolation buffer (IB) pH 7.4   
Mannitol 
Sucrose 
HEPES 
EDTA 
BSA, fatty acid-free 
cOmplete, EDTA-free Protease Inhibitor 
220 mM
80 mM
10 mM
1 mM
1%
1x
M9546 
S7903 
15630056 
E9884 
A7030 
11873580001
Sigma 
Sigma 
Thermo Fisher Scientific 
Sigma 
Sigma 
Sigma 
   
Immunocapture buffer (ICB) pH 7.4   
Potassium chloride 
Magnesium chloride hexahydrate 
Potassium phosphate monobasic 
HEPES 
EDTA 
BSA, fatty acid-free 
cOmplete, EDTA-free Protease Inhibitor 
137 mM
2.5 mM
3 mM
10 mM
1 mM
1%
0.5x
P9333 
630628 
P5655 
15630056 
E9884 
A7030 
11873580001
Sigma 
Sigma 
Sigma 
Thermo Fisher Scientific 
Sigma 
Sigma 
Sigma 
  
MAS-1X pH 7.4   
Mannitol 
Sucrose 
Potassium phosphate monobasic 
Magnesium chloride hexahydrate 
HEPES 
EGTA 
BSA, fatty acid-free 
220 mM
70 mM
10 mM
5 mM
2 mM
1 mM
0.2%
M9546 
S7903 
P5655 
630628 
15630056 
E3889 
A7030 
Sigma 
Sigma 
Sigma 
Sigma 
Thermo Fisher Scientific 
Sigma 
Sigma 
   
Respiration buffer pH 7.4   
Potassium chloride 
Magnesium chloride hexahydrate 
Potassium phosphate monobasic 
HEPES 
Succinic acid 
L-Malic acid 
L-Glutamic acid 
BSA, fatty acid-free 
137 mM
2.5 mM
3 mM
10 mM
5 mM
5 mM
5 mM
0.2%
P9333 
630628 
P5655 
15630056 
S9512 
M1000 
49449 
A7030 
Sigma 
Sigma 
Sigma 
Thermo Fisher Scientific 
Sigma 
Sigma 
Sigma 
Sigma 
   
RIPA buffer pH 8.0   
Tris HCl 
Sodium chloride 
EDTA 
Triton X100 
NP-40 
SDS 
cOmplete, EDTA-free Protease Inhibitor 
50 mM
150 mM
0.1 mM
1%
0.25%
0.1%
1x
T5941 
3957.1 
E9884 
T9284 
I3021 
05030 
11873580001
Sigma 
Roth 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
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RIPA buffer 2 pH 8.0   
Tris HCl 
Sodium chloride 
EDTA 
Sodium deoxycholate 
Triton X100 
SDS 
50 mM
150 mM
5 mM
0.5%
1%
0.1%
T5941 
3957.1 
E6758 
D6750 
T9284 
05030 
Sigma 
Roth 
Sigma 
Sigma 
Sigma 
Sigma 
   
Tris-Glycine SDS buffer   
Tris Base 
Glycine 
SDS 
25 mM
192 mM
0.1% 
T1503 
G8898 
05030 
Sigma 
Sigma 
Sigma 
   
TWOBIN buffer   
Tris Base 
Glycine 
Methanol 
25 mM
192 mM
20%
T1503
G8898 
20846.326 
Sigma 
Sigma 
Merck 
   
SDT lysis buffer pH 7.6   
Tris HCl 
DTT 
SDS 
100 mM
100 mM
4%
T5941 
43816 
05030 
Sigma 
Sigma 
Sigma 
 
Blocking solution   
Fish gelatin 
FBS 
BSA, fatty acid-free 
PBS pH 7.4, 10x 
2%
2%
2%
1x
G7765 
10100147 
A7030 
- 
Sigma 
Thermo Fisher Scientific 
Sigma 
- 
   
Heat-induced antigen retrieval buffer (HIER) 1-7   
Sodium citrate buffer pH 6.0; HIER1 
Tri-sodium citrate 
Tween20 
10 mM
0.05%
4088.3 
P1379 
Roth 
Sigma 
   
Citrate buffer pH 6.0; HIER2 
Citric acid 
Tween20 
10 mM
0.05%
X863.1 
P1379 
Roth 
Sigma 
 
Citrate-EDTA buffer pH 6.2; HIER3 
Citric acid 
EDTA 
Tween20 
10 mM
2 mM
0.05%
X863.1 
E6758 
P1379 
 
Roth 
Sigma 
Sigma 
 
EDTA buffer pH 8.0; HIER4 
EDTA 
Tween20 
1 mM
0.05%
E6758 
P1379 
Sigma 
Sigma 
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Tris-EDTA buffer pH 9.0; HIER5 
Tris base 
EDTA 
Tween20 
10 mM
1 mM
0.05%
 
T1503 
E6758 
P1379 
 
Sigma 
Sigma 
Sigma 
   
Tris buffered saline (TBS) pH 9.0; HIER6 
Tris base 
Sodium chloride 
Tween20 
50 mM
150 mM
0.05%
T1503 
3957.1 
P1379 
Sigma 
Roth 
Sigma 
   
Tris buffer pH 10.0; HIER7 
Tris base 
Tween20 
10 mM
0.05%
T1503 
P1379 
Sigma 
Sigma 
   
Monomer solution (for expansion microscopy)   
Sodium acrylate 
Acrylamide 
N,N’-Methylenebisacrylamide 
Sodium chloride 
PBS pH 7.4, 10x 
8.6%
2.5%
0.15%
11.7%
1x
408220 
1610140 
M7279 
3957.1 
- 
Sigma 
BioRad 
Sigma 
Roth 
- 
Add 4-Hydroxy-TEMPO 
        TEMED 
        Ammonium persulfate 
0.01%
0.2%
0.2%
176141 
T7024 
A3678 
Sigma 
Sigma 
Sigma 
 
Digestion buffer   
Tris Base 
EDTA 
Sodium chloride 
Triton X100 
Proteinase K 
50 mM
1 mM
740 mM
0.5%
8 U/ml
T1503
E6758 
3957.1 
T9284 
V3021 
Sigma 
Sigma 
Roth 
Sigma 
Promega 
 
EM fixative pH 7.2   
Glutaraldehyde 
Paraformaldehyde 
Sodium cacodylate buffer 
2.5%
4%
0.1 M
16300 
15700 
11654 
Electron Microscopy Sciences 
Electron Microscopy Sciences 
Electron Microscopy Sciences 
 
EPON  
2-Dodecenylsuccinic acid anhydride 
Glycid ether 100 
Methylnadic anhydride pract. 
2,4,6-Tris(dimethylaminomethyl)phenol 
115.0g
171.3g
89.0g
6.5ml
20755.02 
21045.02 
29452.03 
36975.01 
Serva 
Serva 
Serva 
Serva 
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3.1.4. Animal models 
Mouse line ID MGI Reference 
B6N.Cg-Tg(ACTFLPe)9205Dym/CjDswJ #019100 5473808 Rodriguez et al. (2000) 
B6N.Cg-Gt(ROSA)26Sortm1(CAG-EGFP*)Thm/J #032675 6296994 This study (MitoTag) 
Thy1:mito-RFP - - Breckwoldt et al. (2014) 
C57BL/6NCrl 027 2683688 Charles River 
B6.129S2-Emx1tm1(cre)Krj/J #005628 3617405 Gorski et al. (2002) 
B6;129S6-Chattm2(cre)Lowl/J #006410 3699161 Rossi et al. (2011) 
B6.Cg-Tg(Gabra6-cre)B1Lfr/Mmucd  4358481
Fünfschilling and Reichardt 
(2002) 
B6.129-Tg(Pcp2-cre)2Mpin/J #004146 2174502 Barski et al. (2000) 
B6.Cg-Tg(Gfap-cre)77.6Mvs/2J #024098 5554256 Gregorian et al. (2009) 
STOCK Tg(Rbp4-cre)KL100Gsat/Mmucd 
031125-
UCD 
4367068
Gong et al. (2007); Gong et al. 
(2003) 
B6.Cg-Tg(SOD1*G93A)1Gur/J #004435 2181028 Gurney et al. (1994) 
APP23/PS45 : 
Tg(Thy1-APP)3Somm 
Tg(Thy1-PSEN1*G384A)45Jckr 
- 
#030504 
- 
- 
2447146
4819105
Busche et al. (2008); 
(Sturchler-Pierrat et al., 1997); 
(Herzig et al., 2004) 
C57BL/6N-Mcutm1a(EUCOMM)Hmgu/H 07445 5557399 MMRRC 
Mcutm1c - 6122827 This study 
C57BL/6N-Rmdn3tm1a(KOMP)Wtsi/MbpMmucd 049471 6347157 MMRRC
B6;129-Gt(ROSA)26Sortm4(CAG-EGFP*)Nat/J 021429 5571611 Jeremy Nathans, Johns Hopkins University 
Tg(Pvalb-EGFP)1Mony - 6117392 Meyer et al. (2002) 
 
3.1.5. Primer sequences 
Primer Sequence 5’ → 3’ Product (bp) 
ACTB-FLPe TGC CGG TCC TAT TTA CTC GT 
TAC TTC TTT AGC GCA AGG GGT AG 
100 
APP23 GAATTCCGACATGACTCAGG 
GTTCTGCTGCATCTTGGACA 
246 
Cre GCCGAAATTGCCAGGATCAG 
AGCCACCAGCTTGCATGATC 
650 
Gabra6:Cre (ctr) CCCTGCAAGCAGAGATTGTT 
GCCTAGAGTCTGCCAGGTCA 
217 
Gabra6:Cre (mut) CCCTGCAAGCAGAGATTGTT 
TGCCGCCTTTGCAGGTGTGTCTTAC 
586 
GFP CACGCTTCAAAAGCGCACGTCTG 
GTTGTGCCCAGTCATAGCCGAATAG 
280 
GFP-OMM (mut) CAAGATCCGCCACAACATCG 
TATCTCACGAAGGCCCAAAC 
324 
GFP-OMM (WT) GCACTTGCTCTCCCAAAGT 
CATAGTCTAACTCGCGACACTG 
600 
Mcu (mut) TGGGTGTTGATTACAAAGTTTTCA 
GGTTGTCCTCTGACCTCCAC 
462/118 
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Primer Sequence 5’ → 3’ Product (bp) 
Mcu (WT) TGGGTGTTGATTACAAAGTTTTCA 
GAACTTCGGAATAGGAACTTCG 
300 
PS45 CAGGTGCTATAAGGTCATCC 
ATCACAGCCAAGATGAGCCA 
291 
Rbp4-Cre GGGCGGCCTCGGTCCTC 
CCCCAGAAATGCCAGATTACGTAT 
600 
Rmdn3 (mut) GGGATCTCATGCTGGAGTTCTTCG 
GGTCTATGTAACTCCAGCCGTCTGG 
546 
Rmdn3 (WT) GCCTCAGCAGCGAGTACTTTTACCC 
GCCCCTAGGCTGAAGAGATGGC 
231 
Mito-GFP (mut) GCA CTT GCT CTC CCA AAG TC 
GTT ATG TAA CGC GGA ACT CC 
300 
Mito-GFP (WT) GCA CTT GCT CTC CCA AAG TC 
CAT AGT CTA ACT CGC GAC ACT G 
557 
SOD1 CATCAGCCCTAATCCATCTGA 
CGCGACTAACAATCAAAGTGA 
236 
Thy1:mito-RFP CGCCAAGATCCATTCGTT 
TTCTGCTGCCGTACATGAAG 
254 
 
3.1.6. Cell lines and reagents 
Item # Company 
U-2 OS cell line ATCC HTB-96 ATCC 
IDG 3.2 murine hybrid ES cell line 
(129S6/SvEv/Tac x C57Bl/6) 
- Ralf Kühn 
DMEM, high glucose, GlutaMax 61965059 ThermoFisher Scientific
Fetal Bovine serum, FBS 10100147 ThermoFisher Scientific 
G418 10131027 ThermoFisher Scientific 
PBS pH7.4 10010015 ThermoFisher Scientific 
TrypLE Express Enzyme, no phenol red 12604013 ThermoFisher Scientific
X-treme GENE 9 DNA reagent 06365779001 Roche 
 
3.1.7. Antibodies 
3.1.7.1. Antibodies used for immunofluorescence staining (Chapter 3.2.14) 
Antigen Species # Dilution Company 
Acads Rabbit ab156571 1:200 Abcam 
Ak3 Mouse IgG1 sc-398571 1:100 Santa Cruz 
Ak4 Mouse IgG1 sc-271161 1:100 Santa Cruz 
Amyloid-β (1-16) 6E10 Mouse IgG1 803020 1:500 BioLegend 
Amyloid-β (17-24) 4G8 Mouse IgG2b 800712 1:1,000 BioLegend 
Amyloid-β (8-17) 6F/3D Mouse IgG1 M0872 1:100 Dako
Catalase Rabbit 100-4151 1:200 Rockland 
Calbindin Chicken CPCA-Calb 1:1000 EnCor Biotechnology Inc.
ChAT Goat AB144P 1:500 Sigma 
Cox4i1 Rabbit AP22111a 1:200 Abgent 
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Antigen Species # Dilution Company 
Cpt1a Rabbit 15184-1-AP 1:50 ProteinTech 
Gfap Chicken ab4674 1:2,000 Abcam
GFP Chicken ab13970 1:1,000 Abcam 
Gldc Rabbit HPA002318 1:400 Sigma 
Gls (KGA) Rabbit 20170-1-AP 1:200 ProteinTech 
Gls2 Rabbit AP6650d 1:400 Abgent 
Got2 Rabbit ab171739 1:400 Abcam 
Ldhd Rabbit ab182146 1:100 Abcam 
MaoB Mouse IgG1 sc-515354 1:100 Santa Cruz 
Mavs Rabbit #4983 1:200 Cell Signaling 
Mcu Rabbit HPA016480 1:400 Sigma 
NeuN Rabbit MAB377 1:100 Sigma 
NeuN-Alexa Fluor 488 Rabbit ab190195 1:50 Abcam
Nipsnap1 Rabbit #13226 1:200 Cell Signaling 
Ociad2 Rabbit HPA040979 1:200 Sigma 
Ociad2 Rabbit ab91576 1:200 Abcam
Pex14 Rabbit - 1:1,000 Gift from Denis Crane  
Pptc7 Rabbit ab122548 1:200 Abcam 
Rmdn3 Rabbit ab189845 1:400 Abcam 
Slc25a20 Rabbit 19363-1-AP 1:400 ProteinTech 
Sfxn5 Rabbit ab172971 1:500 Abcam 
Snph 1-100 Rabbit ab192605 1:400 Abcam 
Snph 225-428 Rabbit - 1:400 Gift from Zu-Hang Sheng
Tst Rabbit ab166625 1:500 Abcam 
Tubulin βIII-AF 555 Mouse IgG2a 560339 1:200 BD Bioscience 
α-chicken IgY-AF 488 Goat A-11039 1:1,000 ThermoFisher Scientific 
α-chicken IgY-AF 647 Goat A-21449 1:1,000 ThermoFisher Scientific 
α-goat IgG-AF 594 Donkey A-32758 1:1,000 ThermoFisher Scientific 
α-mouse IgG Fab Goat 115-007-003 1:100 Jackson Immunoresearch 
α-mouse IgG1-AF 594 Goat A-21125 1:1,000 ThermoFisher Scientific 
α-mouse IgG-AF 647 Donkey 715-605-151 1:2,000 Jackson Immunoresearch 
α-rabbit IgG-AF 555 Donkey A-31572 1:2,000 ThermoFisher Scientific 
α-rabbit IgG-AF 568 Goat A-11011 1:1,000 ThermoFisher Scientific 
α-rabbit IgG-AF 594 Goat A-11012 1:1,000 ThermoFisher Scientific 
 
3.1.7.2. Antibodies used for western blot analysis (Chapter 3.2.11) 
Antigen Species # Dilution Company 
Ak4 Mouse IgG1 sc-271161 1:100 Santa Cruz 
ATP5a Mouse IgG1 ab14748 1:10,000 Abcam 
Cox4i1 Rabbit AP22111a 1:1,000 Abgent 
CypD Mouse IgG1 ab110324 1:5,000 Abcam
Emre Rabbit sc-86337 1:500 Santa Cruz 
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Antigen Species # Dilution Company 
GFP Mouse IgG2b sc-9996 1:500 Santa Cruz 
Gldc Rabbit HPA002318 1:1,000 Sigma
Got2 Rabbit ab171739 1:1,000 Abcam 
Mcu Rabbit HPA016480 1:1,000 Sigma 
Ociad2 Rabbit HPA040979 1:1,000 Sigma 
Rmdn3 Rabbit ab189845 1:2,000 Abcam 
Sfxn5 Rabbit ab172971 1:2,000 Abcam 
Tomm20 Rabbit ab78547 1:1,000 Abcam 
tRFP Rabbit AB234 1:5,000 Evrogen
α-mouse IgG-HRP Goat 1706516 1:5,000 BioRad 
α-rabbit IgG-HRP Goat 1706515 1:5,000 BioRad
 
3.1.7.3. Antibodies used for flow cytometry (Chapter 3.2.13) 
Antigen Species # Dilution Company 
Mouse IgG-APC Mouse IgG1 130-113-758 1:25 Miltenyi Biotec 
Tom22-APC Mouse IgG1 130-107-733 1:25 Miltenyi Biotec 
 
3.1.8. Kits 
Item # Company 
ImmPRESS® HRP Anti-Rabbit IgG (Peroxidase) 
Polymer Detection Kit 
MP-7451 Vector Lab 
Mitochondria Isolation kit, mouse tissue 130-096-946 Miltenyi Biotec 
Pierce 660 nm Protein Assay kit 22660 ThermoFisher Scientific 
Pierce BCA Protein Assay kit 23225 ThermoFisher Scientific 
QIAquick Gel Extraction Kit 28706 QIAGEN
QIAQuick PCR Purification Kit 28106 QIAGEN 
Zenon Alexa Fluor 647 Rabbit IgG Labeling Kit Z25308 ThermoFisher Scientific 
μMACS GFP Isolation kit 130-091-125 Miltenyi Biotec 
 
3.1.9. Western blot reagents and equipment 
Item # Company 
DL-Dithiothreitol solution (DDT) 43816 Sigma 
ECL Prime Western Blotting Detection Reagent RPN2232SK GE Healthcare Life Sciences 
Fusion FX7 - Vilber Lourmat 
Mini-PROTEAN Tetra Vertical Electrophoresis Cell 1658004 BioRad 
PowerPac™ Basic Power Supply 1645050 BioRad 
PVDF membrane, 0.2 μm 1620177 BioRad 
SDS polyacrylamide gel,  
12%; AnyKDa; 4-20% 
4561096 
4569036 
4561043 
BioRad 
Skim milk 70166 Sigma 
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Item # Company 
Sodium azide S8032 Sigma 
SYPRO™ Ruby Protein Blot Stain S11791 ThermoFisher Scientific 
Trans-Blot Turbo Transfer System 1704150 BioRad 
TruPAGE LDS sample buffer PCG3009 Sigma 
WYPAL*X60 115-2058 Kimberly Clark 
 
3.1.10. Mass spectrometry reagents and equipment 
Item # Company 
Acetonitrile 1.00017 Supelco 
Benzonase E8263 Sigma 
Column oven - Sonation 
Easy nLC-1,000 nano UHPLC - Thermo Fisher Scientific 
LysC V1671 Promega 
Nanospray Flex electrospray ion source - Thermo Fisher Scientific 
Q-Exactive HF mass spectrometer - Thermo Fisher Scientific 
Q-Exactive mass spectrometer - Thermo Fisher Scientific 
Trypsin V5111 Promega 
Urea U4883 Sigma 
VialTweeter, sonication - Hielscher Ultrasonics 
Vivacon filter VN01H02 Sartorius 
 
3.1.11. Microscopy reagents and equipment 
Item # Company 
BX51WI - Olympus 
Retiga EXi - Qimaging 
FV1000 - Olympus
20xO/N.A. 0.85 UPlanSApo Olympus 
FV3000 - Olympus 
20x/N.A. 0.75 UPlanSApo Olympus
40x/N.A. 0.95 UApo N340 Olympus 
JEM-1400 - Jeol Tokyo 
60xO/N.A. 1.42 PlanApo Olympus 
100xW/N.A. 1.0 LumPlanFL Olympus 
10x/N.A. 0.4 UPlanSApo Olympus
20xW/N.A. 0.5 LumPlanFL Olympus 
Lambda 10-3 LB10-NWIQ Sutter 
4x/N.A. 0.16 UPlanFL N Olympus 
4x/N.A. 0.28 XLFluor 4x/340 Olympus
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3.1.13. Chemicals and other reagents 
Item # Company 
Acryloyl-X, SE, 6-((acryloyl)amino)hexanoic 
Acid, Succinimidyl Ester (Acryloyl-X SE) 
A20770 Thermo Fisher Scientific 
ADP 01905 Sigma
Antimycin A 8674 Sigma 
Autofluorescence Eliminator Reagent 2160 Merck 
BglI R0143 New England BioLabs 
Calcium chloride C1016 Sigma 
CalciumGreen-5N, hexapotassium salt C3737 Thermo Fisher Scientific 
Calf intestinal phosphatase M0289 New England BioLabs 
CCCP C2759 Sigma
Dako Diluent 52022 Dako 
Dako REAL Peroxidase-Blocking Solution S202386-2 Dako 
DAPI D9542 Sigma
DNA polymerase I M0209 New England BioLabs 
Ferrocyanide - Science Services 
Fluoromount Mounting Medium F4680 Sigma 
GoTaq(R) G2 Hot Start Green Master Mix M7423 Promega
HBSS, calcium, magnesium 14025092 Thermo Fisher Scientific 
Heparin sodium salt H3149 Sigma 
HindIII R3104 New England BioLabs 
Hoechst 33342 H3570 Molecular Probes 
Ultro stain (lead citrate) 16707235 Leica 
anti-CD4 microbeads, human (mouse IgG1) 130-045-101 Miltenyi Biotec 
NEB 5-α E.coli C2988J New England BioLabs 
NotI R3189 New England BioLabs 
Oligomycin A 75351 Sigma
OsO4 E19130 Science Services 
L-palmitoylcarnitine 61251 Sigma 
Phalloidin-Alexa Fluor 647 A30107 Thermo Fisher Scientific 
Proteinase K 351100902 Biozym
Pyruvic acid 107360 Sigma 
Quick-Load® 2-Log DNA Ladder N0469S New England BioLabs 
Rotenone 557368 Calbiochem
Ru360 557440 Sigma 
SeaKem LE Agarose Lonzo 733-0829 VWR 
Streptavidin-Alexa Fluor 405 S32351 Thermo Fisher Scientific 
T4 ligase M0202 New England BioLabs 
TAE buffer 50x CL86.1 Roth 
TSA FP1170 Perkin Elmer 
Uranyl acetate E22400 Science Services 
Vectashield Mounting medium H-1,000 Vector Laboratories 
Wash Buffer 53006 Dako 
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Item # Company 
XbaI R0145 New England BioLabs 
α-bungarotoxin-biotin B1196 Thermo Fisher Scientific 
β-Mercaptoethanol M6250 Sigma 
 
3.1.14. Other equipment 
Item # Company 
35x10 mm petri dish 351008 Corning, FALCON 
CLARIOstar - BMG Labtech 
CyAn ADP 9 flow cytometer - Beckman Coulter 
KIMBLE Dounce tissue grinder set D9063 Sigma 
Leica UltraCut2 - Leica 
LS column 130-042-401 Miltenyi Biotec 
Parr bombe disruption vessel 4635-39 Parr Instrument Company 
Pre-separation filter, 30 m 130-041-407 Miltenyi Biotec 
QuadroMACS separator 130-090-976 Miltenyi Biotec 
Seahorse XFe96 Extracellular Flux Analyzer - Agilent
Vibratome VT1200 Leica
 
3.1.15. Software 
Software Version Company 
FlowJo 10.5.3 TreeStar 
GenoPlex 7.12.09.0 BiHELab 
GraphPad Prism 8.2.1 GraphPad Software 
Illustrator CS5 15.0.2 Adobe 
Image Studio Lite 5.2.5 Licor 
ImageJ/Fiji 1.52f Schindelin et al. (2012) 
MaxQuant 1.5.4.1
1.5.5.1 
Cox et al. (2014) 
Microsoft Excel 2016 Microsoft Office 
Perseus 1.6.1.1. Tyanova et al. (2016) 
Photoshop 12.0.4 Adobe 
Seahorse XFe96 Wave  2.3.0.19. Agilent
μManager 1.48v www.micro-manager.org 
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3.2. Methods 
The methods described in this thesis are partially published in the related article Fecher et al. 
(2019) and I have written this part with input from all co-authors. 
3.2.1. Molecular cloning of expression plasmids carrying GFP-OMM 
We generated expression plasmids via site-specific restriction enzyme digest and blunt-end 
cloning. In brief, 4 μg of parent plasmid containing insert or vector were cut with the described 
restriction enzymes overnight at 37°C. The reaction was stopped by heat inactivation, the ends 
of DNA fragments blunted by DNA polymerase I at 24°C for 15 minutes and reaction stopped 
by addition of 10 mM EDTA and heating at 75°C for 20 minutes. The products were run on a 
1% agarose/TAE gel to separate product from remaining parent plasmid, and purified using 
the QIAQuick Gel Extraction Kit. The vector plasmid was further dephosphorylated using 0.5 
unit calf intestinal phosphatase per μg DNA at 37°C for one hour and cleaned using the 
QIAQuick PCR Purification Kit. For ligation, a vector to insert ratio of 1:5 was mixed to the 
following reaction and incubated overnight at 16°C: 
DNA vector 50 ng 
DNA insert 10 x (insert size/vector size) ng 
Ligase buffer, 10x 1 μl 
T4 ligase 1 μl 
 ad 10 μl water 
5 μl reaction were used to transform chemically-competent NEB 5-α E.coli. DNA from positive 
clones was purified and controlled for proper integration via restriction enzyme digest. Finally, 
we transiently transfected cells in culture for functional validation. 
 
3.2.1.1. pCMV-GFP-OMM 
GFP-OMM is a fusion protein consisting of green fluorescent protein (GFP) and the C-terminal 
anchor of OMP25/Synj2bp (37 amino acids; Figure 5a) and was characterized by Nemoto and 
De Camilli (1999) and Horie et al. (2002). I generated the pCMV-GFP-OMM plasmid via NotI 
digestion of the plasmid pMXs-IP GFP-Omp25 (Yoshii et al., 2011) to obtain the GFP-OMM 
insert, and via HindIII and XbaI digest of the vector plasmid pDsRed2-Mito. Vector and insert 
were combined via blunt-end cloning (Figure 5b) and tested in cell culture (Figure 5c). 
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3.2.1.2. pEx-CAG-stop-GFP-OMM-bpA 
Laura Trovò (L.T.; Institute of Neuronal Cell Biology, TUM) obtained the GFP-OMM sequence 
consisting of 848 base pairs via NotI digestion of the plasmid pMXs-IP GFP-Omp25 (Yoshii et 
al., 2011). Next, L.T. opened the expression vector pEx-CAG-stop-bpA via BglI digest and 
inserted the GFP-OMM DNA fragment via blunt-end cloning (Figure 5d). 
3.2.2. Cell culture 
U-2 OS cells were cultured in DMEM with GlutaMax and 10% FBS at 37°C, 5% CO2. At 70% 
confluence, cells were sub-cultured by de-attachment with TrypLE Express Enzyme for 1 
minute, washing cells with medium and plating them 1:5 in fresh medium. 
I transiently transfected U-2 OS cells with plasmids using X-treme GENE 9 DNA transfection 
reagent according to the manufacturer’s instructions. Briefly, a ratio of 1 μg DNA to 3 μl 
reagent in 100 μl serum-free medium was used for transfection. Cells were used for 
experiments two days post transfection. 
Figure 5│ GFP-OMM fusion protein, its vectors for expression and transfection in cells. (a) Amino 
acid (AA) sequence map of OMP25/Synj2bp and GFP-OMM. The C-terminal 37 amino acids 
facilitate localization to the outer mitochondrial membrane (OMM). Protein domains: PDZ, Helix, 
transmembrane (black), eGFP. (b) Vector map of CMV-driven GFP-OMM for the transient 
transfection of cells in culture. KanaR, kanamycin resistance. (c) Transient expression of GFP-OMM 
in U-2 OS cells. Nuc, nuclear counter stain. Scale bar: 10 μm. (d) Vector map of CAG-driven, stopped 
GFP-OMM for the generation of MitoTag mice. AmpR, ampicillin resistance; attB, phiC31 integrase 
recognition site; loxP, Cre recombinase recognition site; puroR, puromycin resistance; STOP, 
multiple stop codons; bpA, bovine growth hormone polyadenylation site. 
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3.2.3. Animal models 
All animal experiments were approved by the responsible regulatory agencies. Mice of mixed 
C57BL/6 N and J background were kept in ventilated IVC racks on a 12/12 light/dark cycle with 
standard chow diet and water supply. Transgenic mice were genotypes through PCR of tail 
biopsies, which were performed by animal caretakers and laboratory technicians using 
standard protocols. If not mentioned differently in the text, experimental animals were from 
both sexes and within the age range of 1.5 to 6 months. 
3.2.3.1. Rosa26 GFP-OMM knock-in mice (MitoTag mouse line) 
MitoTag mice harboring GFP-OMM under control of the cytomegalovirus early enhancer 
element, chicken β-actin promoter, rabbit β-globin splice acceptor, in short CAG promoter 
and Cre recombinase (Cre) and were generated as previously described (Hitz et al., 2009; Ortiz 
et al., 2013). The knock-in was established via recombinase-mediated cassette exchange into 
the Rosa26 locus of mouse embryonic stem cells and was performed and planned by Oskar 
Ortiz and Ralf Kühn (Institute of Developmental Genetics, Helmholtz Zentrum München).  
First, the donor vector (pEx-CAG-stop-GFP-OMM-bpA) was co-electroporated together with 
the C31-integrase expression vector into ID G3.2 embryonic stem cells. Cassette exchange is 
mediated by phiC31 integrase attB recognition sites in the donor vector (Figure 5d, red) and 
phiC31 integrase attP recognition sites in one allele of the Rosa26 locus of the embryonic stem 
cells. This allows for integration of a single copy of the GFP-OMM cassette. Secondly, selection 
of positive embryonic stem cells was confirmed via neomycin resistance upstream of the CMV 
early enhancer/chicken β-actin promoter (Figure 5d, neomycinR). Cells were cultured with  
140 μg/ml G418 for one week. Resistant colonies were isolated and screened for vector 
orientation by southern blot analysis (Hitz et al., 2007; Hitz et al., 2009). Thirdly, confirmed 
clones were injected into C57BL/6 blastocysts to obtain chimeric animals, which were 
screened by PCR probing for GFP. We further bred positive chimaera with C57BL/6 mice to 
obtain founder animals. These heterozygous mice were crossed to C57BL/6 mice for 8 
generations before generating the homozygous colony of MitoTag mice. 
We further genotyped MitoTag mice with four primers to distinguish homozygous (PCR 
product: 604 bp) and heterozygous (PCR products: 604 bp, 324 bp) animals. The MitoTag 
mouse line is transferred to The Jackson Laboratory and available as JAX#032675 (Rosa26-
CAG-LSL-GFP-OMM). 
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3.2.3.2. APP23/PS45 and SOD1G93A mouse model 
I obtained transgenic APP23/PS45 mice (Busche et al., 2008) as model for Alzheimer’s disease 
(AD) from Arthur Konnerth (Institute of Neuroscience, TUM) and SOD1G93A mice (Gurney et 
al., 1994) as model for amyotrophic lateral sclerosis (ALS) to visualize mitochondrial 
morphology changes in disease models. Animals at the age of 9 month and within the age 
range of 2-5 month were examined for AD and SOD, respectively. Transgenic APP23/PS45 mice 
express mutant amyloid precursor protein (APP) KM670/671NL (Swedish double mutation, 
APPSwe Sturchler-Pierrat et al., 1997) and mutant presenilin 1 G384A (PS45 Herzig et al., 2004) 
from human driven by the Thy1 promoter. 
3.2.3.3. Mcutm1c mouse model 
We obtained the Mcutm1a knockout-first allele (C57BL/6N-Mcutm1a(EUCOMM)Hmgu/H; Figure 6) 
from the MMRRC. As previously described (Harrington and Murphy, 2015), no homozygous 
Mcutm1a mice were born due to embryonal lethality on C57BL/6 background. To generate 
conditional Mcutm1c mice (Figure 6b), I crossed Mcutm1a mice with ACTB-FLPe mice (Rodriguez 
et al., 2000) and tested the cassette removal of lacZ reporter and neomycin selection by PCR 
(products: 462 bp, 118 bp). Granule cell-specific Mcu deletion was achieved by breeding 
Mcutm1c with Gabra6:Cre-driver mice (Fünfschilling and Reichardt, 2002). I confirmed 
successful deletion by immunofluorescence staining and western blot analysis                          
(Figure 38a and b). McuGC:ko mice were viable and normal in behavior. Mice of the age 1 to 5 
month were used for experiments. 
3.2.3.4. Rmdn3tm1a mouse model 
We obtained the Rmdn3 knockout-first allele (C57BL/6N-Rmdn3tm1a(KOMP)Wtsi/MbpMmucd; Figure 7) 
from the KOMP Repository (project: 3U01HG004080; www.komp.org) where it was generated 
together with the Wellcome Trust Sanger Institute and the Children’s Hospital Oakland 
Research Institute as part of the Knockout Mouse Project (Skarnes et al., 2011). The embryonic 
stem cell clone EPD0131_4_D01 was used for generation. Rmdn3tm1a mice are born in normal 
Mendelian ratios, are fertile and normal in behavior. The mutant allele was identified by PCR 
(product: 546 bp) and I confirmed deletion of Rmdn3 protein by immunofluorescence staining 
and western blot analysis (Figure 40a and b).  
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Figure 6│ Knockout-first allele of the murine Mcu locus. (a) The Mcu protein 
consists of eight exons coding for a 350 amino acid (AA) long protein. The 
Mcutm1d allele disrupts the Mcu locus creating a truncated 167 AA long 
protein. MTS, mitochondrial translocation signal; coiled, coiled domain; 
Helix, helical structure prior to transmembrane domain; *, stop. (b) Genetic 
modifications of the knockout-first allele of Mcu, Mcutm1a : insertion of the 
lacZ and neomycinR cassette prior to the critical exon 5 (red) and loxP site 
flanking of exon 5. Here, Mcu expression is disrupted. After FLP site 
recombination, the conditional allele Mcutm1c is generated without 
disruption of Mcu expression. After crossing with Cre-driver lines, the cell 
type-specific Mcu deletion is generated (Mcutm1d), which generates a non-
functional, truncated 167 AA long protein. *, stop. Modified from 
documentation of the MMRRC (www.mmrrc.org). 
Figure 7│ Knockout-first allele of the murine Rmdn3 locus. (a) Rmdn3 protein consists of 13 exons 
coding for a 470 amino acid (AA) long protein. The Rmdn3tm1a allele disrupts the Rmdn3 locus 
creating a lacZ-exon 2 fusion protein. AA, amino acid; coiled, coiled domain; Helix, helical structure 
prior to transmembrane domain; TPR domain, tetratricopeptide repeat domain. (b) Genetic 
modifications of the knockout-first allele of Rmdn3: insertion of the lacZ and neomycinR cassette 
prior to the critical exon 3 and 4 (red) and loxP site flanking of this critical region. Here, Rmdn3 
expression is disrupted. Modified from documentation of the KOMP Repository (www.komp.org). 
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3.2.4. Genotyping of transgenic mice 
Animal caretakers obtained tail biopsies and laboratory technicians performed DNA 
extraction, PCR and gel electrophoresis using standard protocols. DNA was isolated via 
proteinase K extraction using: 
Proteinase K 0.5 μg/ml  
55°C for 5 hours; 
95°C for 5 minutes; 
4°C ∞ 
Triton X100 0.5%  
β-Mercaptoethanol 1%  
Gitocher buffer 1x  
 ad 150 μl water  
PCR products were amplified using: 
GoTaq 1x  95°C for 2 minutes; 
32 cycles: 
95°C, 15s 
58°C, 30s 
72°C, 15s; 
72°C for 5 minutes; 
4°C ∞ 
Primers 10 pmol  
DNA 1 μl  
 ad 20 μl water  
Products and 1K DNA ladder were separated on a 1.5% agarose/TAE gel via electrophoresis at 
180 V, 30 minutes. DNA bands were visualized under 312 nm UV light and documented with 
GenoPlex software. 
3.2.5. Time-lapse imaging of mitochondrial transport in motor axons 
Laura Trovò (L.T.; Institute of Neuronal Cell Biology, TUM) probed mitochondrial transport ex 
vivo in nerve-muscle explants of transgenic mice as previously described (Kerschensteiner et 
al., 2008). Briefly, the rib cage including the triangularis sterni muscle and its innervating 
intercostal nerves was excised post mortem and transferred to a dish with oxygenated 
Ringer’s solution. Extraneous tissue and fat were removed and the explant pinned down with 
insect pins into a Sylgard-coated 35 mm dish. During the entire experiment, the explant was 
super-fused with oxygenated Ringer’s solution at 33°C to 35°C. Time-lapse imaging was 
performed using an Olympus BX51WI upright down, epifluorescence microscope equipped 
with a 20xW/0.5 and a 100xW/1.0 water immersion objective, an automated filter wheel, 
neutral density filters and a cooled CCD camera (Retiga EXi). The acquisition was controlled by 
μManager. 
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To asses mitochondrial transport in MitoTag mice, we crossed Rosa26-GFP-OMM mice to 
ChAT:Cre+-driver mice (Rossi et al., 2011) and Thy1:mito-RFP mice (Breckwoldt et al., 2014). 
Because GFP-OMM in motor neurons was dimmer than observations made by Rosa26-
mitoGFP, L.T. evaluated transport based on mito-RFP signals – a transgenic mouse line with 
matrix localized, bright RFP. Comparisons were made between                          
ChAT:Cre−/GFP-OMMxThy1:mito-RFP and ChAT:Cre+/GFP-OMMxThy1:mito-RFP litter mates. 
3.2.6. Neuromuscular health assessment 
Laura Trovò (L.T.; Institute of Neuronal Cell Biology, TUM) performed the assessment of 
neuromuscular junction (NMJ) area and acetylcholine receptor density at NMJs in motor 
neurons expressing GFP-OMM ex vivo. For this, triangularis sterni muscles were fixed with 4% 
paraformaldehyde in PBS on ice for one hour. Thereafter, the muscle was dissected from the 
rib cage and stained with α-bungarotoxin-biotin (10 mg/μl) and phalloidin conjugated to Alexa 
Fluor 647 (4 U/ml) at 4°C overnight. Next, the samples were washed with PBS and incubated 
with streptavidin-Alexa Fluor 405 (1:500) in PBS at room temperature for one hour. Muscles 
were mounted with Vectashield Mounting medium and flattened by magnets at 4°C 
overnight. 
Comparisons were made between tissues from ChAT:Cre−/GFP-OMMxThy1:mito-RFP and 
ChAT:Cre+/GFP-OMMxThy1:mito-RFP litter mates. The α-bungarotoxin staining was 
thresholded with the Otsu algorithm in ImageJ/Fiji (Schindelin et al., 2012) to obtain the area 
of neuromuscular junction. Next, within this area the intensity of α-bungarotoxin staining was 
measured and background subtracted. 
3.2.7. Mitochondrial purification 
I isolated mitochondria from freshly collected mouse tissue as described in Wettmarshausen 
and Perocchi (2017). In brief, mice were anesthetized with a lethal dose of isoflurane and 
transcardially perfused with heparin (19.5 U/ml) in PBS. The tissue of interest was dissected, 
weighed and minced with a Dounce glass homogenizer using three complete up and down 
cycles of an A-type pestle in isolation buffer (IB). During all steps, I kept the sample on ice or 
at 4°C. Next, cells were opened by nitrogen cavitation using a cell disruption vessel (model 
4635-39) at 800 psi and under stirring at 60 rpm for 10 minutes. Upon release from the 
disruption vessel, protease inhibitor was added to the resulting total tissue fraction. Nuclei 
and debris were removed by centrifugation at 600 g for 10 minutes. The supernatant was 
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transferred and centrifuged again. The resulting post-nuclear tissue fraction was filtered 
through a 30 µm pre-separation filter. 
3.2.7.1. Differential centrifugation 
To obtain the crude mitochondrial fraction (CMF) from the post-nuclear tissue fraction, a 
volume equivalent to 20 mg initial tissue was centrifuged at 12,000 g for 3 minutes. The pellet 
washed twice with IB without BSA. For respiratory measurements, I gently resuspended the 
final CMF in 30 µl IB with 0.2% BSA. For western blot analysis, I immediately stored the pellet 
at -20°C. 
3.2.7.2. Immunocapture 
For immunocapture (IC) against Tom22 (Franko et al., 2013; Hornig-Do et al., 2009) or                  
GFP-OMM, the post-nuclear tissue fraction was diluted to a concentration of maximal 2 mg 
tissue/ml in immunocapture buffer (ICB). 50 µl microbeads coated with mouse IgG1 subtype 
antibodies (Miltenyi Biotec) against Tom22, GFP or CD4 were added and incubated on a shaker 
(60 rpm) at 4°C for 30 to 90 minutes. Incubation was dependent on cell type abundance within 
the tissue and was adjusted accordingly, e.g. 30 minutes for Emx:Cre+/GFP-OMM and                         
90 minutes for ChAT:Cre+/GFP-OMM. To separate microbeads-coated mitochondria from the 
solution, I placed LS columns in a magnetic QuadroMACS Separator and equilibrated them 
with 3 ml ICB. The IC was applied to the column in 3-ml-steps, followed by three 3-ml-wash- 
steps with ICB. I removed the column from the magnet and gently flushed out mitochondria 
in 4 ml ICB using the plunger. Isolated mitochondria were pelleted by centrifugation at 12,000 
g for 3 minutes and washed twice with IB without BSA. For respiratory measurements, I gently 
resuspended the final pellet in 30 µl IB with 0.2% BSA. For western blot analysis, I immediately 
stored samples at -20°C.  
We deliberately avoided the use of an additional Percoll gradient for further purification (Sims 
and Anderson, 2008) in order to preserve organelle interactions and mitochondrial integrity 
(Wang et al., 2011b). This results in some level of commonly known contaminations with non-
mitochondrial proteins; however, this is in the analysis largely eliminated by normalization to                   
IC Tom, where it is equally present. Still, if one desires purity over organelle viability, yield and 
time, cell type-specific mitochondria can be further purified via a Percoll gradient. 
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3.2.8. Protein amount measurement 
I determined protein amount concentration in samples by using the Pierce BCA Protein assay 
kit according to the manufacturer’s instructions with BSA as standard. Assay dependent 
sample buffers were used to correct for alterations due to detergent or BSA. 
3.2.9. Oxygen consumption measurement in isolated mitochondria 
3.2.9.1. Seahorse assay 
Laura Trovò (L.T.; Institute of Neuronal Cell Biology, TUM) performed oxygen consumption 
measurements in isolated mitochondria, which were isolated by myself (Figure 13 and 15) and 
by L.T. (Figure 36).  
Mitochondrial oxygen consumption rate (OCR) was measured in the assay solution MAS-1X 
using a Seahorse XFe96 Extracellular Flux Analyzer with typical mix (1 minute) and 
measurement cycle times (3 minutes).  CMF or immunocaptured mitochondria (Table 2) were 
added in a volume of 10 µl per well of a 96-well plate and centrifuged at 2,000 g, 4°C for                     
20 minutes to attach mitochondria. Substrate mixtures (Table 3) were added and the plate 
was equilibrated at 37°C.  
Table 2. Amounts of mitochondria per substrate and tissue origin. 
 Complex I Complex II Beta-oxidation 
Tissue Isolation μg CCCP (μM) μg CCCP (μM) μg CCCP (μM) 
Cortex CMF 2 10 2 10 - - 
IC 2 10 1 10 - - 
Cerebellum IC 3 7.5 2 7.5 8 3 
 
Table 3. Substrates and inhibitors used for testing mitochondrial respiration. 
 Complex I Complex II Beta-oxidation 
state 2 Substrates PyruvateMalate 
10 mM
2 mM
Succinate
Rotenone
10 mM
2 µM
L-Palmitoylcarnitine 
Malate 
50 μM
2 mM
state 3 ADP 4 mM 
state 4o Oligomycin 1.5 μM 
state 3u CCCP (see Table 2) 
non-mito 
OCR 
Antimycin A 
Rotenone 
4 μM 
2 μM 
Mitochondrial respiration was determined for complex I in the presence of pyruvate+malate, 
complex II with succinate+rotenone and beta-oxidation with L-palmitoylcarnitine+malate 
(Watkins et al., 1991; Demarquoy and Le Borgne, 2015). With a series of injection oxygen 
consumption was measured under basal conditions (state 2), after the addition of ADP                
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(state 3, ADP-uncoupled respiration), after oligomycin injection (state 4o, proton leak), with 
CCCP (state 3u, maximal respiration) and finally upon antimycin A and rotenone application 
to disrupt mitochondrial respiration (non-mitochondrial residual oxygen consumption).  
Per sample, eight technical replicates were run, of which at least three successful replicates 
were necessary for inclusion in the analysis. L.T. excluded measurements that showed no 
response to an injection and in which mitochondria had deattached during the assay. 
3.2.9.2. OCR analysis 
Analysis was performed with the Agilent Seahorse XFe96 Wave software and Microsoft Excel 
2016 by calculating coupling efficiency (CE), respiratory control ratio (RCR) and spare 
respiration capacity (SRC): 
CE= (   ) ; RCR= (   ) ; SRC=   . 
Prior to these calculations, all measurements were corrected for non-mitochondrial residual 
oxygen consumption by subtracting the OCR with antimycin A and rotenone (mean of the last 
four measurements). To illustrate OCR dynamics of individual experiments across substrates, 
I generated OCR graphs normalized to basal respiration values (mean of first five 
measurements) from representative experiments showing the mean of technical replicates 
with s.e.m. (for example see Figure 13b). 
3.2.10. Mitochondrial Ca2+ uptake assay 
Ca2+ uptake of immunocaptured mitochondria was performed as described in 
Wettmarshausen and Perocchi (2017) with the following modifications: I resuspended 50 μg 
mitochondria in respiration buffer (RB) supplemented with 100 nM CalciumGreen-5N and in 
the absence or presence of 10 µM Ru360. Fluorescence (ex.485/em.530) was measured via a 
microplate reader (CLARIOstar) in 2 seconds intervals for a total of 24 minutes with the 
injection of 20 µM CaCl2 in assay buffer every 3 minutes at 25°C. I used animals within the age 
range of 2 to 4 months. 
I calculated the Ca2+ uptake capacity as the differential area under the curve (ΔAUC) between 
the presence and absence of Mcu inhibitor Ru360. In Brief, the first CaCl2 injection was ignored 
due to residual EDTA from immunocapture. Traces were background corrected, normalized to 
the injection time point and AUC was calculated. Finally, the difference between AUC-Ru360 and 
AUC+Ru360 per sample (ΔAUC) is shown as percentage of AUC+Ru360. 
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3.2.11. Western blot analysis 
3.2.11.1. Sample preparation 
For western blot analysis, I first lysed material in RIPA buffer supplemented with protease 
inhibitor (cOMPLETe, EDTA-free) on ice for 30 minutes with frequent vortexing. Protein 
concentration was determined via BCA assay, samples were mixed with 1x LDS sample buffer 
supplemented with 50 mM DDT and boiled at 70°C for 10 minutes.  
3.2.11.2. Western blotting and detection 
Per sample 10 µg protein was used in the case of mitochondrial isolations and whole tissue 
comparison; 20 µg was used in the case of total cerebellum lysates to evaluate Rmdn3 
expression. Using SDS polyacrylamide gels (12% or 4-20%), samples were separated via 
electrophoresis with Tris-Glycine buffer and transferred on PVDF membrane (0.2 µm pore 
size) with TWOBIN buffer using the TurboBlot semi-dry system with the following settings:              
20 V max., 1.3 A, 12 minutes.  
After transfer, membranes were washed with water and air dried, followed by SyproRuby 
staining for total protein quantification according to the manufacturer’s instructions. 
SyproRuby signals were acquired using UV light on the Fusion FX7 machine. To remove total 
protein staining, membranes were incubated in 3% skim milk in TBSt at room temperature for 
30 minutes and blocked for further 30 minutes in fresh solution.  
Incubation with primary antibody was performed overnight under agitation at 4°C in 3% skim 
milk in TBSt using antibodies listed in Chapter 3.1.7.2. Membranes were washed three times 
in TBSt at room temperature under agitation for 10 minutes, followed by a 2 hours incubation 
with HRP-conjugated secondary antibody in 3% skim milk in TBSt under agitation at room 
temperature. After washing, membranes were incubated with ECL Prime according to the 
manufacturer’s instructions and signals were acquired using the Fusion FX7 machine. A second 
round of antibody probing was performed for antibodies from a different species. After 
extensive washing in TBSt with 0.8% sodium azide at room temperature, membranes were 
blocked again and incubated overnight with primary antibody. Cross-reactivity of antibodies 
from different species was excluded in prior experiments. 
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3.2.11.3. Analysis 
For quantification, samples were run as technical triplicates on one membrane and the mean 
was further used for graphs and statistics – with the exception of Figure 17, where sample 
amounts limited the analysis to one per experiment and Figure 37 and 38, where samples 
were run as duplicates. I used only non-saturated images and calculated relative dosimetry 
with Image Studio Lite software and Microsoft Excel 2016. Signals per lane were background 
subtracted, normalized with total protein signals (SyproRuby) and results expressed as fold 
change to a given sample on the same membrane. I further used mitochondrial content 
(evaluated by ATP5a, CypD, Tomm20) for normalization between different isolations. 
Uncropped western blots for all depicted blots in figures are shown in the Appendix 7.6. 
3.2.12. Mass spectrometry 
Stephan Müller (S.M.; Lichtenthaler laboratory, German Center for Neurodegenerative 
Diseases) prepared mass spectrometry samples, acquired them and performed the first 
analysis in MaxQuant and Microsoft Excel. 
3.2.12.1. Sample preparation 
I generated mass spectrometry samples from 8- to 9-week-old, male mice. Mitochondria were 
immunocaptured from cerebellum according to the described protocol (see Chapter 3.2.7.2) 
with the alteration that the final mitochondrial pellet was washed twice in IB without EDTA 
and BSA. S.M. lysed samples in 100 µL SDT lysis buffer by heating at 95°C for 5 minutes and 
ultrasonication (Vialtweeter: 6 times for 30 s, 100% Amplitude, 50% cycle, max. power). Debris 
and non-dissolved material was removed by centrifugation at 20,000 g for 10 minutes. Protein 
concentrations were estimated using the Pierce 660 nm Protein assay supplemented with the 
ionic detergent compatibility reagent with a dilution series of BSA in SDT buffer for calibration. 
An amount of 15 µg was subjected to protein digestion using the filter-aided sample 
preparation (FASP) with small modifications (Wisniewski et al., 2009). Briefly, 30 kDa Vivacon 
filters were used. The alkylation step was followed by incubation with 50 U benzonase in 50 
mM Tris HCl, pH 8 and 1 mM magnesium chloride. Afterwards, three washing steps with 100 
µl of 8M urea in 100 mM Tris HCl, pH 8 were implemented. Proteins were digested with 0.3 
µg of LysC for 16 h followed by 4 h incubation with 0.15 µg of trypsin. Peptides were eluted 
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into collection tubes and desalted using C18 stop-and-go extraction (Rappsilber et al., 2003). 
Samples were dried after elution by vacuum centrifugation. 
Whole cerebellum samples were lysed in RIPA buffer 2. Cell debris and undissolved material 
was removed by centrifugation at 16,000 g, 4°C for 10 minutes. A protein amount of 20 µg 
was further dilute 1:2 with water and 10 mM magnesium chloride was added. Afterwards,               
25 U benzonase were added and the DNA digestion was performed for 30 minutes at 37°C. 
Protein digestion was performed using FASP as described above without addition of 
benzonase. 
3.2.12.2. Data acquisition 
S.M. analyzed samples on an Easy nLC-1,000 nano UHPLC coupled online via a Nanospray Flex 
electrospray ion source equipped with a column oven to either a Q-Exactive or a Q-Exactive 
HF mass spectrometer. An amount of 1.3 µg peptides was separated on self-packed C18 
columns (300 µm × 75 µm, ReproSil-Pur 120 C18-AQ, 1.9 µm; Dr. Maisch) using a binary 
gradient of water (A) and acetonitrile (B) supplemented with 0.1% FA (0 minutes, 2% B;                        
5 minutes, 5% B; 185 minutes, 25% B; 230 minutes, 35% B; 250 minutes, 60% B). 
The dataset from Purkinje cell mitochondria was analyzed on a Q-Exactive mass spectrometer. 
Full mass spectrometry spectra were acquired at a resolution of 70,000 (AGC target: 3E+6). 
The ten most intense peptide ions were chosen for fragmentation by higher-energy collisional 
dissociation (resolution: 17.5 k, isolation width: 2 m/z, AGC target: 1E+5, NCE: 25%). A dynamic 
exclusion of 120 s was applied for fragment ion spectra acquisition.  
The datasets from cerebellum, granule cell mitochondria and astrocytic mitochondria were 
analyzed on a Q-Exactive HF mass spectrometer with slightly adjusted settings. For full mass 
spectrometry spectra, a resolution of 120,000 was applied. The 15 most intense ions were 
chosen for fragmentation (resolution: 15 k, isolation width: 1.6 m/z, AGC target: 1E+5, NCE: 
26%). 
3.2.12.3. Data analysis primary 
S.M. performed peptide identification, label-free quantification (LFQ) and intensity-based 
absolute quantification (iBAQ) of proteins in MaxQuant for each dataset separately (version 
1.5.4.1 for the Purkinje cell mitochondria dataset; 1.5.5.1 for the dataset from cerebellum, 
granule cell mitochondria and astrocytic mitochondria) using default settings (Cox et al., 
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2014). In brief, a canonical database of the reviewed reference mouse proteome (UniProt, 
2019; download: June 8th, 2016; 16,798 entries) was used for database search. The astrocytic 
mitochondria dataset from cerebellum was analyzed together with data from astrocytic 
mitochondria from cortex because both dataset (cerebellum and cortex) were generated in 
parallel from the same biological replicate. As increased sample numbers increase the number 
of peptide identifications, this part was done together – however, all further data analysis 
steps were exclusively performed on cerebellar mitochondria. The false discovery rate (FDR) 
for both peptides and proteins was adjusted to less than 1% using a target and decoy approach 
(concatenated forward/reverse database). The ‘match between runs’ option was enabled 
using a time window of 2 minutes. LFQ required at least two ratio counts of unique peptides. 
The data sets are available in the ProteomeXchange Consortium via the PRIDE partner 
repository (Vizcaino et al., 2016): mitochondria from Purkinje cells (PXD010772), mitochondria 
from granule cells (PXD010774) and mitochondria from astrocytes (PXD010781); whole 
cerebellum (PXD013380). 
3.2.12.4. Data analysis secondary 
I further analyzed and compared protein intensities in Perseus (Tyanova et al., 2016; Cox and 
Mann, 2012). The bioinformatics analysis is depicted in Figure 8. First protein IDs from the 
three mass spectrometry experiments were merged against the reviewed reference mouse 
proteome including annotation from MitoCarta (Calvo et al., 2016) and LocTree3 (Goldberg et 
al., 2014) for subcellular localization. Only proteins with at least two unique peptides were 
further considered for relative quantification. Protein LFQ intensities were log2 transformed. 
Second, for relative quantification, the protein log2 LFQ ratios were calculated by subtracting 
the log2 value of IC Tom from IC GFP separately for each biological replicate. Next, proteins 
which were relatively quantified in less than three biological replicates, were removed, leading 
to a group of 3,130 protein which were consistently quantified in all three datasets from 
Purkinje cells, granule cells and astrocytes. Finally, the log2 fold change of each protein 
between cell types (comparisons: PC/GC, PC/A and GC/A) was analyzed by a two-sided, 
unpaired t-test (with ≥3 biological replicates, randomizations: 500, permutation-based 
FDR≤0.05). Proteins with log2 fold changes that passed the permutation-based FDR criterion 
are marked as blue, filled circles (see Figure 23a). The scatter plot summarizing changes in 
PC/A vs GC/A is depicted in Figure 23b by showing proteins that passed the FDR criterion in at 
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Figure 8│ Flow chart depicting secondary analysis of mass spectrometry data comparing 
mitochondrial proteomes from Purkinje cells, granule cells and astrocytes. IC, immunocapture; 
LFQ, label free quantification; FC, fold change. Modified from Fecher et al. (2019), Supplementary 
Figure 6. 
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least one of the two t-tests. In the text, mass spectrometry statistics are called out as, e.g. for 
Cox4i1, two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: *0.554, 
0.0268; GC vs A: *0.496, 0.0002; PC vs GC: 0.058, 0.9085. (*) indicates a significant result with 
the first following value being the fold change and the second value the permutation-adjusted 
q-value for multiple comparison. 
From the pairwise t-tests between cell types, proteins were considered as changed, if their 
log2 fold change ≥│1│. Thus, they were further analyzed for their enrichment in a specific cell 
type by using the online Venn diagram tool (http://bioinformatics.psb.ugent.be/ 
webtools/Venn/). Here, 18, 51 and 114 proteins were identified to be enriched in Purkinje 
cells, granule cells and astrocytes, respectively (Figure 24a); using the following definitions for 
cell type-specificity:  
Table 4. Criteria for cell type enrichment. 
PC-enriched 
FC≥1 in PC/A 
combination A (FC≥1 in PC/A & PC/GC) 
combination B (FC≥1 in PC/GC only) 
GC-enriched 
FC≥1 in GC/A 
combination A (FC≤-1 in PC/A & PC/GC, FC≥1 in GC/A) 
combination B (FC≥1 in GC/A, FC≤-1 in PC/GC) 
combination C (FC≤-1 in PC/GC only) 
A-enriched FC ≤ -1 in PC/A and/or GC/A 
I color-coded these groups in the scatter plot in Figure 24 comparing PC/A vs GC/A. 
For Over-Representation Analysis (ORA) of the ‘biological process’ category of gene ontology 
processes (GOTerm; Figure 31b, top) and KEGG pathways (Figure 31b, bottom), the WEB-
based GEne SeT AnaLysis Toolkit (WebGestalt 2019; Liao et al., 2019) I used with the following 
data sets:  
− reference set: genome_protein-coding, mmusculus as background (n=27,331);  
− candidates enriched in astrocytes (n=114); 
− candidates enriched in neurons (GC-enriched, PC-enriched, GC & PC-enriched; n=74).  
Standard parameters for the enrichment analysis were used with the following settings: 
Minimum number of Entrez Gene IDs in the category: 5; Maximum number of Entrez Gene IDs 
in the category: 2,000; FDR Method: BH (Multiple Test Adjustment); Significance Level: 
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FDR≤0.05. In Appendix 7.4, the full results are documented, whereas in Figure 31b the top 10 
hits per category are listed for KEGG and the clustered gene sets for GOTerms. 
For heat map generation of mitochondrial functions, the following KEGG and GOTerm 
annotations (AmiGO version 2.5; Ashburner et al., 2000; The Gene Ontology, 2019) were used: 
Table 5. Annotation list for core mitochondrial functions. 
Beta-oxidation mmu00071, fatty acid degradation;
Adeva-Andany et al. (2019); Pei et al. (2003); Iacobazzi et al. (2004); He et al. (2011) 
mtRibosome GO:0005762, mitochondrial large ribosomal subunit;
GO:0005763, mitochondrial small ribosomal subunit 
Complex I GO:0005747, mitochondrial respiratory chain complex I
Complex II GO:0005749, mitochondrial respiratory chain complex II, succinate dehydrogenase 
complex (ubiquinone) 
Complex III GO:0005750, mitochondrial respiratory chain complex III
Complex IV GO:0005751, mitochondrial respiratory chain complex IV
Complex V GO:0000276, mitochondrial proton-transporting ATP synthase complex, coupling 
factor F(o); 
GO:0005753, mitochondrial proton-transporting ATP synthase complex 
CoQ synthesis Acosta et al. (2016)
TCA cycle GO:0006099, tricarboxylic acid cycle
The lists were further curated for mitochondrial annotation of proteins and additional 
information provided on the UniProt profile (update: October 16th, 2019, UniProt, 2019) and 
from previous reports. 
Enrichment of mitochondrial protein abundance was calculated based on iBAQ values (Shin et 
al., 2013). First, I calculated the average log 𝑖𝐵𝐴𝑄 value per protein per group of biological 
replicates for immunocaptures (IC Tom, IC GFP). Second, I generated the average over all 
proteins annotated as mitochondrial as well as non-mitochondrial based on MitoCarta               
(Calvo et al., 2016) and LocTree3 (Goldberg et al., 2014) annotations. Finally, the difference 
between these two groups was transformed to fold change (linear). Similar calculations were 
performed on the proteomics datasets from whole cerebellum and the reference dataset of 
Percoll purified mitochondria from Pagliarini et al. (2008). 
To compare the immunocapture approach to recent studies, I generated Venn diagrams with 
the online Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn/) 
comparing IC Tom from cerebellum to the proteomic dataset from cerebellar mitochondria 
published by Pagliarini et al. (2008), from whole cerebellum published by Sharma et al. (2015) 
and MitoCarta (Figure 20). For this comparison, proteins found in ≥9 biological replicates of                   
IC Tom were considered. 
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3.2.13. Fluorescence cytometry 
After mitochondrial isolation (see Chapter 3.2.7.1), I resuspended the crude mitochondrial 
fraction (CMF) of 20 mg cortex samples in 100 µl 4% paraformaldehyde in PBS and incubated 
it in the dark at room temperature for 5 minutes. Samples were washed three times with PBS 
and resuspended in 100 µl 0.5% BSA in PBS. 20 µl fixed mitochondria were used per staining. 
First, I washed the sample with 0.5% BSA in PBS. Then the sample was incubated with                    
APC-conjugated mouse IgG1 or mouse Tom22 (1:25) in the dark, at 4°C, 60 rpm for 60 minutes. 
Samples were washed three times with 0.5% BSA in PBS and finally resuspended in 100 µl PBS. 
For flow cytometry, Sylvia Heink (Experimental Neuroimmunology, Klinikum rechts der Isar, 
TUM) acquired samples on a CyAn ADP 9 flow cytometer (equipped with 405 nm, 488 nm and 
642 nm lasers) and was consulted for analysis. We diluted sampled 1:20 with PBS. To allow for 
optimal identification and separation of small particles, the flow rate was adjusted accordingly 
and optical parameters (forward scatter, FSC, and sideward scatter, SSC) were scaled 
Figure 9│ Gating strategy to quantify cell type-specific mitochondria in Cre+/GFP-OMM mouse 
lines. Crude mitochondria from cortex of Emx1:Cre−/GFP-OMM and Emx1:Cre+/GFP-OMM mice 
were labeled with Tom22-APC or IgG1-APC. (a) First gating step: forward and sideward scatter, and 
pulse width of wild type mitochondria. (b) Zebra plots and histograms of FITC and APC intensity 
shown for wild type mitochondria with IgG1-APC and Tom22-APC, as well as for Emx1:Cre+/GFP-
OMM mitochondria. Taken from Fecher et al. (2019), Supplementary Figure 4. 
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logarithmically. Based on light-scattering properties (FSC-log vs SSC-log), 100,000 events were 
acquired per sample. 
Using FlowJo software, I gated mitochondria by FSC and SSC, as well as pulse width to 
discriminate doublets. Then Tom22-APC staining (APC, Em. 665/20) intensities were manually 
gated against mouse IgG1-APC control samples to define mitochondria. From this, individual 
gates for GFP-OMM (FITC, Em. 530/40) and mito-RFP (PE, Em. 575/25) were gated according 
the wild type mitochondria (Figure 9). In Figures, the histogram of the samples closest to mean 
is shown with IgG1 control (gray histogram) as well as the mean±s.e.m. of n≥4 biological 
replicates. 
3.2.14. Immunofluorescence staining 
Mice were killed with isoflurane and transcardially perfused first with heparin (19.5 U/ml) in 
PBS followed by 4% paraformaldehyde in PBS. Tissues were kept in 4% paraformaldehyde in 
PBS at 4 °C overnight. Similarly, fixation of rat and zebra finch tissue was performed, while 
tissue from embryonal day 19 chicken and Cuban tree frog were fixed by immersion fixation 
in 4% paraformaldehyde in PBS at 4°C overnight. All tissues were subsequently cut using a 
vibratome. Tissue from rat, zebra finch, chicken and Cuban tree frog were kindly provided by 
Grass Fellows, Marine Biological Laboratory, Woods Hole 2019. 
3.2.14.1. Mitochondrial markers in mouse tissue 
If not mentioned differently, I performed all steps at room temperature under agitation (100 
rpm). First, I tested antibodies against candidates with a series of antigen retrieval conditions 
including Triton X100 and different heat-induced antigen retrieval buffer (HIER 1-7; Figure 10). 
From this test, the best condition was further used for experiments. Depending on epitope, 
tissue sections were permeabilized with different conditions (Table 6), extensively washed and 
blocked using blocking solution for one hour. For primary antibodies produced in mouse, 
sections were incubated with goat anti-mouse Fab fragments (1:100 in PBS) for one hour. 
Incubation with primary antibody (see Chapter 3.1.7.1) was performed in 10% blocking 
solution in PBS at 4°C overnight. After extensive washing, secondary antibodies were applied 
in 10% blocking solution in PBS for two hours. Tissue section were further stained with 
Hoechst (Hoechst 33342; 100 μg/ml in PBS) for 10 minutes and mounted using Vectashield 
Mounting medium. 
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Table 6. Details for immunofluorescence staining of mitochondrial markers in 
mouse tissue. Modified from Fecher et al. (2019), Supplementary Table 1. 
Epitope # Species Dilution Treatment 
Acads ab156571 Rabbit 1:200 Tris pH 10 
Ak3 sc-398571 Mouse IgG1 1:100 Tris-EDTA pH 9 
Ak4 sc-271161 Mouse IgG1 1:100 Tris-EDTA pH 9 
Catalase 100-4151 Rabbit serum 1:200 Tris pH 10 
Cox4i1 AP22111a Rabbit 1:200 Citrate-EDTA pH 6.2 
Cpt1a 15184-1-AP Rabbit 1:200 Tris-EDTA pH 9 
Figure 10│ Detection of candidates via heat-induced antigen retrieval. Sagittal cerebellum 
sections (50 μm) from Gfap:Cre+/GFP-OMM mice were pretreated with 0.1% Triton X100 
and subsequent treated with PBS at room temperature (no HIER) or different buffers at 
90°C for 30 minutes (HIER 1-7). (a) Tissue morphology after heat-induced antigen retrieval. 
Note that some conditions partially clear the tissue und lead to expansion. Scale bar:   
2 mm. (b) Following blocking, immunofluorescence staining against GFP (green, 1:1000) 
and Cpt1a (magenta, 1:200) was performed. While with ‘no HIER’ I observed nuclear 
localization of Cpt1a as previously reported (Mazzarelli et al., 2007), HIER5 and HIER7 
performed best with low background and mitochondrial localization of Cpt1a. Scale bars: 
20 μm (detail 10 μm). 
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Epitope # Species Dilution Treatment 
Gldc HPA002318 Rabbit 1:400 Tris pH 10 
Gls 20170-1-AP Rabbit 1:200 Tris-EDTA pH 9 
Gls2 AP6650D Rabbit 1:400 Tris-EDTA pH 9 
Got2 ab171739 Rabbit 1:400 Tris pH 10 
Ldhd ab182146 Rabbit 1:100 Tris pH 10 
MaoB sc-515354 Mouse IgG1 1:100 Tris pH 10 
Mavs #4983 Rabbit 1:200 EDTA pH 8 
Mcu HPA016480 Rabbit 1:400 EDTA pH 8 
Nipsnap1 #13226 Rabbit 1:200 Tris-EDTA pH 9 
Ociad2 HPA040979 Rabbit 1:200 Tris-EDTA pH 9 
Ociad2 ab91576 Rabbit 1:200 Tris-EDTA pH 9 
Pex14 - Rabbit 1:1,000 0.2% Tx100/PBS 
Pptc7 ab122548 Rabbit 1:200 TBS pH 9 
Rmdn3 ab189845 Rabbit 1:400 Tris-EDTA pH 9 
Sfxn5 ab172971 Rabbit 1:500 0.2% Tx100/PBS 
Slc25a20 19363-1-AP Rabbit 1:400 Tris-EDTA pH 9 
Snph 1-100 ab192605 Rabbit 1:400 Tris pH 10 
Snph 225-428 - Rabbit 1:400 Tris pH 10 
Tst ab166625 Rabbit 1:500 0.2% Tx100/PBS 
 
3.2.14.2. Mitochondrial markers in human tissue 
Human sample were provided by Doron Merkler (Department of Pathology and Immunology, 
University of Geneva, Switzerland) and Ingrid Wagner (I.W.; Department of Pathology and 
Immunology, University of Geneva, Switzerland) performed immunofluorescence staining in 
human tissue with assistance from me regarding antibody dilutions. I performed acquisition 
of the samples at the Institute of Neuronal Cell Biology, Munich. 
For human tissue sections (4 μm thickness), the following changes for immunohistochemical 
staining were applied (see Table 7 for details): after de-paraffination, I.W. performed heat-
induced antigen-retrieval on paraformaldehyde fixed tissue. Following blocking with 10% FCS 
in PBS, sections were incubated with primary antibodies in Dako Diluent (Dako) at 4°C 
overnight. After extensive washing with Wash Buffer (Dako) and autofluorescence removal 
treatment (Merck), secondary antibodies and DAPI (1:2,000) were diluted in PBS and 
incubated at room temperature for one hour. Slides were cover slipped with Fluoromount 
Mounting Medium.  
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For sections requiring Tyramide Signal Amplification (TSA), endogenous peroxidase blockade 
with Dako REAL Peroxidase-Blocking solution was performed prior to addition of 10% FCS in 
PBS. Following primary antibodies incubation, slides were incubated with anti-rabbit HRP at 
room temperature for 30 minutes, followed by incubation with TSA (FP1170, Perkin Elmer) at 
room temperature for 10 minutes as a secondary system. Autofluorescence removal 
treatment was performed prior to DAPI staining.  
Table 7. Details for immunofluorescence staining of mitochondrial markers in 
human tissue. Taken from Fecher et al. (2019), Supplementary Table 2. 
Epitope # Species Dilution Treatment Detection 
Amyloid β (8-17) M0872 Mouse 1:100 
Tris-EDTA 
pH 9 
Alexa Fluor 
Cox4i1 Ap22111a Rabbit 1:200 HRP/TSA 
Cpt1a 15184-1-AP Rabbit 1:50 Alexa Fluor 
Gfap ab4674 Rabbit 1:2,000 Alexa Fluor 
Got2 ab171739 Rabbit 1:2,000 Alexa Fluor 
Mcu HPA016480 Rabbit 1:200 HRP/TSA 
NeuN-AF 488 ab190195 Rabbit 1:50 - 
NeuN MAB377 Mouse 1:100 Alexa Fluor 
Nipsnap1 #13226 Rabbit 1:200 Alexa Fluor 
Ociad2 HPA040979 Rabbit 1:500 HRP/TSA 
Rmdn3 ab189845 Rabbit 1:2,000 Alexa Fluor 
Sfxn5 ab172971 Rabbit 1:2,000 Alexa Fluor 
 
Use of human samples was in accordance with institutional ethical guidelines and approved 
by the ethics committee of the University of Geneva (Switzerland). Written informed consent 
to use autopsy samples for research purposes were obtained for all samples with exceptions 
for autopsies that were performed more than 20 years ago. In all cases, no samples were used 
from patients that refused for being involved in research projects. Patient information are 
listed in Appendix 7.5. The data from human cerebellum is representative for one experiment; 
data from human cortex and spinal cord is representative for one experiment performed on 
at least three different cases. 
3.2.14.3. Double labeling of mitochondrial markers via Zenon IgG kit 
To perform double labeling of mitochondrial markers with antibodies raised in the same 
species, I used the Zenon™ Alexa Fluor™ 647 Rabbit IgG Labeling kit according to the 
manufacturer’s instructions. Briefly, 1 µg rabbit anti-Sfxn5 antibody was linked to 10 µl 
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component A and incubated for 5 minutes at room temperature. I added 10 µl of component 
B and waited further 10 minutes. After incubation of secondary antibody and extensive 
washing, sections were incubated with Zenon complex and Hoechst for two hours. The 
sections were washed three times with PBS for 5 minutes. Importantly, to stabilize staining 
for longer storage, I further incubated sections with 1:100 Acryloyl-X SE in PBS at 4°C for four 
hours and mounted them using Vectashield Mounting medium. 
3.2.14.4. Amyloid-β plaques and Aβ deposition 
To visualize amyloid-β plaques and Aβ deposition in APP23/PS45 animals, I used the Hoechst 
which superiorly detected the amyloid-β plaque– a feature previously reported for AD mouse 
models by Uchida and Takahashi (2008). I further confirmed Aβ detection using the antibody 
clones 4G8 and 6E10 conjugated to Alexa Fluor-647, which however penetrated less well in 
our staining conditions. For human tissue, I.W. used the amyloid-β (8-17) antibody (clone 
6F/3D). 
3.2.15. Confocal microscopy 
We scanned tissue sections either on an upright FV1000 confocal microscopy system 
(Olympus) equipped with 4x/0.28, 10x/0.4, 20xO/0.85, 40xO/1.35 and 60xO/1.42 objectives 
or on an inverted FV3000 confocal microscopy system (Olympus) equipped with 4x/0.16, 
20x/0.75 and 40x/0.95 objectives. Images were acquired using standard filter sets and 
intensity projections were generated using the open source software ImageJ/Fiji (Schindelin 
et al., 2012) and Adobe Photoshop. 
3.2.16. Image processing and representation 
For figure representation, we combined different channels of confocal image series in pseudo-
color using the ‘screen’ function in Adobe Photoshop. We equally adjusted contrast and 
brightness in the entire image. In Appendix 7.3, I acquired immunofluorescence staining on 
Cre− tissue and control (omission of primary antibody) with the same settings and adjusted 
images with the same processing parameters. In non-quantitative panels, I adjusted gamma 
non-linearly to enhance visibility of low-intensity objects. We assembled figures in Adobe 
Illustrator. 
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3.2.17. Protein retention expansion microscopy 
I performed expansion microscopy on mouse cortical tissue sections as previously described 
(Tillberg et al., 2016). In brief, the cerebrum of Emx1:Cre+/GFP-OMMxThy1:mito-RFP mice was 
fixed using 4% paraformaldehyde in PBS and sectioned in 100 µm thick, sagittal section using 
a vibratome. To enhance GFP-OMM signals, sections were stained against GFP as described 
before using 0.2% Triton X100 in PBS for permeabilization. Next, samples were cross-linked 
with 1:100 Acryloyl-X SE in PBS at 4°C for 6 hours and gelled with freshly prepared monomer 
solution at 37°C. Next, samples were digested with proteinase K (8 U/ml) in Digestion buffer 
at 37°C overnight. For expansion, I first incubated digested samples in PBS, then in distilled 
water. An expansion factor of ∼2-3 fold was estimated from the sample. Data in Figure 11e is 
representative for n=2 independent experiments. 
3.2.18. Electron microscopy 
3.2.18.1. Sample preparation 
Nicolas Snaidero (N.S.; Institute of Neuronal Cell Biology, TUM) and I performed sample 
preparation for electron microscopy. N.S. further cut samples, contrasted them and acquired 
images. I performed data analysis as blinded investigator. 
Isolated mitochondria (as CMF or IC) were incubated in electron microscopy (EM) fixative for 
10 minutes before being centrifuged and after supernatant removal, resuspended in 2% low 
melting point agarose. The agarose mitochondria pellets were then embedded for electron 
microscopy using 2% OsO4 for four hours followed by ethanol/acetone dehydration and Epon 
embedding.  
To analyze mitochondrial morphology in cerebellar cells in situ, I perfused 2- to 3-month-old 
animals with 5 mL HBSS with heparin (19.5 U/ml), followed by 30 mL EM fixative. The brain 
was extracted and further post-fixed in EM fixative at 4°C for 8 hours. N.S. dissected cerebella 
and sectioned them in thin slices, below 1 mm. Sections were further dissected in piece of two 
to three lobes and post-fixed with 2% OsO4 and 1.5% ferrocyanide, dehydrated by 
ethanol/acetone and Epon embedded. Epon blocks were further trimmed and 50 nm thick 
sections (Leica UltraCut2) were obtained from the thickest part of the sample. The section 
were post stained with 4% uranyl acetate for 30 minutes followed by lead citrate for                          
5 minutes.  
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3.2.18.2. Data acquisition 
For isolated mitochondria, N.S. acquired images approximately 20-50 µm away from the pellet 
edge with a JEM-1400 Transmission Electron Microscope using 20,000x magnification. 
Quantification for mitochondria morphology in cerebellum was done at 6,000x – 20,000x 
magnification.  
3.2.18.3. Analysis 
For data analysis, I was blinded for the genetic background of samples. The open source 
software ImageJ/Fiji (Schindelin et al., 2012) was used to define total mitochondrial perimeter 
and percent mitochondrial perimeter in ≤30 nm distance to the endoplasmic reticulum (ER). 
Contact frequency in percent is shown as box plot over cell numbers and over mitochondria 
per genetic background. In the case of granule cells, a larger number of cells had to be 
analyzed due to cellular morphology (see Figure 39b). Granule cell perikarya are densely 
packed in the granule cell layer with a small region of cytoplasm around the nucleus giving 
space to only 1-4 mitochondria per 50 nm section. Therefore, statistical analysis was 
performed on mitochondria as unit (see Figure 39c). For orientation, I color-coded electron 
micrographs in figures for organelle content: mitochondria, magenta; ER, light orange; contact 
sites, red. 
3.2.19. Statistics 
All data sets are shown as box plots consisting of median, box spanning quartile 1 to 3                         
(Q1-Q3) and whiskers to the maximum and minimum (max./min. value) as well as the 
underlying individual values. To see overlapping data points, individual points have an opacity 
of 30% (EM data: 10%). Values used throughout the text represent mean±s.e.m. and if used 
in Figures, are defined in the figure legend. Within the text, mass spectrometry data is 
represented as: “[…] two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: 
*FC, q-value […]”and statistical significance of P ≤0.05 indicated with (*). 
We tested data distribution for normality using the Shapiro-Wilk normality test to determine 
statistical tests. Exclusion of data points was only performed in oxygen consumption 
measurements for technical replicates, in which one of the multiple injections failed during 
the experiment; no other data points were excluded. The statistical details for each 
experiments can be found in the figure legend and further information (sample size, n of 
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independent experiments, testing and P values) is provided in Appendix 7.7.                          
A P ≤0.05 was considered statistically significant and indicated by (*); P ≤0.01 (**);                          
P ≤0.001 (***). I performed statistical analyses using Microsoft Excel 2016 and GraphPad 
Prism software. No statistical methods were used to pre-determine sample sizes but the 
chosen sample sizes are similar to those reported in previous publications (e.g. Brill et al. 
(2016), Baughman et al. (2011), Pagliarini et al. (2008)). Samples were not randomized during 
data collection and animals assigned to experimental groups according to genotype. 
Randomization was not possible due to constraints in animal availability, and determination 
of experiment by given genotype. Data collection and analysis were performed blinded to the 
conditions in the following experiments: Figure 13b, 15b, 39c and 40c. In all other 
experiments, the experimenters were not blinded. 
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Chapter 4: Results 
The experiments and conclusions of this section have been published as Fecher et al. (2019) 
in Nature Neuroscience and parts of this article were prior published as a preprint (Fecher et 
al., 2018). Similarities might arise to these manuscripts that are authored by Laura Trovò (L.T.), 
Thomas Misgeld (T.M.) and myself. In this chapter, content stated with ‘I’ reflects my own 
opinion and work, while statements with ‘We’ reflect the collaborative work product of the 
article Fecher et al. (2019) by L.T., T.M., myself and our collaborators. 
4.1. Validation of the MitoTag mouse model 
Recently the isolation and profiling of subcellular structures, such as ribosomes (Heiman et al., 
2008; Doyle et al., 2008), mitochondria (Chen et al., 2016), nuclei (Roh et al., 2017) and 
lysosomes (Abu-Remaileh et al., 2017) enabled the analysis of compartmentalized 
transcriptomes, proteomes and metabolomes, as well as the cell type-specific analysis of 
transcriptomes and epigenomes (see Chapter 1.5). For example, the RiboTag mouse has 
provided us with a cell type-specific, in vivo tool to characterization actively translated mRNA 
from polysomes (Sanz et al., 2009); however, such an approach remained unavailable for 
mitochondria. We therefore generated in analogy MitoTag mice to enable cell type-defined 
mitochondrial research by probing functional organelles from their in situ context. 
4.1.1. MitoTag mice enable tagging of cell type-specific mitochondria in vivo 
In collaboration with Wolfgang Wurst’s laboratory (Oskar Ortiz and Ralf Kühn; Institute of 
Developmental Genetics, Helmholtz Zentrum München), Rosa26 knock-in mice were 
generated that harbor an expression cassette generated by Laura Trovò (Institute of Neuronal 
Cell Biology, TUM). This cassette (Figure 11a) contains a ubiquitous promoter – CAG – followed 
by a ‘stop’ sequence flanked with loxP sites and GFP localized to the outer mitochondrial 
membrane (GFP-OMM). We named this mouse line ‘MitoTag’ in the style of RiboTag mice and 
I crossed them to a variety of Cre-recombinase (Cre) diver lines to test faithful, cell type-
specific expression. While I observed no GFP-OMM expression in ‘stopped’ mice (Figure 11b), 
robust GFP-OMM signals were detected in a cell type- and cell lineage-specific manner with a 
number of Cre lines (see Appendix 7.1).  
For example, using the empty spiracles homeobox 1 gene promoter – Emx1-IRES-Cre line 
(Emx1:Cre; Gorski et al., 2002) – GFP-OMM tagged mitochondria are present in olfactory bulb,  
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Figure 11│ MitoTag mice enable the cell type-specific expression of outer mitochondrial 
membrane targeted GFP (see next page for legend). 
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neocortex and hippocampus, as well as in the corticospinal tract (Figure 11c). As described by 
Gorski et al. (2002), DNA recombination at loxP sites takes place in astrocytes and excitatory 
neurons. I further confirmed mitochondrial localization of GFP-OMM in Emx1:Cre+/GFP-OMM 
cortex by immunofluorescence staining of the endogenous protein cytochrome c oxidase 
subunit 4 isoform 1 (Cox4i1; Figure 11d). This nuclear encoded protein is localized to the 
mitochondrial inner membrane, where it contributes to cytochrome c oxidase of the electron 
transport chain. Using confocal microscopy, I detected substantial overlap of Cox4i1 with GFP-
OMM. Interestingly, in some cases GFP-OMM signals enclosed Cox4i1 puncta as one would 
predict from their localization in outer and inner mitochondrial membrane. However, due to 
the diffraction limit of light, confocal microscopy cannot resolve objects below a XY resolution 
of 180 – 250 nm (Schermelleh et al., 2010). I therefore used expansion microscopy, a super-
resolution microscopy technique, to further address GFP-OMM localization in mitochondria. 
In expansion microscopy, proteins are cross-linked to an expandable matrix. Upon trypsin 
digestion of the tissue, the matrix isotropically expands in water creating a magnified version 
of the specimen. Trypsin cleaves peptides after lysine and arginine; however, beta barrel 
structures – as present in fluorescence proteins – are protected from cleavage and therefore 
can be imaged after digest. I compared GFP-OMM localization to a mitochondrial matrix 
localized red fluorescent protein (mito-RFP) in mouse cortex. For this, Emx1:Cre+/GFP-OMM 
mice were crossed to Thy1:mito-RFP mice, in which the majority of neurons express the 
transgene (Breckwoldt et al., 2014). Hence, I observed the presence of both transgenes in 
most excitatory neurons in cortex.  I confirmed spatial separation of the transgenes using 
expansion microscopy with GFP-OMM surrounding bright mito-RFP signals (Figure 11e). 
Figure 11│ MitoTag mice enable the cell type-specific expression of outer mitochondrial membrane 
targeted GFP. (a) Genetic Rosa26 locus describing the expression cassette of MitoTag mice. Upon 
Cre recombinase mediated excision of the loxP site flanked ‘stop’ element, GFP-OMM is expressed. 
e1/e2, exon 1 and 2; P, promoter. (b) In Cre−/GFP-OMM no GFP fluorescence is detected. Shown is 
mouse cortex with layer I to VI and CA1 region of the hippocampus. Nuc, nuclear counter stain. 
Scale bar: 100 μm. (c) In Emx1:Cre+/GFP-OMM, GFP-OMM signals are observed in cortex and 
hippocampus (same orientation as in b), and in corticospinal projections of the spinal cord (detail). 
Scale bars: 100 μm (cortex/hippocampus orientation); 1 mm (brain overview); 50 μm (cortex, spinal 
cord detail); 500 μm (spinal cord). (d) Confocal image of Emx1:Cre+/GFP-OMM cortex 
immunostained for Cox4i1 and GFP. Scale bar: 5 μm. (e) Confocal image after expansion microscopy 
of Emx1:Cre+/GFP-OMMxThy1:mito-RFP cortex. GFP signals were enhanced with anti-GFP staining 
prior to digestion. Expansion is estimated to be 2-3 fold. Scale bar: 5 μm. Modified from Fecher et 
al. (2019), Figure 1 and Supplementary Figure 1. 
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4.1.2. GFP-OMM expression does not alter mitochondrial or cellular physiology 
Because GFP-OMM is an artificially introduced protein, we asked if its presence in the outer 
mitochondrial membrane interferes with mitochondrial or cellular health. The Misgeld 
laboratory has generated a number of transgenic mouse lines, which express mitochondrial 
targeted fluorescent proteins or biosensors in neurons via elements of the Thy1.2 promoter 
(Vidal et al., 1990; Caroni, 1997). For the validation of these lines, neuronal and mitochondrial 
health is regularly analyzed in motor neurons, and axonal transport rates have been proven 
to be sensitive measurements for transgene effects (Misgeld et al., 2007; Marinkovic et al., 
2012; Breckwoldt et al., 2014). For this assay, we crossed ChAT:Cre+/GFP-OMM mice with the 
Thy1:mito-RFP line to avoid phototoxicity during widefield imaging, because I observed 
weaker GFP signals with the OMM localization than with a matrix localized GFP 
(ChAT:Cre+/mito-GFP). Laura Trovò (L.T.; Institute of Neuronal Cell Biology, TUM) performed 
time-lapse, widefield imaging of mitochondrial transport in a nerve-muscle explants of the 
thin triangularis sterni muscle, which is localized at the thorax inside. Once the thorax is 
flattened and kept in physiological state, superficial axons of the intercostal nerve are 
accessible. L.T. quantified normal mitochondrial transport rates of 4.2±0.3 vs 4.1±0.2 
organelles per minute in anterograde direction and 2.5±0.3 vs 2.9±0.2 organelles per minute 
in retrograde direction (mean±s.e.m.; ChAT:Cre− vs ChAT:Cre+; Figure 12a). Statistical testing 
indicated no difference between groups. From these images, L.T. determined the length and 
width of mitochondria with no statistical difference between groups (length: 23.0±0.7 vs 
22.4±0.6 μm; width: 3.3±0.1 vs 3.2±0.05 μm; Figure 12b). Next, L.T. analyzed synaptic size and 
receptor density at the neuromuscular junction (NMJ; Figure 12c). α-bungarotoxin binds to 
the nicotinic acetylcholine receptor (AChR) at the postsynaptic site of the NMJ and is used to 
define NMJ area and receptor density. Again, neither synapse size nor AChR density were 
changed between groups (size: 396±16 vs 418±16 μm2; receptor density: 937±37 vs 883±52 
AU; Figure 12d). This indicated that GFP-OMM expression in motor neurons is not interfering 
with mitochondrial function and synaptic physiology as tested by our assays. However, we 
further questioned whether other neural cells might handle transgene expression differently. 
We therefore tested a basic mitochondrial function – oxidative phosphorylation – in 
Emx1:Cre+/GFP-OMM mice. For this experiment, I isolated mitochondria from cortex of 
Emx1:Cre−/GFP-OMM and Emx1:Cre+/GFP-OMM mice via differential centrifugation   and  
obtained   the  crude  mitochondrial   fraction  (CMF;  Figure  13a).  These  
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Figure 12│ Axonal transport, 
mitochondrial shape and NMJ area are 
normal in ChAT:Cre+/GFP-OMM mice. (a) 
Antero- and retrograde mitochondrial 
transport quantified in the intercostal 
nerve of the triangularis sterni muscle. 
Mitochondria are time-lapse imaged via 
Thy1:mito-RFP in ChAT:Cre−/GFP-OMM 
or ChAT:Cre+/ GFP-OMM mice using an 
ex vivo nerve-muscle explant. n≥29 
axons from five mice. (b) Mitochondrial 
length and width quantified from data 
generated in a. n≥170 mitochondria 
from five mice. (c) Confocal image of 
ChAT:Cre+/GFP-OMM triangularis sterni 
muscle immunostained for neuron-
specific tubulin βIII (red) and for the 
acetylcholine receptor (AChR) via    
α-bungarotoxin (blue). Muscle signals 
are background from AChR channel and 
reduced in detail by gamma adjustment. 
Scale bars: 10 μm. (d) Quantification of 
NMJ size and AChR density via    
α-bungarotoxin staining from samples    
in a. n≥83 for NMJ size; n≥54 for AChR 
density from five mice. Box plot: median, 
quartile 1-3 and whisker from min./max. 
value, and individual data points;    
P values from statistical testing are 
shown. Modified from Fecher et al. 
(2019), Supplementary Figure 2. 
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mitochondrial preparations were further tested in oxygen consumption assays by L.T. in 
collaboration with Fabiana Perocchi’s laboratory (Gene Center, LMU). Mitochondria respired 
normal under either pyruvate+malate (complex I; Figure 13b) or succinate+rotenone (complex 
II; Figure 13c). Interestingly, under pyruvate+malate ADP-stimulated oxygen consumption 
Figure 13│ Mitochondrial respiration is normal in GFP-OMM tagged mitochondria from cortex.   
(a) Isolation of mitochondria via differential centrifugation from the cortex of Emx1:Cre−/GFP-
OMM and Emx1:Cre+/GFP-OMM mice. CMF, crude mitochondrial fraction. (b, c) Oxygen 
consumption rate (OCR) as percentage of basal respiration with indicated injections, and 
calculated parameters: coupling efficiency (CE), respiratory control ratio (RCR) and spare 
respiratory capacity (SRC). Left side: representative data from one experiment; right side: n=5 mice 
from three independent experiments. Mitochondrial respiration was probed using (b) 
pyruvate+malate (complex I) and (c) succinate+rotenone (complex II) as substrates. Line graph: 
mean±s.e.m.; box plot: median, quartile 1-3, whisker from min./max. value, and individual data 
points; P values from statistical testing are shown. Modified from Fecher et al. (2019), 
Supplementary Figure 2. 
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rates (state 3) approximately doubled compared with state 3 under succinate+rotenone, while 
uncoupled respirations rates (state 3u) were comparable (Figure 13b and 13c – left side, OCR 
line graphs normalized to basal respiration). These differences can be explained by a 
differential net proton force pumped per mole of pyruvate+malate and succinate+rotenone 
(see calculation by Mookerjee et al. (2017) and Chapter 1.2.1). L.T. calculated coupling 
efficiency (CE), respiratory control ratio (RCR) and spare respiration capacity (SRC) to compare 
genetic groups, and none of the parameters were significantly changed. While the CMF of 
Emx1:Cre+/GFP-OMM cortex contains a mixture of tagged and untagged mitochondria, I 
confirmed by flow cytometry that 74±5% of mitochondria (gated as Tom22+ events) are GFP-
OMM positive. Hence, GFP-OMM tagged mitochondria represent a significant population in 
the analyzed tissue and any effect of transgene expression would have been detected in 
oxygen consumption assays, if present. 
We concluded from these experiments that GFP-OMM tagged mitochondria are functional in 
terms of their transport rates in neurons and their respiratory activity. Furthermore, neuronal 
health is normal as analyzed at the NMJ. Thus, any differences observed among cell                       
type-specific mitochondrial populations should arise from their biological diversity and not 
from an effect of our MitoTag model. 
4.1.3. Intact mitochondria are captured via GFP-OMM 
The cell type-specific expression of a mitochondrial localized fluorescent protein is not                 
novel – in fact, Jeremy Nathans (Johns Hopkins University) donated a Rosa26 CAG-stop-mito-
GFP mouse line to the JAX repository a decade ago (Agarwal et al., 2017). However, the major 
difference between existing ‘mito lines’ and our MitoTag line is the localization of the tag:                  
in previous mouse models, the tag is localized to the mitochondrial matrix and inaccessible for 
isolation via immunoprecipitation, while in the MitoTag line the tag is accessible on the outer 
mitochondrial membrane. Although it might be argued for the first case that mitochondria 
could be isolated via fluorescence activated cell sorting, Laura Trovò (Institute of Neuronal Cell 
Biology, TUM) initially performed such experiments and was unsuccessfully in isolating 
healthy mitochondria. Only recently, MacDonald et al. (2019) reported a costume-made 
nanoscale flow cytometry-based method that achieves the isolation of intact mitochondria, 
termed fluorescence-activated mitochondria sorting (FAMS). Thus, our model allows the 
visualization of cell type-specific mitochondria, but also provides a ‘handle’ for these 
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organelles. I therefore tested different approaches to immunoprecipitate GFP-OMM tagged 
mitochondria while preserving their integrity and function. 
Initial experiments included standard immunoprecipitation protocols using: (i) agarose beads 
or magnetic beads; (ii) different buffer systems to keep mitochondria healthy and intact; and 
(iii) different antibodies against GFP. I tested these conditions in a mitochondrial mixing 
experiment with the starting material consisting of GFP-OMM tissue and mito-RFP tissue in a 
∼1:1 ratio. Conditions were evaluated via western blot analysis probing for GFP-OMM and 
mito-RFP content with the goal of GFP-OMM enrichment and mito-RFP depletion. To my 
surprise, none of the initially tested conditions could deplete mito-RFP (data not shown). 
While I enriched mitochondria with GFP antibodies from the tissue lysate, tagged 
mitochondria always co-purified with a significant amount of mito-RFP mitochondria. This 
outcome indicated a clumping of mitochondria and/or the formation of intermediate fusion 
events (Meeusen et al., 2004). While OMM fusion cannot be complete under the isolation 
conditions (Brandt et al., 2016), OMM attachment through close proximity of mitochondria, 
e.g. via centrifugation or transient association on beads (data not shown), could lead to                          
co-purification of mitochondria. Consequently, I optimized the purification protocol to 
prevent mitochondria attachment via proximity. To this end, two modifications were made 
that significantly improved the isolation process that we termed immunocapture (IC): 
(1) Starting material for immunocapture: 
 While a fast separation of mitochondria from cytosol and other organelles might be 
favored for mitochondrial purification, the generation of a mitochondrial pellet via                 
high-speed centrifugation impairs organelle separation. Therefore, the post-nuclear lysate 
was used for immunocapture and further diluted to a concentration of ≤2 mg tissue per 
ml buffer during bead incubation. 
(2) Immunocapture via paramagnetic microbeads: 
 Standard agarose or magnetic beads have a diameter of 150 – 40 μm and 4 – 1 μm, 
respectively; and trap simultaneously multiple mitochondria on their surface. This 
facilitates attachment of neighboring mitochondria. In contrast, the used microbeads have 
a diameter of 50 nm and accumulate on the mitochondrial surface via epitope-antibody 
binding. Several beads are necessary to trap a mitochondrion in the magnetic field and 
allow for its purification. 
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Figure 14│ Immunocapture enriches mitochondria. (a) Mitochondria are enriched via the 
optimized immunocapture (IC) protocol starting with the post-nuclear tissue lysate (conc. 2 
mg/ml). Mitochondria can be isolated via centrifugation (12,000 g; CMF) and IC against GFP or 
Tom22. Following microbeads incubation, mitochondria are separated on a magnetic stand and 
the final elution pelleted by centrifugation. (b) Electron micrographs of isolated mitochondria from 
Emx1:Cre+/GFP-OMM cortex using centrifugation or immunocapture. Mitochondria are 
highlighted in magenta. Details 1-3 below. Scale bars: 250 nm. (c) Western blot analysis of 
mitochondrial preparation probing for different mitochondrial compartments and GFP-OMM. 
Whole, whole tissue lysate; CMF, crude mitochondrial fraction; OMM, outer mitochondrial 
membrane; IMM, inner mitochondrial membrane; Tomm20, mitochondrial import receptor 
subunit TOM20 homolog; ATP5a, ATP synthase subunit alpha; CypD, cyclophilin D; kDa, molecular 
weight in kilo Dalton. Modified from Fecher et al. (2019), Figure 1 and Supplementary Figure 3.
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Magnetic microbeads cross-linked with anti-Tom22 antibody were previously used by Franko 
et al. (2013) to isolate mitochondria from tissue. Mitochondrial import receptor subunit 
TOM22 homolog (Tom22) is a ubiquitously expressed outer mitochondrial membrane protein 
and part of the protein import machinery. In this report, the authors used 5-10 mg tissue per 
ml buffer to incubate microbeads with mitochondria and separated them via a magnetic 
column. I used these conditions with magnetic microbeads cross-linked to anti-GFP antibody 
and observed significant mito-RFP contamination. Therefore, I tested different                           
tissue-to-buffer ratios and  achieved mito-RFP depletion at a concentration of 2 mg tissue per 
ml buffer and below. 
To demonstrate mitochondrial enrichment with immunocapture, I used Emx1:Cre+/GFP-OMM 
cortex, generated the post-nuclear tissue lysate and purified mitochondria using differential 
centrifugation, immunocapture with Tom22 as bait (IC Tom) and with GFP-OMM as bait                  
(IC GFP; Figure 14a). In collaboration with Nicolas Snaidero (N.S.; Institute of Neuronal Cell 
Biology, TUM), I prepared these samples for electron microscopy and N.S. performed image 
acquisition. In the crude mitochondrial fraction (CMF), I observed that mitochondria were 
frequently enclosed in membranes, presumably synaptosomes (Figure 14b, d1) and that the 
majority of objects could not be identified as mitochondria. In contrast, the majority of objects 
in IC Tom and IC GFP were free mitochondria. Furthermore, mitochondrial cristae structure 
was well preserved after immunocapture (Figure 14b, d2 and d3). Next, I evaluated 
mitochondrial enrichment between CMF and immunocapture by western blot analysis             
(Figure 14c). Compared to the whole tissue lysate, all conditions enriched the probed 
mitochondrial proteins localized to OMM, inner mitochondrial membrane (IMM) and matrix. 
However, immunocaptures enriched these proteins more than CMF. GFP-OMM was only 
slightly higher enriched in IC GFP compared with IC Tom because the majority of mitochondria 
are GFP-OMM tagged in the tissue lysate (Emx1:Cre+/GFP-OMM: 74±5%). 
To validate that immunocaptured mitochondria are functional, we tested isolated organelles 
in oxygen consumption assays. I enriched mitochondria with the described protocol from 
either Emx1:Cre−/GFP-OMM cortex using IC Tom or Emx1:Cre+/GFP-OMM cortex using IC Tom 
and IC GFP (Figure 15a), and Laura Trovò (Institute of Neuronal Cell Biology, TUM) performed 
oxygen consumption assays. While we observed a higher degree of variability among the 
immunocapture samples than the CMF samples, no significant difference was detected among 
groups using pyruvate+malate or succinate+rotenone as substrate (Figure 15b).  
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This confirmed that immunocaptured mitochondria via GFP-OMM and Tom22 are intact 
(Figure 14b and c) and functionally indistinguishable between Emx1:Cre−/GFP-OMM and 
Emx1:Cre+/GFP-OMM tissue (Figure 15b).  
Figure 15│ Mitochondrial respiration is unaltered between GFP-OMM tagged and untagged 
organelles after immunocapture. (a) Isolation of mitochondria via immunocapture from 
Emx1:Cre−/GFP-OMM cortex and Emx1:Cre+/GFP-OMM cortex. (b) Oxygen consumption rate 
(OCR) as percentage of basal respiration with indicated injections and calculated parameters: 
coupling efficiency (CE), respiratory control ratio (RCR) and spare respiratory capacity (SRC). Left 
side: representative data from one experiment; right side: n≥4 mice from three to four 
independent experiments. Mitochondrial respiration was probed using pyruvate+malate (complex 
I; upper graph) and succinate+rotenone (complex II; lower graph) as substrates. Line graph: 
mean±s.e.m.; box plot: median, quartile 1-3, whisker from min./max. value, and individual data 
points; P values from statistical testing are shown. Modified from Fecher et al. (2019), Figure 1.
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4.1.4. Immunocapture separates cell type-specific mitochondria from complex tissue 
With the immunocapture protocol at hand, I further ask what the remaining level of untagged 
mitochondria is. For this, I used the introduced mitochondrial mixing experiment with a 
starting lysate containing Emx1:Cre+/GFP-OMM cortex and Thy1:mito-RFP cortex in a ∼1:1 
tissue mix (Figure 16a). This generated an initial ratio of approximately 54% GFP-OMM to 46% 
mito-RFP tagged mitochondria as determined by flow cytometry (Figure 16b) and by excluding 
non-fluorescent mitochondria. Using 20 mg tissue lysate as input, I purified mitochondria and 
analyzed them by western blot analysis probing for GFP-OMM and mito-RFP as well as 
endogenous mitochondrial proteins localized to OMM, IMM and matrix. With IC Tom,                          
I recovered similar GFP-OMM to mito-RFP ratios as with the CMF, which represents the initial 
ratio of mitochondria (Figure 16c). When using microbeads cross-linked with anti-CD4 
antibody as negative control, no mitochondria were purified. Only IC GFP enriched GFP-OMM 
tagged mitochondria and reduced mito-RFP signals. No mitochondria could be isolated with 
IC GFP from a pure mito-RFP lysate or wild type lysate. I  observed  with  IC  GFP  an  enrichment  
of  4.6±0.38-fold  for  GFP-OMM  and a reduction to 0.2±0.07-fold for mito-RFP compared to 
CMF, while IC Tom recovered 0.98±0.14-fold GFP-OMM and 0.79±0.18-fold mito-RFP (Figure 
16d). GFP-OMM enrichment and mito-RFP reduction were significantly changed between                   
IC Tom and IC GFP (one-tailed, ratio-paired t-test: GFP-OMM, P=0.002; mito-RFP, P=0.0368; 
n=5 experiments). 
From this result, we further asked if small populations of GFP-OMM tagged mitochondria, i.e. 
from rare cell types, can be purified as efficiently as big populations. To test this hypothesis,              
I modified the mitochondrial mixing experiment by creating different GFP-OMM to mito-RFP 
ratios ranging from 100% to 5% GFP-OMM content (Figure 17a). While in Figure 16a similar 
amounts of tissue were mixed prior to lysate generation, the mixing in this experiment is 
performed with post-nuclear lysate. Using western blot analysis (Figure 17b), I observed with 
IC GFP in the presence of GFP-OMM tagged mitochondria (content of 100% to 5% GFP-OMM) 
an average enrichment of 5.1±0.21-fold for GFP-OMM and an average reduction to                 
0.03±0.03-fold for mito-RFP compared to the 50:50 CMF condition (Figure 17c). Statistical 
testing provided no evidence for a significant difference among these conditions in either GFP-
OMM enrichment or mito-RFP reduction (one-way Friedman test with post hoc testing: GFP-
OMM,  P=0.0720;  mito-RFP,  P=0.1211;  n=4  experiments).  However,  total  protein  amounts  
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Figure 16│ Immunocapture enriches GFP-OMM tagged 
mitochondria and separates them from other 
mitochondria. (a) Immunocapture workflow starting with 
the mixed tissue lysate and depicting the possible isolation 
via centrifugation (CMF) and IC against GFP-OMM or 
Tom22. (b) Confocal images of Emx1:Cre+/GFP-OMM 
cortex and Thy1:mito-RFP cortex and histograms of flow 
cytometry experiments showing the percentage of labeled 
mitochondria in cortex samples. Mitochondria are gated 
according to Tom22-APC. The mean±s.e.m. for n=5 mice is 
indicated. Nuclei are visualized by nuclear counter stain.   
FITC,  GFP-OMM   channel;  PE,   mito-RFP  channel. Scale 
bar: 20 μm. (c) Western blot analysis of mitochondrial  
isolations using different starting lysates (GFP-OMM, mito-RFP, 1:1 Mix and wild type) and 
isolation conditions (CMF, IC Tom, IC GFP and IC CD4). The blot is probed for GFP-OMM, mito-
RFP and different mitochondrial compartments: OMM, Tomm20; IMM, ATP5a; matrix, CypD; 
kDa, molecular weight in kilo Dalton. (d) Quantification of the 1:1 Mix condition shown as fold 
change to CMF and normalized to total protein amount and mitochondrial content.  Box plot: 
median, quartile 1-3, whisker from min./max. value, and individual data points; n=5 experiments 
quantified as technical triplicates; statistical testing is indicated. Modified from Fecher et al. 
(2019), Figure 2 and Supplementary Figure 4.
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from IC GFP-recovered mitochondria were depended on GFP-OMM abundance in the lysate 
and proportionally decreased among the conditions.  
In summary, small populations of GFP-OMM tagged mitochondria can be purified as efficiently 
as big populations using the immunocapture protocol. However, for small populations an 
upscaling of column numbers and animals might be necessary dependent on the downstream 
application of isolated mitochondria. 
Finally, we asked if the observed separation efficiency of our protocol is altered in vivo where 
mitochondrial populations are directly present in neighboring cells. To test this hypothesis,                
I crossed Gfap:Cre+/GFP-OMM mice to the Thy1:mito-RFP line and generated animals that 
have GFP-OMM tagged mitochondria in astrocytes and mito-RFP labeled mitochondria in 
neurons (Figure 18a). In cortex from these mice, approximately 29% of mitochondria are             
GFP-OMM tagged, while mito-RFP is present in 63% of organelles. When excluding unlabeled 
mitochondria from the calculation, this creates a ratio of 32% GFP-OMM to 68% mito-RFP 
mitochondria in the post-nuclear tissue lysate. Using western blot analysis, I observed with             
IC GFP an enrichment of 6.7±1.7-fold for GFP-OMM and a reduction to 0.8±0.13-fold of mito-
RFP compared to CMF, while IC Tom recovered 0.91±0.1-fold GFP-OMM and 1.24±0.16-fold 
mito-RFP (Figure 18b). GFP-OMM enrichment was significantly changes between IC Tom and 
IC GFP (one-tailed, ratio-paired t-test: GFP-OMM, P=0.0002; mito-RFP, P=0.0677; n=5 
experiments). In contrast to the previous experiments, I observed no significant reduction of 
mito-RFP in the one-tissue mixing experiment. Furthermore, IC Tom enriched mito-RFP 
compared with CMF. In Thy1:mito-RFP mice, the transgene is highly abundant and likely not 
fully imported into mitochondria due to expression levels. This would leave a small amount of 
Figure 17│ Immunocapture performance persists even for small populations of GFP-OMM tagged 
mitochondria. (a) Immunocapture workflow starting with the mixing of tissue lysate from 
Emx1:Cre+/GFP-OMM cortex and Thy1:mito-RFP cortex (confocal images) in descending ratios from 
100% to 0% GFP-OMM lysate. Mitochondria are isolated by centrifugation (CMF) and IC against 
GFP-OMM or Tom22. In confocal images, nuclei are visualized by nuclear counter stain. Scale bar: 
20 μm. (b) Representative western blot from quantification probed for GFP-OMM and mito-RFP as 
well as mitochondrial proteins localized to OMM, IMM and matrix. Note that due to protein amount 
limitation different amounts of total protein are probed (see mitochondrial markers for IC GFP of 
25-0%). To visualized mito-RFP contamination, the second mito-RFP blot lane has been adjusted to 
saturation. kDa, molecular weight in kilo Dalton. (c) Quantification of GFP-OMM (upper graph) and 
mito-RFP (lower graph) in the different conditions shown as fold change to CMF 50:50 and 
normalized to total protein amount and mitochondrial content. Box plot: median, quartile 1-3, 
whisker from min./max. value, and individual data points; n=5 mice quantified as technical 
triplicates; P values from statistical testing are shown. Modified from Fecher et al. (2019), 
Supplementary Figure 5. 
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Figure 17│ Immunocapture performance persists even for small populations of GFP-OMM tagged 
mitochondria (see previous page for legend). 
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mito-RFP  precursor  protein  in  the  cytosol,  where  it  could be attached and/or imported to 
other mitochondria during the incubation period of ∼60 minutes. In this experiment, the CMF 
was generated immediately after starting the microbeads incubation, i.e. approximately                  
90 minutes earlier than IC Tom, giving a possible explanation for this result. Still, in this 
experiment the mitochondrial content of IC GFP is massively changed compared to IC Tom. 
Thus, this experiment confirms that the immunocapture enriches GFP-OMM tagged 
mitochondria from complex tissue. However, the level of contamination from other 
mitochondrial populations needs to be carefully evaluated for the tissue of interest and the 
downstream application. A source of contamination might be abundant mitochondrial 
proteins (like mito-RFP in our experiment), which cross-contaminate during the 
immunocapture; however, these proteins are likely non-specific for cell types. 
The results of Chapter 4.1 demonstrated that cell type-specific mitochondria can be tagged 
via the MitoTag mouse model and that this mitochondrial population can be enriched from a 
mixture with non-tagged mitochondria. This is possible even if the tagged population of 
mitochondria represents 13% or less. Additionally, mitochondria do not fuse during 
Figure 18│ Immunocapture separates directly adjacent mitochondrial populations from one tissue. 
(a) Confocal image of Gfap:Cre+/GFP-OMMxThy1:mito-RFP cortex and histograms of flow 
cytometry experiments determining the percentage of labeled mitochondria in this crossing. 
Mitochondria are gated according to Tom22-APC. The mean±s.e.m. for n≥4 mice is indicated. 
Nuclei are visualized by nuclear counter stain. FITC, GFP-OMM   channel; PE,   mito-RFP channel. 
Scale bar: 20 μm. (b) Quantification from western blot analysis of immunocaptures from 
Gfap:Cre+/GFP-OMMxThy1:mito-RFP cortex shown as fold change to CMF and normalized to total 
protein amount and mitochondrial content. Box plot: median, quartile 1-3, whisker from min./max. 
value, and individual data points; n=5 experiments quantified as technical triplicates; statistical 
testing is indicated. Modified from Fecher et al. (2019), Figure 2 and Supplementary Figure 4. 
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immunocapture; nonetheless, a small amount of contaminating, untagged mitochondria is to 
be expected. 
  
Figure 19│ Cre-driver lines crossed to the MitoTag mouse line to tag mitochondria in Purkinje cells, 
granule cells and astrocytes. Brain overview shows general expression pattern and detail shows 
the pattern in cerebellum as well as the distribution of cerebellar mitochondria via 
immunofluorescence staining against Cox4i1 (magenta). The schema gives information about the 
cellular position in cerebellar cortex. Grey box, Purkinje cell layer; above, molecular layer; below, 
granule cell layer. (a) Purkinje cells are labeled via L7:Cre; (b) granule cells are labeled via 
Gabra6:Cre; and (c) astrocytes, including Bergmann glia, are labeled via Gfap:Cre. Scale bars: 1 mm 
(brain); 25 μm (cerebellum detail). Modified from Fecher et al. (2019), Figure 3 and Supplementary 
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4.2. Molecular diversity of neural mitochondria in mouse cerebellum 
To explore mitochondrial diversity in vivo, we focused on cell types in mouse cerebellum as 
proof-of-concept model. The cerebellum – like the retina – is a layered structure with                     
well-characterized cell types (see Chapter 1.6). The position of a cell as well as its geometry 
informs well about the cell’s identity, which was an important feature for our validation. In 
addition, Cre-driver lines are available to investigate most cerebellar cell types. Cerebellar 
atrophy and ataxia are frequently observed in patients with mitochondrial disorders                        
(see Chapter 1.7; Peng et al., 2019) implicating a unique dependence on or specialization of 
mitochondrial function in cerebellar cell types, for example Purkinje cells. 
4.2.1. Cell type-specific profiling of mitochondria identifies similarities and differences 
To profile mitochondrial heterogeneity in an unbiased way, we performed label-free mass 
spectrometry to screen for enriched proteins from cell type-specific mitochondria. I generated 
MitoTag mouse lines for three cerebellar cell types, namely: Purkinje cells, an inhibitory 
neuron (L7:Cre+/GFP-OMM, Figure 19a); granule cells, a highly abundant excitatory neuron 
(Gabra6:Cre+/GFP-OMM, Figure 19b); and astrocytes, a glial cell type (Gfap:Cre+/GFP-OMM, 
Figure 19c). Mice at the age of 2 month were sacrificed and I immunocapture mitochondria 
from the cerebellum via IC Tom and IC GFP per biological replicate (n≥5 mice, Figure 8). 
Stephan Müller (S.M.; Lichtenthaler laboratory, German Center for Neurodegenerative 
Diseases) further processed samples for mass spectrometry and label-free quantification 
(LFQ) in MaxQuant (see Chapter 3.2.12.3). IC Tom represented the control sample in this 
experiment by providing the average mitochondrial proteome from the cerebellum, in 
contrast to the cell type-specific mitochondrial proteome obtained with IC GFP. 
Intensity-based absolute quantification (iBAQ) showed that immunocaptures in general 
contained a high abundance of mitochondrial proteins when compared to the quantification 
of a whole tissue sample (Δmean (iBAQmitochondrial peptides-iBAQnon-mitochondrial peptides): 6.51-fold 
(immunocapture) vs 2.64-fold (cerebellum). IC Tom consistently contained 3,718 proteins of 
which 821 were annotated in MitoCarta (coverage 70.9%; Calvo et al., 2016). This MitoCarta 
coverage is similar to previous mass spectrometry studies using Percoll gradient isolated 
mitochondria (Pagliarini et al., 2008) or an in-depth analysis of mouse brain via high-resolution 
mass spectrometry (12,934 proteins identified by mass spectrometry, Sharma et al., 2015; 
Figure 20). 
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By comparing IC GFP to IC Tom per biological sample, we eliminated technical variation among 
experiments and biological variability among mouse cohorts. First, I calculated the cell type-
specific log2 fold change per protein for each biological samples  (log2 FC (IC GFP vs IC Tom)) 
and generated the mean per cell type for proteins found in ≥3 biological replicates. With these 
values, we then asked if core mitochondrial processes were enriched in a cell type-specific 
manner (Figure 21 and 22). Most proteins were unchanged arguing for a conserved core of 
mitochondrial functions and a successful normalization of our data. Still, individual proteins 
(n=7) were cell type-enriched among these core mitochondrial functions.  
For example, mitochondrial inner membrane protein like 2 (Mpv17L2) was significantly 
enriched in the proteome of astrocytic mitochondria (Figure 22a; two-tailed, unpaired t-test 
with permutation-adjusted q-value: PC vs A: *-0.745, 0.0468; GC vs A: *-1.699, <0.0001;                    
PC vs GC: 0.954, 0.0759). Dalla Rosa et al. (2014) showed that Mpv17L2 is necessary for 
mitochondrial ribosome assembly and the generation of mitochondrial encoded proteins.              
It co-sediments with the large ribosome subunit and monosomes and Mpv17L2 depletion 
causes mitochondrial swelling, nucleoid aggregation and a halt of protein synthesis in 
mitochondria.  
Likewise, several components of the coenzyme Q10 biosynthesis pathway (CoQ) were enriched 
in Purkinje cell mitochondria (Coq6, Coq3, Pptc7; Figure 22b). Not surprisingly, mutations in 
CoQ enzymes manifest in patients with ataxia and cerebellar atrophy (Alcazar-Fabra et al., 
2018) and Coq8a deficiency has been shown to cause Purkinje cell dysfunction in mice (Stefely 
et al., 2016b). Surprisingly, AarF domain-containing kinase 1 (Adck1; Figure 22b) was 
significantly enriched in astrocytic mitochondria, while being proposed to participate in CoQ 
synthesis (Stefely et al., 2016b; Acosta et al., 2016). Recently, however, Yoon et al. (2019) 
reported the functional interaction of Adck1 with the protease Yme1L1 to instruct MIC60 and 
Figure 20│ Proteomic comparison among IC Tom, 
mitochondria in Pagliarini et al. (2008) and whole 
tissue in Sharma et al. (2015) to MitoCarta (Calvo 
et al., 2016). Venn diagram depicting the number 
of proteins consistently found in the studies. 
MitoCarta includes 1,158 high confidence 
candidates found in mitochondria. 620 of these 
are shared among the three studies, while 30, 64 
and 57 are only found in IC Tom, Pagliarini et al. 
and Sharma et al., respectively. All studies cover 
≥64% of MitoCarta. Taken from Fecher et al. 
(2019), Supplementary Figure 3. 
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Opa1 in cristae formation and mitochondrial dynamics; thereby given the first experimental 
evidence for CoQ-independent Adck1 function. 
Additionally, two enzymes of the tricarboxylic acid cycle (TCA cycle; Figure 22c) were enriched 
in astrocytic mitochondria, namely: mitochondrial [NADP] isocitrate dehydrogenase                     
(Idh2; two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: *-2.208, <0.001; 
GC vs A: *-1.437, <0.0001; *PC vs GC: -0.771, 0.0029); and succinate-CoA ligase (GTP-forming) 
subunit beta (Suclg2; two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: 
*-2.665, <0.0001; GC vs A: *-2.708, <0.0001; PC vs GC: 0.043, 0.9376). Idh2 catalyzes the 
reversible reaction of   𝑖𝑠𝑜𝑐𝑖𝑡𝑟𝑎𝑡𝑒   𝐼𝑑ℎ2  ⎯⎯  -ketoglutarate +  NADPH   in the TCA cycle. While 
Idh2 is proposed to not contribute to the TCA cycle flux by reverse direction, Hartong et al. 
(2008) reported that Idh2 compensates for Idh3 loss in most tissues except for the retina. 
Figure 21│ Proteomic composition of the electron transport chain in cell type-specific 
mitochondria. The average fold change (log2 fold change (IC GFP vs IC Tom)) of LFQ intensity per 
protein (n≥3 biological replicates) was calculated for mitochondria from Purkinje cells (PC), granule 
cells (GC) and astrocytes (A), and is shown as heat map ranging from -4 (blue) to 4 (red). The fold 
change for GFP-OMM per cell type is shown in the right lower corner. Modified from Fecher et al. 
(2019), Supplementary Figure 8. 
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Besides controlling the TCA cycle (Sazanov and Jackson, 1994), Idh2 also plays a key role in 
oxidative stress and ROS defense by providing NADPH for thioredoxin reductase 2 (White et 
al., 2018) and glutathione reductase (Kong et al., 2018). Here, Idh2 together with nicotinamide 
nucleotide transhydrogenase (Nnt; Hojeberg and Rydstrom, 1977) provide NADPH for the 
regeneration of reduced glutathione and thioredoxins (Vogel et al., 1999). Interestingly,                 
Nnt was also enriched in the proteome of astrocytic mitochondria (Nnt; two-tailed, unpaired 
t-test with permutation-adjusted q-value: PC vs A: *-1.062, 0.0007; GC vs A: *-1.151, 0.0002; 
PC vs GC: -0.089, 0.8621). Disruption of Idh2 function has been linked to grade II-IV glioma 
Figure 22│ Proteomic composition of core mitochondrial processes in cell type-specific 
mitochondria. The average fold change (log2 fold change (IC GFP vs IC Tom)) of LFQ 
intensity per protein (n≥3 biological replicates) was calculated for mitochondria from 
Purkinje cells (PC), granule cells (GC) and astrocytes (A). Proteins are shown as heat map 
ranging from -4 (blue) to 4 (red) for (a) the mitochondrial ribosome; (b) the coenzyme Q10 
synthesis pathway (CoQ); and (c) the tricarboxylic acid cycle (TCA). Significantly enriched 
candidates (*) are: Mpv17L2 (in a); Coq3, Coq6, Pptc7, Adck1 (in b); and Idh2, Suclg2 (in 
c). The fold change for GFP-OMM per cell type is shown in the right lower corner. Crossed 
field, no value. Modified from Fecher et al. (2019), Supplementary Figure 8. 
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(Huang et al., 2019). Suclg2 forms a heterodimer complex with Suclg1, named succinyl-CoA 
ligase (Sucl), and catalyzes the reversible reaction of succinyl-CoA     ⎯⎯  𝑠𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 + 𝐶𝑜𝐴 +𝐺𝑇𝑃  , known as substrate level phosphorylation in the TCA cycle (see Chapter 1.2.1). This 
reaction is an important intersection for multiple metabolic pathways (reviewed in Tretter et 
al., 2016) and together with the mitochondrial nucleoside diphosphate kinase (Nme3) 
provides phosphorylated deoxyribonucleotides to maintain mitochondrial DNA (Kadrmas et 
Figure 23│ Comparison of cell type-specific mitochondrial proteomes among Purkinje cells, granule 
cells and astrocytes. (a) Volcano plot testing for significant proteins between the mitochondrial 
proteome from Purkinje cells (PC) and astrocytes (A). Proteins passing the FDR≤0.05 are marked in 
blue and further considered for b. Right site, volcano plot comparing the mitochondrial proteome 
from granule cells (GC) with astrocytes (A). (b) Scatter plot depicting the fold changes per protein 
between the two volcano plots in a with (PC vs A) on the x-axis and (GC vs A) on the y-axis. Only 
proteins prior passing the FDR in one test are considered (blue filled circles) and proteins with only 
one fold change between cell types are depicted at the axis with ∞ for the missing value. Black 
filled circles, MitoCarta annotated proteins; magenta outlined circles, validated candidates with 
gene name annotation. Modified from Fecher et al. (2019), Figure 3 and Supplementary Figure 7. 
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al., 1991; Tokarska-Schlattner et al., 2008). Mutations in Suclg1 and Sucla2 cause severe 
encephalomyopathy with mitochondrial DNA depletion (Ostergaard, 2008); Suclg2 mutations 
are presumed lethal (Kacso et al., 2016). 
Next, I performed statistical testing in Perseus (Tyanova et al., 2016) to identify cell                        
type-enriched candidates. First, I tested for significantly found proteins between mitochondria 
from Purkinje cells and astrocytes; and between mitochondria from granule cells and 
astrocytes (blue filled circles; two-tailed, unpaired t-test, FDR≤0.05, 500 randomization,                  
n≥3 quantifications per group; Figure 23a). Next, all proteins that passed the applied FDR≤0.05 
in one comparison were included in the scatter plot comparing all three cell types (Figure 23b). 
Here, proteins are annotated by MitoCarta (black filled circles; Calvo et al., 2016) and as 
validated candidates in this study (magenta outline). I considered proteins as cell                          
type-enriched candidates, if their fold change was ≥│1│ in one comparison. 196 proteins met 
this criterion, of which 18, 51 and 114 proteins were enriched in Purkinje cells, granule cells 
and astrocytes, respectively (Figure 24a). 13 candidates were shared between cell types. 
I used MitoCarta (Calvo et al., 2016) and LocTree3 prediction (Goldberg et al., 2014) to 
annotate subcellular localization of candidates (Figure 24b). 89.8% of candidates were 
predicted to be mitochondrial. Only 10.2% of candidates were annotated to another 
subcellular compartment – with 8 candidates predicted to be peroxisomal and exclusively 
enriched in the proteome of astrocytic mitochondria. 
Figure 24│ Cell type-enriched candidates and their predicted localization in cells. (a) Venn diagram 
depicting the enriched candidates (n=196) found in mitochondrial proteomes from Purkinje cells 
(PC, magenta), granule cells (GC, orange) and astrocytes (A, blue). 13 candidates are shared 
between two cell types. Schema depicts cellular position in cerebellum. (b) Pie chart illustrating 
the predicted subcellular localization of candidates according to MitoCarta and LocTree3 
prediction. Distribution of non-mitochondrial proteins is further annotated by cell type (PC, 
magenta; GC, orange; A, blue) and categorized in: Cyto, cytosol; Nuc, nuclear; ER, endoplasmic 
reticulum; Pex, peroxisomal; PM, plasma membrane; and other. Modified from Fecher et al. 
(2019), Figure 3 and Supplementary Figure 3. 
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Finally, I selected 28 candidates for further validation based on antibody availability and prior 
literature regarding protein function, mitochondrial localization and abundance in the central 
nervous system. Using immunofluorescence staining, I confirmed the predicted cell               
type-enrichment in 21 cases in mouse cerebellum (Figure 25, 27 and 30). For the other 7 cases,               
no validation could be achieved due to antibody performance (Table A3). Additionally,                          
I stained for Cox4i1 as a ubiquitously expressed mitochondrial protein that did not pass our 
criteria for being cell type-enriched (two-tailed, unpaired t-test with permutation-adjusted                   
q-value: PC vs A: *0.554, 0.0268; GC vs A: *0.496, 0.0002; PC vs GC: 0.058, 0.9085). 
4.2.2. Candidates enriched in Purkinje cell mitochondria 
In Purkinje cells, all selected candidates colocalized with the genetic GFP-OMM label in 
L7:Cre+/GFP-OMM tissue confirming their mitochondrial localization (Figure 25b). Specifically, 
I confirmed that regulator of microtubule dynamics protein 3 (Rmdn3; two-tailed, unpaired             
t-test with permutation-adjusted q-value: PC vs A: *2.042, <0.0001; GC vs A: 0.238, 0.3951;       
PC vs GC: *1.803, 0.0023) – also known as protein tyrosine phosphatase-interacting protein 
51 (PTPIP51) or cerebral protein 10 – is highly abundant in Purkinje cells. Rmdn3 is a C-tail 
anchored outer mitochondrial protein (Lv et al., 2006) and has been shown to mediate contact 
sites between the endoplasmic reticulum and mitochondria in vitro (via VAPB, De Vos et al., 
2012; via ORP5, ORP8, Galmes et al., 2016).  
Secondly, ovarian carcinoma immunoreactive antigen domain–containing protein 2               
(Ociad2; two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: *2.413, 
<0.0001; GC vs A: 0.587, 0.082; PC vs GC: *1.825, 0.0015) was not included in MitoCarta (Calvo 
et al., 2016) and further annotated as localized to endosomes (Q9D8W7, version 104; UniProt, 
2019). Its paralog Ociad1/Asrij has been reported to localize to endocytic vesicles (Kulkarni et 
al., 2011) and mitochondria (Shetty et al., 2018) via the two helix-motifs in the OCIA domain 
(Sinha et al., 2018). I validated Ociad2 with two distinct antibodies recognizing epitopes in the 
N- or C-terminus. The N-terminus of Ociad2 contains the OCIA domain and its two helix-motifs 
and is to a low degree conserved with Ociad1/Asrij; the C-terminus is Ociad2-specific. In both 
cases, I confirmed colocalization with mitochondria, which were genetically marked by                
GFP-OMM (Figure 26a). However, while the C-terminal antibody confirmed Purkinje cell 
enrichment, the N-terminal antibody colocalized with granule cell mitochondria. Sinha et al. 
(2018) reported partial endosomal localization of Ociad2, which could not be determined in 
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these experiments. I then aligned the reported mouse Ociad2 isoform sequences                          
(four isoforms, version 104; UniProt, 2019) with the mass spectrometry-identified peptides in 
Purkinje cell and granule cell mitochondria (Figure 26b). Both antibodies recognized the                
full-length Ociad2 protein; however, also react to different isoforms. Therefore, differential 
expression of Ociad2 isoforms might a reason for my results obtained with epitope-specific 
antibodies. Functionally, Ociad2 is no well characterized. Han et al. (2014) reported nicastrin 
interaction with Ociad2 via its C-terminus (residues 132-142). Presumably, this leads to                  
Figure 25│ Candidates enriched in Purkinje cells mitochondria. (a) Scatter plot 
summarizing the fold changes of proteins from the pairwise comparison of cell type-
specific mitochondrial proteomes (see Figure 23b). Detail illustrates the enriched 
proteins in Purkinje cell mitochondria with annotation of validated candidates in b. FC, 
fold change. (b) Immunofluorescence staining of candidates in cerebellum from 
L7:Cre+/GFP-OMM mice. Cox4i1 is a ubiquitous mitochondrial protein, while ldhd and 
Got2 are predicted as neuronal. Rmdn3, Ociad2 and Pptc7 are predicted as Purkinje 
cell enriched. All proteins localize to mitochondria. Details show the merge channel 
and the single channels for GFP-OMM (green) and the candidate (magenta). Scale 
bars: 20 μm (detail 10 μm). Modified from Fecher et al. (2019), Figure 3. 
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pre-assembly of the γ-secretase complex and in an increase in amyloid-β production. Further 
involvement of Ociad2 in Alzheimer’s disease is not reported in humans. 
Thirdly, I confirmed enrichment of protein phosphatase PTC7 homolog (Pptc7; two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: *1.571, <0.001; GC vs A: *0.984, 
0.0089; PC vs GC: 0.587, 0.1569) in Purkinje cell mitochondria. Pptc7 is localized to the 
mitochondrial matrix (Ramos et al., 2000) and I observed punctuated immunofluorescence 
signals surrounded by continuous GFP-OMM signals (Figure 25b, Pptc7 detail). Recently, Niemi 
et al. (2019) showed that Pptc7 is essential for postnatal survival via mitochondrial protein 
import and biogenesis. Additionally, Pptc7 activity modulates the TCA cycle via 
dephosphorylation of citrate synthase (CS; Guo et al., 2017). 
Next, probable mitochondrial D-lactate dehydrogenase (Ldhd) was predicated as neuronal 
candidate, i.e. significantly enriched in mitochondria from Purkinje cells and granule cells 
(two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: *2.571, 0.0007;            
GC vs A: *1.633, 0.0026; PC vs GC: 0.938, 0.2091). In agreement with our mass spectrometry 
data, I confirmed enrichment of Ldhd in Purkinje cells, but also robust signals in other 
mitochondria, presumably from granule cell (Figure 25b; note that lack of recombination in 
neighboring Purkinje cell accounts for Ldhd signals without GFP-OMM colocalization). In 
mammals, D-lactate cannot be converted into L-lactate and its reaction to pyruvate was 
questioned due to the lack of a D-lactate dehydrogenase. D-lactate is primarily produced via 
the glyoxalase system to detoxify methylglyoxal, which is a metabolic by-product of glycolysis 
and neurotoxic (reviewed in Allaman et al., 2015; and in the context of neurodegeneration in 
Munch et al., 2012). Ldhd was first reported by de Bari et al. (2002) and Flick and Konieczny 
(2002); still, its function in vivo was not supported in the past. Recently, however,                          
Ldhd function was confirmed in vivo in patients with Ldhd mutations (Monroe et al., 2019). 
Finally, I validated mitochondrial aspartate aminotransferase (also known as glutamate 
oxaloacetate  transaminase  2,  Got2;  or  fatty acid-binding  protein,  FABP-1)  as  significantly 
enriched in Purkinje cells (Figure 25b) and granule cells (Figure 27b; two-tailed, unpaired                    
t-test with permutation-adjusted q-value: PC vs A: *1.093, <0.0001; GC vs A: *1.109, 0.0001; 
PC vs GC: -0.016, 0.9701). Got2 is localized to the mitochondrial matrix (Katunuma et al., 1962) 
and catalyzes the reaction of   𝑜𝑥𝑎𝑙𝑜𝑎𝑐𝑒𝑡𝑎𝑡𝑒     ⎯⎯⎯  𝑎𝑠𝑝𝑎𝑟𝑡𝑎𝑡𝑒 +  -ketoglutarate   or                       𝑔𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒     ⎯⎯⎯ -ketoglutarate  . These reactions represent the fastest steps of the TCA cycle 
and facilitates  ATP production  based on amino acids  without the use of  acetyl-CoA, termed 
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Figure 26│ Ociad2 isoforms are localized to mitochondria in Purkinje cells and granule cells. 
(a) Immunofluorescence staining of Ociad2 using two epitope-specific antibodies (N-
terminal: ab91576; C-terminal: HPA040979) in cerebellum from Cre−/GFP-OMM, 
L7:Cre+/GFP-OMM and Gabra6:Cre+/GFP-OMM mice. Details show the merge channel and 
the single channels for GFP-OMM (green) and the antibody staining (magenta). Ctr, 
omission of primary antibody; Nuc, nuclear counter stain. Scale bars: 25 μm (detail 5 μm). 
(b) Alignment of protein sequences for full-length murine Ociad2 (154 AA), its shorter 
isoforms (light gray), peptides identified by mass spectrometry in Purkinje cell (PC) and 
granule cell (GC) mitochondria (dark gray) and epitopes of antibodies (black). Note the 
exact epitope of ab91576 is proprietary and declared as 17 amino acid long and within the 
N-terminus of human Ociad2. ***, the conserved region within Ociad2 isoforms; MS, mass 
spectrometry. Modified from Fecher et al. (2019), Supplementary Figure 11. 
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‘mini TCA cycle’ (Yudkoff et al., 1994). On the one hand, α-ketoglutarate enters the TCA cycle, 
on the other hand, aspartate plus acetyl-CoA forms N-acetylaspartate, which is important for 
N-acetylaspartylglutamate synthesis, neuronal metabolism and myelin synthesis (Moffett et 
al., 2007). Additionally, Got2 has been reported to function as kynurenine aminotransferase 
producing kynurenic acid, the only endogenous antagonist of NMDA receptors and                           
α7-nicotinic acetylcholine receptors (Han et al., 2011; Guidetti et al., 2007); and as fatty                
acid-binding   protein   for   the   uptake   of   long-chain   fatty   acids  at   the   plasma   
membrane (Stump et al., 1993; Bradbury et al., 2011). In these experiments, I could not 
determine the proposed partial localization of Got2 on the plasma membrane. 
4.2.3. Candidates enriched in granule cell mitochondria 
In granule cells, all selected candidates colocalized with the genetic GFP-OMM label in 
Gabra6:Cre+/GFP-OMM tissue confirming their mitochondrial localization (Figure 27b). First,  
I verified cell type-enrichment of mitochondrial adenylate kinase 4 (Ak4) in granule cell 
mitochondria, with absence of signal in Purkinje cells (Figure 27b; two-tailed, unpaired t-test 
with permutation-adjusted q-value: PC vs A: *-1.127, 0.0004; GC vs A: *1.211, 0.0004;                        
*PC vs GC: -2.338, 0.0007). The family of adenylate kinases maintains nucleotide homeostasis 
by interconversion of nucleoside phosphates. Ak4 and Ak3 are localized to the mitochondrial 
matrix and Ak2 is present in the intermembrane space (Nakazawa et al., 1990; Yoneda et al., 
1998). While Ak3 converts  Mg2+GTP + 𝐴𝑀𝑃     ⎯⎯  Mg2+GDP + 𝐴𝐷𝑃  , Ak4 binds GTP but 
surprisingly lacks phosphotransferase activity (Noma et al., 2001). In contrast to its family 
members, Ak4 plays a role in stress signaling by interacting with the ADP/ATP translocase 
complex (ANT1 or Slc25a4; Liu et al., 2009). In this report, Ak4 binds to ANT upon oxidative 
stress and prevents permeability transition pore opening, cytochrome c release and apoptosis. 
Under normal conditions, Ak4 modulates ANT1 activity by sensing GTP levels in the 
mitochondrial matrix. Controversially, Miyoshi et al. (2009) reported high levels of Ak4 protein 
in Bergmann glia; in contrast to a study by Yoneda et al. (1998) that confirms our result of Ak4 
enrichment in granule cells. I also validated Ak3 as candidate enriched in astrocytic 
mitochondria (Figure 30b; two-tailed, unpaired t-test with permutation-adjusted q-value:              
PC vs A: *-2.1, <0.0001; GC vs A: *-1.335, <0.0001; PC vs GC: *-0.765, 0.0147) and believe that 
the observation from Miyoshi et al. (2009) is related to this paralog, Ak3. Interestingly, GTP 
cannot leave mitochondria, but is generated during substrate phosphorylation in the TCA cycle 
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(Johnson et al., 1998). Here, Ak3 functions as a GTP scavenger and transfers the energy from 
GTP to ADP (Heldt and Schwalbach, 1967; Noma et al., 2001). Importantly, also GTP-forming 
Sucl was significantly enriched in astrocytic mitochondria (Figure 22c). 
Secondly, we were surprised to find the mitochondrial calcium uniporter (Mcu) as well as its 
interactors mitochondrial calcium uptake protein 1 and 3 (Micu1, Micu3) enriched in granule 
cell mitochondria (Figure 27b; Mcu; two-tailed, unpaired t-test with permutation-adjusted              
q-value: PC vs A: *-0.602, 0.0345; GC vs A: *1.404, <0.0001; PC vs GC: *-2.0006, 0.0005). Given 
Figure 27│ Candidates enriched in granule cell mitochondria. (a) Scatter plot 
summarizing the fold changes of proteins from the pairwise comparison of cell type-
specific mitochondrial proteomes (see Figure 23b). Detail illustrates the enriched 
proteins in granule cell mitochondria with annotation of validated candidates in b. FC, 
fold change. (b) Immunofluorescence staining of candidates in cerebellum from 
Gabra6:Cre+/GFP-OMM mice. Cox4i1 is a ubiquitous mitochondrial protein, while Got2 
is predicted as neuronal. Ak4, Mcu, Gls and Gls2 are predicted as granule cell enriched. 
All proteins localize to mitochondria. Details show the merge channel and the single 
channels for GFP-OMM (green) and the candidate (magenta). Scale bars: 20 μm (detail 
10 μm). Modified from Fecher et al. (2019), Figure 3. 
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the importance of mitochondrial Ca2+ buffering in neurons (Devine and Kittler, 2018), we 
expected Mcu to be uniformly expressed, while complex regulation via McuB, Micu1 and 
posttranslational modification has been reported (see Chapter 1.2.3). 
Next, I confirmed enrichment of mitochondrial glutaminase kidney isoform (Gls; two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: 0.328, 0.0832; GC vs A: *1.823, 
<0.0001; PC vs GC: *-1.495, 0.0003) in granule cells (Figure 27b), which is in agreement with 
the glutamatergic nature of these neurons. The glutamine-glutamate cycle is 
compartmentalized between neurons and astrocytes (Daikhin and Yudkoff, 2000). Upon 
glutamate release from excitatory neurons, astrocytic endfeet at the synapse uptake 
glutamate via transporters, convert it to glutamine via glutamine synthetase and export it. 
Glutamine is taken up by neurons and metabolized via the reaction                           𝑔𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒     ⎯⎯  𝑔𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒 + 𝑎𝑚𝑚𝑜𝑛𝑖𝑎. Apart from being used as neurotransmitter, 
glutamate also enters the TCA cycle via Got2 (enriched in neurons; Figure 25b and 27b) or 
mitochondrial glutamate dehydrogenase 1 (Glud1; enriched in astrocytes, two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: *-1.743, <0.0001; GC vs A:                         
*-1.616, <0.0001; PC vs GC: -0.127, 0.6226). Gls was first discovered by Krebs (1935) and two 
isoforms are generated via alternative splicing: KGA and GAC (Elgadi et al., 1999). Both are 
activated by phosphate (Kvamme et al., 1970) and allosterically inhibited by glutamate, and 
localized exclusively to mitochondria (Laake et al., 1999). The antibody used in this study is 
specific for KGA, which is most abundant in mouse brain (Martin-Rufian et al., 2012). 
Interestingly, Gls has a paralog, mitochondrial glutaminase liver isoform (Gls2; two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: 0.385, 0.2687; GC vs A: *2.19, 
0.0001; PC vs GC: *-1.805, 0.0008), which was predicted to be enriched in granule cell 
mitochondria. However, immunofluorescence staining confirmed presence of Gls2 in granule 
cell mitochondria and Purkinje cell mitochondria (Figure 27b and A1c). Purkinje cells are 
GABAergic interneurons and GABA is generated via glutamate. Furthermore, Gls and Gls2 are 
commonly co-expressed in cells raising the question about their redundancy (Campos-
Sandoval et al., 2015). In fact, while these paralogs arose from gene duplication, Gls2 has 
evolved different properties and Gls deficiency is not compensated by Gls2 in mice (Masson 
et al., 2006). From the Gls2 gene two isoforms are generated via alternative transcription 
initiation: GAB and LGA (Martin-Rufian et al., 2012). In contrast to Gls, Gls2 is not activated by 
phosphate and can translocate to the nucleus via interaction motifs (Olalla et al., 2002). 
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Therefore, presumably Gls2 plays a multifunctional signaling role in cells and is less involved 
in glutamate metabolism (Marquez et al., 2006; Marquez et al., 2009).  
In addition to the qualitative validation via immunofluorescence staining, I quantified 
candidate enrichment via western blot analysis by comparing mitochondrial lysates from 
Purkinje cells with granule cells. I chose four unchanged proteins: Cox4i1 as ubiquitous 
mitochondrial protein, Got2 as neuronal protein, and sideroflexin-5 (Sfxn5) and mitochondrial 
glycine dehydrogenase (Gldc) as astrocyte-enriched proteins; as well as two granule cell-
Figure 28│ Western blot analysis of 
mitochondrial proteins found in cell type-
specific mitochondria from Purkinje cells 
and granule cells by mass spectrometry. 
(a) Representative western blot of cell 
type-specific mitochondrial lysates from 
Purkinje cells (PC) and granule cells (GC) 
probing for mitochondrial proteins: 
Cox4i1 (pan-mitochondrial), Got2 
(neuronal), Rmdn3 and Ociad2 (PC-
enriched), Sfxn5 and Gldc (astrocyte-
enriched), Ak4 and Mcu (GC-enriched). 
Differences are quantified in b. #, 
unspecific band not quantified; kDa, 
molecular weight in kilo Dalton.   
(b) Quantification of mitochondrial 
proteins shown as fold change to PC 
mitochondria and normalized to total 
protein amount and mitochondrial 
content. Box plot: median, quartile 1-3, 
whisker from min./max. value, and 
individual data points; n=4 mice 
quantified as technical triplicates.   
(c) Volcano plot testing for significant 
proteins between the mitochondrial 
proteome from granule cells (GC) and 
Purkinje cells (PC). Table inset shows 
average fold change obtained by mass 
spectrometry (MS) and western blot 
analysis (WB) for selected proteins. 
Proteins passing the FDR≤0.05, blue filled 
circles. Modified from Fecher et al. 
(2019), Supplementary Figure 10. 
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enriched (Ak4 and Mcu) and two Purkinje cell-enriched (Rmdn3 and Ociad2) proteins (Figure 
28a). This analysis confirmed the mass spectrometry-predicated fold changes (Figure 28b; 
Figure 28c, Table inset) with the exception of Gldc quantification. In contrast to the 
enrichment of Gldc in granule cell mitochondria over Purkinje cell mitochondria by mass 
spectrometry, I confirmed a rather uniform Gldc present in neurons. This difference could be 
due to antibody specificity in western blot application (Figure 28a, #); however, Gldc signals 
were also undetectable in neurons by immunofluorescence staining (Figure 30b and A1b) 
while strongly enriched in astrocytic mitochondria; hence, confirming the direction of our 
mass spectrometry prediction. 
Prior to our study, a group of mitochondrial proteins had been shown to be expressed in a cell 
type- and/or localized in a cell compartment-specific manner (see Chapter 1.4.1 and 1.4.2). 
Syntaphilin (Snph) is one of these proteins, which we had hoped to find as positive neuronal 
candidate in our mitochondrial profiling. Snph localizes to the outer mitochondrial membrane 
via its C-terminal transmembrane domain and it pauses mitochondrial transport along the 
axon (Kang et al., 2008). In our proteomic profiling, Snph was quantified in neuronal and 
astrocytic mitochondria (two-tailed, unpaired t-test with permutation-adjusted q-value:                  
PC vs A: *0.722, 0.0035; GC vs A: *0.886, 0.0008; PC vs GC: -0.164, 0.4703); however, its fold 
change did not pass our enrichment criterion (FC≥│1│). S ll, I performed immunofluorescence 
staining of Snph in mouse cerebellum to understand this divergence between its literature 
annotation  and  our  proteomic  quantification.  Supporting   our  data,  Snph  signals  did  not 
Figure 29│ Syntaphilin is enriched in cerebellar basket cells and their axons forming the pinceau 
organization. (a) Immunofluorescence staining of syntaphilin (Snph) in cerebellum from wild type 
(Cre−), L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM mice. Details show the 
merge channel with GFP-OMM (green) and the single Snph channels (magenta). Scale bars: 25 μm 
(detail 10 μm). (b) Schema depicting basket cell (Bs) position in molecular layer and relationship to 
Purkinje cell (PC). Bs form pericellular baskets on to PC soma and hillock with specialized terminals, 
termed pinceau. Confocal image showing Bs (green; GFP driven by parvalbumin promoter, 
Pvalb:GFP) and PC (blue; immunofluorescence staining against calbindin, αCalb) in mouse 
cerebellum. Note also stellate cells are labeled in Pvalb:GFP mouse line; however, their axons 
terminate on smooth shafts of PC dendrites. Scale bar: 25 μm. (c) Single confocal planes of a Z-stack 
illustrating basket (green, GFP) surrounding PC soma (blue, αCalb) and enrichment of syntaphilin 
labeling (Snph, magenta). Scale bar: 25 μm. (d) Comparison of two antibodies for Snph showing 
similar enrichment of Snph in Bs axons forming pinceau organization. ab192605 is raised against 
human Snph 1-100 AA; the second antibody (Kang et al., 2008) is raised against 225-428 AA. Here, 
Snph signals are more pronounced in PC – still, Snph is enriched in Bs axon. Ctr, 
immunofluorescence staining with omission of primary antibody; AA, amino acids; GFP, Pvalb:GFP; 
Calb, calbindin. Nuc, nuclear counter stain. Scale bars: 25 μm. Modified from Fecher et al. (2019), 
Supplementary Figure 9. 
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Figure 29│ Syntaphilin is enriched in cerebellar basket cells and their axons forming the pinceau 
organization (see previous page for legend). 
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colocalize with cell type-specific mitochondria visualized by MitoTag (Figure 29a). Still, intense 
Snph signals without GFP-OMM signal were localized at the soma of Purkinje cells (Figure 29a, 
arrowheads). This localization is characteristic for projections from basket cells, inhibitory 
neurons of the molecular layer (Pvalb:GFP, Figure 29b). To evaluate the hypothesis of Snph 
enrichment in basket cell axons, I performed immunofluorescence staining of Snph and 
calbindin in the cerebellum from Pvalb:GFP mice (provided by Arthur Konnerth, Institute of 
Neuroscience, TUM) to distinguish basket cells from Purkinje cells (Figure 29c). Indeed,                
Snph signals colocalized with the pericellular basket formation from basket cells (Buttermore 
et al., 2012) and surrounded Purkinje cell somas. I further corroborated this result with 
another Snph antibody produced by Kang et al. (2008; Figure 29d), with which I additional 
observed weak Snph signals in Purkinje cells. Given that Snph is enriched in another, yet not 
profiled cerebellar cell type and is present in IC Tom, our normalization strategy, i.e. the fold 
change of IC GFP to IC Tom per sample, weakens the cell type-specific contrast for this 
candidate among the profiled cell types. 
4.2.4. Candidates enriched in astrocytic mitochondria 
Finally in astrocytes, all selected candidates colocalized with the genetic GFP-OMM label in 
Gfap:Cre+/GFP-OMM tissue confirming their mitochondrial localization (Figure 30b). Here, the 
strongest enrichment was calculated for mitochondrial glycine dehydrogenase (Gldc;                    
two-tailed, unpaired t-test with permutation-adjusted q-value: PC vs A: *-4.443, <0.0001;              
GC vs A: *-2.625, <0.0001; PC vs GC: -1.818, 0.0653). Previous work established that Gldc is 
enriched in astrocytes, Bergmann glia and Müller cells (Sato et al., 1991), which I confirmed. 
However, surprisingly Gldc has not been used as astrocyte-specific mitochondrial protein since 
this report. Gldc is localized to the mitochondrial matrix and associated with the inner 
mitochondrial membrane (Motokawa and Kikuchi, 1971). While Gldc alone can breakdown 
glycine, it is more efficient in a multienzyme complex with three other protein, termed the 
glycine cleavage system (GCS; Bruin et al., 1973). It catabolizes                           𝑔𝑙𝑦𝑐𝑖𝑛𝑒 + 𝑇𝐻𝐹 + 𝑁𝐴𝐷      ⎯⎯  CH2-THF + CO2 + 𝑎𝑚𝑚𝑜𝑛𝑖𝑎 + 𝑁𝐴𝐷𝐻  (as part of the 1C 
metabolism; Lamers et al., 2009). As such, this system supplies cells with 1C units for 
nucleotide synthesis and DNA methylation (Tibbetts and Appling, 2010), but also degrades 
glycine, an inhibitory neurotransmitter and excitatory modulator of NMDA receptors 
dependent on brain region (Aprison and Daly, 1978; Johnson and Ascher, 1987). Astrocytes 
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recycle glycine via uptake from the synaptic cleft through the Na+/Cl--dependent glycine 
transporter 1 (Slc6a9), and thereby terminate neurotransmission (Verleysdonk et al., 1999). 
Patients with Gldc mutations present with nonketotic hyperglycinemia causing neuronal 
dysfunction in neonates (Kure et al., 2006; Bravo-Alonso et al., 2017).  
Secondly, I confirmed the enrichment of mitochondrial short-chain specific acyl-CoA 
dehydrogenase in astrocytic mitochondria (Acads; two-tailed, unpaired t-test with 
permutation-adjusted q-value: PC vs A: *-2.814, <0.0001; GC vs A: *-2.638, <0.0001; PC vs GC: 
Figure 30│ Candidates enriched in astrocytic mitochondria. (a) Scatter plot summarizing 
the fold changes of proteins from the pairwise comparison of cell type-specific 
mitochondrial proteomes (see Figure 23b). Details illustrate the enriched proteins in 
astrocytic mitochondria as well as pan-mitochondrial protein Cox4i1 with annotation of 
validated candidates in b. FC, fold change. (b) Immunofluorescence staining of candidates 
in cerebellum from Gfap:Cre+/GFP-OMM mice. Cox4i1 is a ubiquitous mitochondrial 
protein. Gldc, Acads, MaoB, Sfxn5 and Ak3 are predicted as astrocyte enriched. All 
proteins localize to mitochondria. Details show the merge channel and the single channels 
for GFP-OMM (green) and the candidate (magenta). Scale bars: 20 μm (detail 10 μm). 
Modified from Fecher et al. (2019), Figure 3.
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-0.176, 0.705; Figure 30b). Acads catalyzes the breakdown of short-chain FA (C4 – C6) in 
mitochondrial beta-oxidation and is localized to the mitochondrial matrix (Ikeda et al., 1983). 
Transcriptome analysis in mouse and human predicted the presence of FA oxidation in brain, 
and specifically an enrichment in astrocytes (Eraso-Pichot et al., 2018). Additionally, multiple 
reports provide strong evidence that neurons do not use FA as fuel (Schonfeld and Reiser, 
2017). Acads deficiency in humans causes a spectrum of phenotypes from metabolic acidosis 
to developmental delay and epilepsy (Jethva et al., 2008). 
Next, I confirmed monoamine oxidase type B enrichment in astrocytes (MaoB; two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: *-2.75, <0.0001; GC vs A: *-2.696, 
<0.0001; PC vs GC: -0.054, 0.9121; Figure 30b) as previously reported by Luque et al. (1995). 
MaoB is localized to the outer mitochondrial membrane (Cotzias and Dole, 1951; Schnaitman 
et al., 1967) and inactivates biogenic amines like dopamine, octopamine, tyramine, but also 
benzylamine and phenylethylamine (Waldmeier, 1987). In positron emission tomography, 
MaoB is used to visualize human brain activity (Fowler et al., 2002). 
Finally, I found the inner mitochondrial membrane protein sideroflexin-5 (Sfxn5; two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: *1.91, <0.0001; GC vs A: *-2.054, 
<0.0001; PC vs GC: 0.144, 0.7328) enriched in astrocytes (Figure 30b). First, sideroflexins were 
believed to transport iron (specifically Sfxn1; Fleming et al., 2001), later citrate as 
tricarboxylate carrier (Azzi et al., 1993), and currently only Sfxn1 and 3 function has been 
confirmed as serine transporters (Kory et al., 2018). In contrast, Sfxn4 has been associated 
with iron-sulfur cluster biogenesis (Paul et al., 2019). Miyake et al. (2002) reported neuronal 
localization of TCC, likely Sfxn3, and BBG-TCC enrichment in Bergmann glia, likely Sfxn5 (Rivell 
et al., 2019). I confirm Sfxn5 enrichment in Bergman glia and extend it to astrocytes in brain, 
retina and spinal cord. 
In summary, these examples of confirmed cell type-specific candidates demonstrate how 
mitochondrial biology is fine-tuned within the nervous system. While in many cases prior 
scientific reports documented cell type-enrichment for mitochondrial proteins, this 
knowledge has not surfaced further functional validation or protein relevance in the described 
cell types.  
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4.2.5. Neuronal and astrocytic candidates hint to differential pathways 
One reason for the lack in our understanding of cell type-enriched mitochondrial proteins 
might be their case-by-case description, from which further pathway analysis is needed to 
draw functional conclusions. I therefore performed pathway enrichment analysis probing for 
functional differences between neuronal (n=74) and astrocytic (n=114) candidates                     
(Figure 31a). I subgrouped the analysis in gene ontology terms, specifically biological process 
(GOTerm), and the pathway database of Kyoto encyclopedia of genes and genomes (KEGG), 
and compared the over-representation enrichment ratio between candidates and the mouse 
protein-encoding genome using WebGestalt (Liao et al., 2019; Figure 31b). Neuronal 
candidates grouped to the following significant terms: for GOTerm – mitochondrial transport 
Figure 31│ Pathway analysis of enriched candidates in mitochondria from astrocytes and cerebellar 
neurons. (a) Venn diagram depicting distribution of candidates among cell types. Neuronal 
candidates are grouped to n=74; astrocytic candidates to n=114. (b) Gene sets found via over-
representation analysis (ORA) of candidates against the coding mouse genome. Depicted terms are 
all significantly enriched (FDR<0.05, multiple testing corrected) and q-values are indicated per 
term. GOTerm was probed via biological process category and top gene sets were further clustered 
for maximal gene coverage. Individual gene sets can be found in Appendix 7.4. M., metabolism; p., 
process. Modified from Fecher et al. (2019), Supplementary Figure 8. 
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(e.g. Mfn2, Mcu, Slc25a22), cellular amino acid metabolism (e.g. Gls, Got2, Aars2), and organic 
acid biosynthetic process (e.g. Gls2, Got2, Hk1); for KEGG – ubiquinone biosynthesis                        
(e.g. Coq3, Coq6) and arginine biosynthesis (e.g. Gls, Got2, Gls2). Astrocytic candidates 
significantly grouped to the terms: for GOTerm – peroxisome organization (e.g. Acox1, Pex14, 
Mavs), fatty acid metabolism (e.g. Acads, Acadm, Cpt1a), and small molecule metabolism                   
(e.g. Oat, Gldc, Eci2); for KEGG – fatty acid degradation (e.g. Cpt1a, Cpt2, Acads), valine, 
leucine, isoleucine degradation (e.g. Echs1, Mut, Acads) and peroxisome (e.g. Cat, Dao, 
Pex14). Several gene sets recapitulated the previously described functions of validated 
candidates, for example the metabolic role of Got2, Gls and Acads.  
Surprisingly, the term ‘peroxisome’ appeared among the top enrichment ratios of astrocytic 
candidates in GOTerm and KEGG analysis. In addition, peroxisomal proteins were also among 
candidates as the biggest group of non-mitochondrial proteins (8 out of 20; Figure 24b).                         
I therefore chose two proteins, peroxisomal membrane protein PEX14 (Pex14; two-tailed, 
unpaired t-test with permutation-adjusted q-value: PC vs A: *-1.359, 0.0021; GC vs A: -0.872, 
0.0543; PC vs GC: -0.487, 0.3165; Figure 32) and catalase (Cat; two-tailed, unpaired t-test with 
permutation-adjusted q-value: PC vs A: *-2.255, <0.0001; GC vs A: *-2.237, <0.0001; PC vs GC: 
-0.018, 0.9694; Figure 32) for further investigation via immunofluorescence staining. Pex14 is 
Figure 32│ Peroxisomal proteins 
among mitochondrial proteomes 
from cell type-specific mitochondria. 
Scatter plot from Figure 23b 
depicting the fold changes per 
protein between the two volcano 
plots with (PC vs A) on the x-axis and 
(GC vs A) on the y-axis. Pex14 and 
Cat are among cell type-enriched 
candidates. Proteins with only one 
fold change between cell types are 
depicted at the axis with ∞ for the 
missing value. Blue filled circles, 
proteins passing at least one t-test 
between cell types; black filled 
circles, MitoCarta annotation; 
yellow outlined circles, peroxisomal 
annotation in LocTree3; PC, Purkinje 
cell; GC, granule cell; A, astrocyte. 
Note several peroxisomal proteins 
are included in MitoCarta. Modified 
from Fecher et al. (2019), Figure 3 
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localized to the peroxisomal membrane and is an essential part of the protein import 
machinery as well as responsible for organelle movement via tubulin interaction (Fransen et 
al., 1998; Bharti et al., 2011). In mouse cerebellum, I observed small puncta with Pex14 
antibody that are characteristic for peroxisomes. Punctate signals were equally distributed 
among cerebellar cell type, thereby excluding an enrichment due to overall peroxisomal 
enrichment in astrocytes (Figure 33a). While GFP-OMM signals were closely associated with 
Pex14 signals in all three cell types, I could not observed strict colocalization of signals as one 
would predicted for mitochondrial localization of Pex14 (Figure 33a, details in black box). This 
was in contrast to Cat immunofluorescence staining. Here, I observed intense, punctate 
staining in astrocytes – especially in Bergmann glia – as well as moderate signals that 
colocalized with GFP-OMM (Figure 33b, details in black box). Previously, Nagase et al. (2004) 
reported a similar distribution of Cat and Pex14 in mouse cerebellum. Cat detoxifies hydrogen 
peroxide in the lumen of peroxisomes. However, under respiratory conditions in 
Figure 33│ Peroxisomal Pex14 and catalase mainly localize to peroxisomes. 
Immunofluorescence staining of Pex14 (a) and catalase (Cat; b) in cerebellum from 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM mice. Details 
show the merge channel with GFP-OMM (green) and single channels of GFP-OMM and 
the candidate (magenta). Scale bars: 20 μm (detail 10 μm); 2 μm (detail in black box). 
Modified from Fecher et al. (2019), Supplementary Figure 9c. 
108 
 
Saccharomyces cerevisiae, Petrova et al. (2004) showed that Cat relocalizes to mitochondria 
despite the lack of an import signal. This study is in agreement with an earlier report of Cat 
activity in rat heart mitochondria (Radi et al., 1991). In fact, peroxisomes and mitochondria 
share an intimate relationship in cells: Sugiura et al. (2017) demonstrated that peroxisome    
de-novo biogenesis involves membrane recruitment from the endoplasmic reticulum and 
mitochondria; several proteins are localized to both organelles (see Figure 32, black filled 
circles with yellow outline; Costello et al., 2017; Costello et al., 2018); and in peroxisome 
disorders, like the Zellweger syndrome (Braverman et al., 2016), proteins are mislocalized to 
mitochondria due to the absence of peroxisomes (Sacksteder et al., 2000; Sugiura et al., 2017).  
Therefore in astrocytes, the significant enrichment of peroxisomal proteins with astrocytic 
mitochondria could point to a functional coupling of these organelles in vivo,                          
e.g. for beta-oxidation – a function shared between mitochondria and peroxisomes              
(Lazarow and De Duve, 1976); and here predicted to be enriched in astrocytic mitochondria 
(Figure 31b). 
4.3. Enhanced lipid oxidation in astrocytic mitochondria 
To expand our investigation of mitochondrial diversity on the functional level, we focused on 
the catabolic role of mitochondria to produce ATP via oxidative phosphorylation. In my initial 
selection process of cell type-specific candidates (see Chapter 4.2.1), I already noticed an 
abundance of enzymes involved in beta-oxidation among astrocytic candidates. This was 
further confirmed by our pathway analysis naming ‘fatty acid degradation’ (mmu00071;             
Figure 34│ Proteins involved in beta-oxidation are enriched in astrocytic mitochondria.   
Heat map depicting the average fold change (log2 FC (IC GFP vs IC Tom)) of LFQ intensity per 
protein involved in fatty acid (FA) degradation (related to mmu:00071). Proteins are 
grouped in FA import and FA degradation in the mitochondria matrix, and were curated 
according to localization in mitochondria (MitoCarta and previous reports). Values are 
obtained from Purkinje cell (PC), granule cell (GC) and astrocytic (A) mitochondria via mass 
spectrometry. * indicates a significant difference of FC ≥ │1│to the other values (one-tailed, 
unpaired t-test with FDR≤0.005) ; crossed field, no data; heat map ranges from -4 (blue) to 
4 (red). Modified from Fecher et al. (2019), Figure 5a. 
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Table A5) as most enriched gene set among astrocytic candidates. While astrocytes (Edmond 
et al., 1987; Sayre et al., 2017) and hypothalamic neurons (McFadden et al., 2014) in culture 
respire on fatty acids (FA), the use of long-chain FA (≥C14) is debated in the central nervous 
system (reviewed in Schonfeld and Reiser, 2013; and Panov et al., 2014). In support of neural 
FA oxidation, Ebert et al. (2003) calculated that 20% of steady state cerebral energy is 
generated by mitochondrial beta-oxidation based on octanoic acid metabolism in rats. 
Furthermore, neural stem/progenitor cells depend on FA oxidation in their quiescent state 
(Knobloch et al., 2017; see Chapter 1.4.2). We therefore further corroborated beta-oxidation 
in immunocaptured mitochondria from the adult mouse cerebellum. 
For mitochondrial beta-oxidation, FA are first imported over the mitochondrial membranes 
and then metabolized to acetyl-CoA (see Chapter 1.2.1.1). The majority of proteins involved 
in these two steps were significantly enriched in our mitochondrial proteome from cerebellar 
astrocytes compared to Purkinje cell and granule cell mitochondria (Figure 34, *; Table A2). 
For FA metabolism, FA need to be converted to their active acyl-CoA form via a family of acyl-
CoA synthetases (Acs; reviewed in Watkins, 2008). Of these, medium-chain (Acsm5) and short-
chain (Acss1, Acss3) Acs were significantly enriched in astrocytic mitochondria (Figure 34, *, 
FA import). In contrast to long-chain FA, FA ≤C12 can cross mitochondrial membranes and are 
Figure 35│ Import machinery for long-chain fatty acids is enriched in astrocytic mitochondria. 
Immunofluorescence staining of (a) Cpt1a and (b) Slc25a20 in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM mice. Details show the 
merge channel with GFP-OMM (green) and the single channels. Scale bars: 25 μm (detail 10 μm). 
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conjugated to CoA in the mitochondrial matrix (Williamson et al., 1968). Long-chain FA are 
activated via CoA conjugation in the cytosol, which were not enriched in our proteomic 
profiling, and imported via the carnitine shuttle system into mitochondria. Here, Cpt1a 
conjugates  acyl-CoA + L-carnitine     ⎯⎯⎯⎯  𝑎𝑐𝑦𝑙𝑐𝑎𝑟𝑛𝑖𝑡𝑖𝑛𝑒 + 𝐶𝑜𝐴, which was reported to be    
rate-limiting in astrocytes (Blazquez et al., 1998). Acylcarnitine is transported over the inner 
mitochondrial membrane via Slc25a20 (Iacobazzi et al., 2004) and Cpt2 converts                           𝑎𝑐𝑦𝑙𝑐𝑎𝑟𝑛𝑖𝑡𝑖𝑛𝑒 + 𝐶𝑜𝐴      ⎯⎯⎯  acyl-CoA + L-carnitine   (Bonnefont et al., 2004). 
To verify our proteomics data, we first performed immunofluorescence staining of proteins 
involved in FA import in mouse cerebellum. Laura Trovò (L.T.; Institute of Neuronal Cell 
Biology, TUM) optimized Cpt1a immunofluorescence staining and I performed the experiment 
shown in Figure 35a confirming enrichment of Cpt1a in astrocytes, including Bergmann glia. 
Cpt1a signals colocalized with cell type-specific GFP-OMM confirming its mitochondrial 
localization. Similar cell type enrichment of Cpt1a was previously reported by Jernberg et al. 
(2017). Secondly, I optimized and confirmed Slc25a20 enrichment in astrocytic mitochondria 
(Figure 35b). Again, signals colocalized with GFP-OMM confirming mitochondrial localization. 
For FA degradation, imported acyl-CoA is shortened to acetyl-CoA via Acads and the 
trifunctional protein in repeated cycles. The majority of proteins involved in this process were 
enriched in astrocytic mitochondria (Figure 34, *, FA degradation). We therefore thought to 
determine the ability of astrocytic mitochondria to respire on long-chain fatty acids in 
comparison to neuronal mitochondria. For this, L.T. immunocaptured mitochondria from 
mouse cerebellum using L7:Cre+/GFP-OMM or Gfap:Cre+/GFP-OMM mice (Figure 36a). To 
normalize experimental and genetic variabilities between groups, mitochondria were isolated 
Figure 36│ Astrocytic mitochondria respire better on long-chain fatty acids than neuronal 
mitochondria. (a) Isolation of mitochondria via immunocapture from L7:Cre+/GFP-OMM 
cerebellum and Gfap:Cre+/GFP-OMM cerebellum. (b-d) Oxygen consumption rate (OCR) of 
immunocapture mitochondria from L7:Cre+/GFP-OMM (PC, magenta) and Gfap:Cre+/GFP-OMM (A, 
blue) mice. OCR is shown as percentage of basal respiration with indicated injections and 
calculated parameters: coupling efficiency (CE), respiratory control ratio (RCR) and spare 
respiratory capacity (SRC). For comparison, calculated parameters are normalized to 
corresponding IC Tom value (dashed line). Left side: representative data from one experiment per 
genotype; right side: quantification. Mitochondrial respiration was probed using   
(b) L-palmitoylcarnitine+malate (beta-oxidation; n≥9 mice from 12 independent experiments);   
(c) pyruvate+malate (complex I; n≥6 mice from 9 independent experiments) and   
(d) succinate+rotenone (complex II; n≥6 mice from 9 independent experiments) as substrates. Line 
graph: mean±s.e.m.; box plot: median, quartile 1-3, whisker from min./max. value, and   
individual data points; P values from statistical testing are shown. Modified from Fecher et al. 
(2019), Figure 5.  
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Figure 36│ Astrocytic mitochondria respire better on long-chain fatty acids than neuronal 
mitochondria (see previous page for legend). 
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via IC Tom and IC GFP, and results normalized to IC Tom, which represents the average 
cerebellar mitochondrion. First, L.T. analyzed oxygen consumption measurements in the 
presence of L-palmitoylcarnitine+malate (Figure 36b). Prior evidence suggested that astrocytic 
mitochondria could be coupled to peroxisomes in a cell type-specific manner (see Chapter 
4.2.5). We therefore used the pre-conjugate of L-palmitate (C16:0), given that its carbon chain 
length and carnitine-conjugate are prerequisites for beta-oxidation in mitochondria, but not 
peroxisomes (Wanders et al., 2016). Astrocytic mitochondria oxidized significantly more                   
L-palmitoylcarnitine than Purkinje cell mitochondria and performed in all calculated 
parameters better than neuronal organelles (one-tailed, unpaired Welch’s test: CE, 1.18-fold, 
P=0.0297; RCR, 1.60-fold, P<0.0001; SRC, 1.74-fold, P<0.0001; n≥9 mice). This was in stark 
contrast to their respiration on pyruvate+malate (complex I, Figure 36c) and 
succinate+rotenone (complex II, Figure 36d), where we found no significant difference 
between cell type-specific mitochondria. Still, comparing the oxygen consumption ratios of 
astrocytic mitochondria across substrates indicated that for beta-oxidation, four times more 
mitochondrial mass was necessary to achieve respiration rates close to complex II respiration 
(8 vs 2 μg; see Table 2). 
In summary, these experiments independently confirmed our prediction of enhanced                  
beta-oxidation in astrocytic mitochondria and their superior performance on                          
L-palmitoylcarnitine compared to Purkinje cell mitochondria. However, in comparison to other 
probed substrates, beta-oxidation seemed rather inefficient even in astrocytes, which is in 
agreement with other reports comparing beta-oxidation capacity of brain mitochondria to 
liver and heart (Bird et al., 1985; Yang et al., 1987). 
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4.4. Enhanced Ca2+ buffering in granule cell mitochondria via Mcu 
We were initially intrigued by our profiling result revealing enrichment of Mcu (Figure 27b) 
and to a similar degree of its interactors: Micu1 (two-tailed, unpaired t-test with              
permutation-adjusted q-value: PC vs A: -0.137, 0.5076; GC vs A: *1.385, 0.0001; PC vs GC:                 
*-1.522, 0.0005) and Micu3 (two-tailed, unpaired t-test with permutation-adjusted q-value: 
PC vs A: -0.216, 0.2469; GC vs A: *1.406, <0.0001; PC vs GC: *-1.622, 0.0007) in granule cell 
mitochondria. The finding of robust differences in Mcu complex between neuronal subtypes 
was unexpected given the known regulation of the Mcu complex via Micu1-3, its modification 
depending on McuB incorporation (see Chapter 1.2.3) and its long half-life (De Stefani et al., 
2016). 
I therefore verified Mcu enrichment qualitatively via immunofluorescence staining in mouse 
cerebellum and confirmed its enrichment in granule cell mitochondria (Figure 37a). Whereas                     
I observed no Mcu signals in Purkinje cell mitochondria, astrocytic mitochondria colocalized 
with dim Mcu signals and granule cell mitochondria with intense signals. To quantitatively 
corroborate this data, I performed western blot analysis using cell type-specific mitochondria 
from cerebellum (Figure 37b). While Mcu levels between granule cell and astrocytic 
mitochondria were not significantly different and only showed a trend towards lower levels in 
astrocytes (A: 45.4±12.0% compared to GC), Mcu protein levels were significantly reduced to 
31.7±5.7% in Purkinje cell mitochondria (one-way Friedman test with post hoc testing:               
PC vs GC, P=0.0047; n=5 isolations). As previously reported (Sancak et al., 2013), protein levels 
of mitochondrial essential MCU regulator (Emre) correlate with Mcu levels and were also 
reduced in Purkinje cell and astrocytic mitochondria. 
Next, I explored the capacity of cell type-specific mitochondria to uptake extramitochondrial 
Ca2+ and confirmed Mcu enrichment on the functional level in granule cells. In this in vitro 
assay, isolated mitochondria are spiked with Ca2+ injections and Ca2+ uptake is indirectly 
measured via the low-affinity Ca2+ indicator CalciumGreen-5N, which is impermeant. I isolated 
cell type-specific mitochondria from Purkinje cells, granule cells and astrocytes and probed 
their Ca2+ uptake in the absence or presence of Ru360, a Mcu inhibitor (Figure 37c). While 
mitochondria from granule cells (69.5±7.3%) and astrocytes (43.9±9.6%) buffered the Ca2+ 
pulse compared to the ‘+Ru360’ condition, Purkinje cell mitochondria demonstrated a 
significantly reduced capacity (Figure 37d; 20.5±5.9%; one-way ANOVA with post hoc testing:  
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Figure 37│ Mcu is enriched in granule cell mitochondria and enables their Ca2+ uptake capacity. 
(a) Immunofluorescence staining of Mcu in cerebellum from wild type (Cre−), L7:Cre+/   
GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM mice. Details show the merged 
channel with GFP-OMM (green) and single channels. Scale bars: 25 μm (detail 10 μm).   
(b) Western blot analysis of Mcu levels in cell type-specific mitochondria. Top: representative 
western blot of mitochondrial lysates from Purkinje cells (PC), granule cells (GC) and   
astrocytes (A) probing for Mcu, Emre and ATP5a. Bottom: quantification of Mcu shown as fold 
change to GC mitochondria and normalized to total protein amount and mitochondrial content. 
kDa, molecular weight in kilo Dalton; n=5 isolations quantified as technical duplicates. (c-d) Ca2+ 
uptake assay in cell type-specific mitochondria. (c) Representative experiment of 
immunocaptured mitochondria in the absence (black line) or presence of Ru360 (blue line). Ca2+ 
uptake is reflected by a decrease of extramitochondrial CaGreen-5N fluorescence after 20 μM 
CaCl2 pulse (triangle). (d) Quantification of Ca2+ uptake related to the first CaCl2 pulse and is 
shown as ΔAUC/AUCRu360. n≥5 isolations; box plot: median, quartile 1-3, whisker from 
min./max. value, and individual data points; P values from statistical testing are shown. 
Modified from Fecher et al. (2019), Figure 6. 
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PC vs GC, P=0.0018; n≥5 isolations). Again, astrocytic mitochondria showed a tendency 
towards a lower Ca2+ uptake capacity (GC vs A, P=0.1023; n≥5 isolations). 
To further verify that Mcu expression was responsible for the observed Ca2+ uptake in granule 
cells, I generated a granule cell-specific Mcu knockout mouse model (see Chapter 3.2.3.3).   
For this, Gabra6:Cre+/GFP-OMM mice were crossed to Mcutm1c mice, which harbor loxP sites 
around exon 5 of the murine Mcu locus. First, I confirmed Mcu deletion in granule cells by 
immunofluorescence staining (Figure 38a). While in McuGC:WT mice GFP-OMM colocalized with 
Mcu signals, this colocalization was absent in McuGC:ko mice and Mcu signals were most 
prominent in neural cells of the molecular layer, likely interneurons or Bergmann glia. 
Secondly, I immunocaptured granule cell mitochondria from Mcutm1c crossings and quantified 
Mcu deletion by western blot analysis (Figure 38b). Here, Mcu protein levels were significantly 
reduced to 54.7±4.4% in McuGC:+/− and 6.1±0.8% in McuGC:ko animals (one-way REML with 
Geisser-Greenhouse correction and post hoc testing: P<0.0001; n≥6 mice). Additionally,              
Emre was undetectable in McuGC:ko mitochondria. 
Finally, I tested these mitochondria in Ca2+ uptake assays and confirmed that Mcu deletion 
abolishes the observed Ca2+ uptake in granule cell mitochondria (Figure 38c). While 
immunocaptured mitochondria from McuGC:WT (69.5±7.3%) and McuGC:+/− animals (54.9±6.2%) 
buffered Ca2+ compared to the ‘+Ru360’ condition, mitochondria from McuGC:ko failed in this 
assay (Figure 38d; -0.14±6.7%; one-way ANOVA with post hoc testing: GC:WT vs GC:ko and 
GC:+/− vs GC:ko, P<0.0001; n≥5 mice). Interestingly, despite the reduction of Mcu to 54.7% in 
heterozygous McuGC:+/− animals, mitochondrial Ca2+ uptake was not significantly different 
compared to McuGC:WT (GC:WT vs GC:+/−, P=0.3344; n≥5 mice). I observed similar results in 
astrocytic mitochondria, where Mcu is reduced to 45.4% compared to granule cell 
mitochondria; also, here, no significant difference was noticed in Ca2+ uptake capacity               
(Figure 37d). 
In summary, these experiments functionally corroborated our finding of the enhanced 
expression of the Mcu complex in granule cell mitochondria and their related superior ability 
to buffer Ca2+ compared to other cerebellar cell types. Interestingly, while neuronal 
mitochondria from Purkinje cells were unable to uptake Ca2+ in vitro, astrocytic mitochondria 
performed well in this task despite lower Mcu expression. Surprisingly, granule cell-specific 
ablation of Mcu did not cause behavioral alterations or neuronal death up to 6 month of age. 
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Figure 38│ Ablation of Mcu in granule cells disrupts Ca2+ uptake capacity. Granule cell-specific 
ablation of Mcu was generated by breeding Gabra6:Cre+ mice (GC:Cre+) with Mcutm1c mice.   
(a-b) Validation of Mcu depletion in granule cells. (a) Mcu staining in cerebellum from 
GC:Cre+/GFP-OMMxMcuGC:WT and GC:Cre+/GFP-OMMxMcuGC:ko mice. Details show the merged 
channel with GFP-OMM (green) and single channels. Scale bars: 25 μm (detail 10 μm).   
(b) Western blot analysis of Mcu levels in granule cell mitochondria with McuGC:WT, McuGC:+/− and 
McuGC:ko background. Top: representative western blot of mitochondrial lysates from McuGC:WT 
(GC:WT, black), McuGC:+/− (GC:+/−, dark gray) and McuGC:ko (GC:ko, light gray) probing for Mcu, 
Emre and ATP5a. Bottom: quantification of Mcu shown as fold change to WT mitochondria and 
normalized to total protein amount and mitochondrial content. kDa, molecular weight in kilo 
Dalton; n≥6 mice quantified as technical duplicates. (c-d) Ca2+ uptake assay in Mcu-deficient 
granule cell mitochondria. (c) Representative experiment of immunocaptured granule cell 
mitochondria with McuGC:WT, McuGC:+/− and McuGC:ko background in the absence or presence of 
Ru360 (blue line). Ca2+ uptake is reflected as a decrease of extramitochondrial CaGreen-5N 
fluorescence after 20 μM CaCl2 pulse (triangle). (d) Quantification of Ca2+ uptake related to the 
first CaCl2 pulse and is shown as ΔAUC/AUCRu360. n≥5 mice; box plot: median, quartile 1-3, 
whisker from min./max. value, and individual data points; P values from statistical testing are 
shown. Modified from Fecher et al. (2019), Figure 6. 
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4.5. Enhanced ER-mitochondria contact sites in Purkinje cells via Rmdn3 
Mitochondria form privileged sites of contact with a number of other cellular organelles. 
These sites are established via tether and spacer proteins (reviewed in Scorrano et al., 2019) 
and establish cellular communication and signaling (see Chapter 1.2.4). Given the importance 
of these organelle contact sites, we were especially interested in Rmdn3 among the 
candidates enriched in Purkinje cells. This outer mitochondrial membrane protein (Lv et al., 
2006) has been described as tether between the endoplasmic reticulum (ER) and 
mitochondria (Stoica et al., 2014) via the interaction with ER-resident proteins, like VAPB (De 
Vos et al., 2012) and ORP5/8 (Galmes et al., 2016). Koch et al. (2009) previously reported 
neuronal expression of Rmdn3 and specifically its enrichment in a subpopulation of Purkinje 
cells with strong signals in dendrites. I therefore optimized immunofluorescence staining of 
Rmdn3 in mouse tissue and validated its abundance in Purkinje cells (Figure 39a). In contrast 
to Koch et al. (2009), I detected Rmdn3 uniformly in all Purkinje cells and throughout their 
cellular geometry. Penetration issues often hinder axonal labeling of mitochondria; however, 
frequently Purkinje cell axons were positive for Rmdn3 – especially in recurrent axon branches 
to neighboring Purkinje cells. Furthermore, our Rmdn3 antibody recognized the full-length 
isoform of 51 kDa and additional higher molecular weight forms (Figure A5b), while the 
antibody by Koch et al. (2009) mainly detected a smaller, 30-34 kDa band in cerebellum. 
Rmdn3 signals colocalized with GFP-OMM signals in L7:Cre+/GFP-OMM tissue further 
confirming its mitochondrial localization, while mitochondria in granule cells and astrocytes 
were devoid of Rmdn3 signals. 
Related to the abundant in vitro literature of Rmdn3 and VAPB as tether between the ER and 
mitochondria, we hypothesized that Rmdn3 abundance in Purkinje cells might be linked to an 
increased ER-mitochondria contact in vivo. To test this theory, we performed ultrastructural 
analysis of organelle contacts in wild type cerebellum. Nicolas Snaidero (N.S.; Institute of 
Neuronal Cell Biology, TUM) performed tissue preparation for electron microscopy and 
acquired images, which were further quantified by me in a blinded manner. I quantified 
contact sites within a distance of ≤30 nm between mitochondrial perimeter and ER using 
images from Purkinje cell and granule cell perikarya as well as from areas around the nucleus 
of astrocytes, which adjoined Purkinje cell perikarya (Figure 39b). While the cellular 
organization of Purkinje cell and adjoined astrocyte was similar in terms of organelle 
composition and  space, the  cytoplasm  of granule cells  was thin due to the dense packing of 
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Figure 39│ Rmdn3 and ER-mitochondria 
contact sites are enriched in Purkinje cells. 
(a) Immunofluorescence staining of   
Rmdn3 in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-
OMM and Gfap:Cre+/GFP-OMM mice. 
Details show the merged channel with 
GFP-OMM (green) and single channels. 
Scale bars: 25 μm (detail 10 μm).   
(b)  Electron micrographs from wild   
type cerebellum depicting intracellular 
organelles in Purkinje cell (PC), astrocyte 
(A) and granule cell (GC). For granule cells, 
an overview with multiple cells in the 
granule cell layer is shown (cell outline, 
white) and detail. Right side: organelles are   
color-coded: mitochondria, magenta;   
ER, yellow; contact sites ≤ 30 nm, orange.   
Scale bars: 400 nm (GC overview 5 μm).   
(c) Ultrastructural analysis of ER-
mitochondria contact sites shown as % 
mitochondrial perimeter in ≤30 nm 
distance to the ER. Per cell type, the 
quantification is shown with cells (left   
side; n≥10 cells from two animals) and 
mitochondria (right side; n≥120 
mitochondria from two mice) as entities. 
Box plot: median, quartile 1-3, whisker 
from min./max. value, and individual data 
points; P values from statistical testing are 
shown and were performed based on 
mitochondria as entities due to differences 
in cell geometry. Modified from Fecher et 
al. (2019), Figure 7. 
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cells in the  granule  cell layer (Figure 39b,  granule cells  overview). In contrast, mitochondrial 
size was similar between granule cells and astrocytes, while Purkinje cell mitochondria were 
smaller (see scale bar difference, Figure 39b). Quantification of ER-mitochondria contact sites 
revealed a significant increase in Purkinje cells (37.7±1.3%) compared to either granule cells 
(6.1±0.7%) or astrocytes (14.5±0.9%; one-way Kruskal-Wallis test with post hoc testing:                          
in all cases, P<0.0001; n≥120 mitochondria from two mice; Figure 39c).  
Still, the observations so far represented a correlation between high abundance of Rmdn3 and 
high frequency of ER-mitochondria contact sites in Purkinje cells, which might be unrelated to 
Rmdn3 itself. To demonstrate that Rmdn3 directly mediates organelle contacts in vivo, we 
obtained a knockout-first allele of Rmdn3 from the KOMP Repository (Rmdn3tm1a; see Chapter 
3.2.3.4). These mice harbor an expression cassette between exon 2 and 5 of the murine 
Rmdn3 locus, which disturbs normal expression. First, I confirmed Rmdn3 deletion in Rmdn3ko 
mice by immunofluorescence staining (Figure 40a). While I observed strong Rmdn3 signals in 
Purkinje cells of Rmdn3WT cerebellum, these signals were absent in the cerebellum from 
Rmdn3ko mice. Here, weak signals in Bergmann glia were observed, which are likely unspecific 
and caused by antibody binding in the absence of target. Secondly, I quantified Rmdn3 protein 
levels by western blot analysis (Figure 40b). I probed total cerebellum with Rmdn3 antibody 
and confirmed a significant reduction of full-length Rmdn3 protein and its higher molecular 
weight forms in Rmdn3ko tissue (11.4±3.5%; RM one-way ANOVA with post hoc testing: all 
conditions, P<0.001; n=4 animals). No smaller molecular weight bands were detected with our 
antibody in Rmdn3ko tissue (Figure A5b). Additionally, the mouse model reduced Rmdn3 levels 
in a gene dose-dependent manner with Rmdn3  protein levels of 46.5±3.3% in Rmdn3+/− tissue 
when compared to Rmdn3WT. 
Finally, we characterized ER-mitochondria contact sites in Rmdn3ko tissue. For this,                          
N.S. performed sample preparation and image acquisition in perikarya of Purkinje cells and 
adjoined astrocytes, and I quantified the frequency of organelle contacts within a distance of 
≤30 nm in a blinded manner. While the frequency of ER-mitochondria contact sites was 
unchanged in astrocytes upon Rmdn3 depletion (Figure 40c, right side; one-way ANOVA with 
post hoc testing: P=0.0935; n≥10 cells from 2-3 mice), organelle contacts were significantly 
reduced in Purkinje cells in a gene dose-dependent manner: Rmdn3WT, 37.1±1.8%; Rmdn3+/−, 
28.3±1.3%; Rmdn3ko, 19.6±1.3% (Figure 40c, left side; one-way ANOVA with post hoc testing: 
WT vs +/−, P=0.0022; WT vs ko, P<0.0001; +/− vs ko, P=0.0016; n≥8 cells from 2-3 mice). 
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Figure 40│ Rmdn3 mediates ER-mitochondria contact sites in Purkinje cells in vivo.   
(a-b) Validation of Rmdn3 depletion in cerebellum of Rmdn3tm1a mice.   
(a) Immunofluorescence staining of Rmdn3 in cerebellum from wild type (Rmdn3WT) and 
Rmdn3tm1a (Rmdn3ko) mice. Details show the merged channel with nuclear counter stain 
(Nuc) and single channels. Note defuse antibody signals in Rmdn3ko tissue likely due to 
antibody specificity. Scale bars: 25 μm (detail 10 μm). (b) Western blot analysis of Rmdn3 
levels in mouse cerebellum from Rmdn3WT (black), Rmdn3+/− (dark gray) and Rmdn3ko (light 
gray) mice. Top: representative western blot of total cerebellum lysate probing for Rmdn3, 
ATP5a and CypD. Bottom: quantification of Rmdn3 (51-130 kDa) shown as fold change to 
Rmdn3WT and normalized to total protein amount and mitochondrial content. kDa, 
molecular weight in kilo Dalton; n=4 mice quantified as technical triplicates.   
(c) Ultrastructural analysis of ER-mitochondria contact sites in Purkinje cells (left side, 
magenta) and astrocytes (right side, blue) from Rmdn3WT, Rmdn3+/− and Rmdn3ko mice. 
Quantification is shown as % mitochondrial perimeter in ≤30 nm distance to the ER and per 
cell type. Either cells (PC, n≥8 cells; A, n≥10 cells from 2-3 mice) or mitochondria (PC, n≥189 
mitochondria; A, n≥105 cells  from 2-3 mice) were used as entities. Box plot: median, 
quartile 1-3, whisker from min./max. value, and individual data points; P values from 
statistical testing are shown and were performed based on cells as entities for the 
comparison among genotypes. Modified from Fecher et al. (2019), Figure 7. 
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In summary, we demonstrated that Rmdn3 is highly enriched in Purkinje cells as predicted by 
our cell type-specific profiling of mitochondria. In Purkinje cells, it participates in 
approximately half of the established contact sites between the ER and mitochondria given 
that the organelle contact frequency drops in Rmdn3ko Purkinje cells from 37.1% to 19.6%. 
Interestingly, on the one hand, other tether proteins are not compensating for the loss of 
Rmdn3, which speaks for the specificity of its tethering function and interaction partners. On 
the other hand, Rmdn3ko mice behave normal without Purkinje cell loss up to an age of one 
year, which might hint to compensation by other pathways unrelated to ER-mitochondria 
contact sites. 
4.6. Mitochondrial diversity in health and disease 
Our profiling of cell type-specific mitochondria in mouse cerebellum has led us to the 
discovery of a number of unique specializations among neural mitochondria. In Chapter 4.2,             
I have linked the validation of selected candidates by immunofluorescence staining to their so 
far reported biological function, which in many cases is incomplete and not studied with 
regard to the here reported cell type-enrichment. In the case of beta-oxidation in astrocytes, 
mitochondrial Ca2+ uptake in granule cells and ER-mitochondrial contact sites in Purkinje cells, 
we have confirmed our profiling prediction and further corroborated the cell type-specific 
enrichment of these mitochondrial functions in the respective cell types. 
However, apart from characterizing individual candidates in their function and contribution to 
cellular physiology, these proteins also represent cell type-specific ‘markers’ of mitochondria 
in neural tissue – with the current validation in mouse cerebellum. Mitochondrial form is 
frequently used for the analysis of disease models and pathology (reviewed in Eisner et al., 
2018; Friedman and Nunnari, 2014) and it is intimately related to mitochondrial function 
(Benard et al., 2007; reviewed in Zick et al., 2009). Therefore, the application of cell type-
specific mitochondrial markers in the central nervous system might be a powerful tool to 
investigate mitochondrial contribution to development, health and disease.  
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4.6.1. Mitochondrial markers are conserved across neural tissues and species 
To establish cell type-specific mitochondrial ‘markers’ as tool to characterize mitochondrial 
involvement in development, health and disease, further validation was necessary in other 
neural tissues and potential species of interest. 
First, I confirmed the presence of mitochondrial markers in mouse cortex (Figure 41) and 
spinal cord (Figure 42). Here, GFP-OMM was used to confirm mitochondrial localization using 
the Cre-driver lines Rbp4:Cre for excitatory neurons of layer 5 (Figure 41a), Gfap:Cre for 
astrocytes and ChAT:Cre for cholinergic neurons including motor neurons in spinal cord 
(Figure 42a). While Cox4i1 signals colocalized with GFP-OMM in all three crossings, other 
mitochondria were labeled in addition as previously seen in cerebellum (Figure 19).                          
This further confirmed Cox4i1 as pan-mitochondrial protein. 
Among mitochondrial markers enriched in neurons, I confirmed enrichment of Ociad2 and 
Protein NipSnap homolog 1 (Nipsnap1). In cerebellum, Ociad2 was enriched in Purkinje cells 
(Figure 25b and 26a) and was previously introduced as outer mitochondrial membrane 
protein. In mouse cortex, Ociad2 colocalized with a subset of neurons in the cortex and CA3 
region of the hippocampus. Interestingly, Ociad2 signals overlapped well with the genetic 
label from Rbp4:Cre in layer 5/6 neurons. In spinal cord, Ociad2 signals appeared dim and 
mostly restricted to neuronal perikarya (Figure 41b). Astrocytic mitochondria were devoid of 
Ociad2 signal in both tissues (Figure 41c and 42c).  
From our initial profiling of cerebellar mitochondria, we found Nipsnap1 (two-tailed, unpaired 
t-test with permutation-adjusted q-value: PC vs A: *0.79, 0.0027; GC vs A: *1.169, 0.0002;              
PC vs GC: -0.38, 0.1036) significantly enriched in granule cell mitochondria and I validated its 
neuronal enrichment in cerebellum as one of the selected candidates (Figure  A1d).   
Immunofluorescence   staining   could  not   confirm   a  higher  fold   change  in  granule  cell  
Figure 41│ Cell type-specific mitochondrial markers distinguish neuronal and astrocytic mitochondria 
in cortex. (a) Cre-driver lines crossed to the MitoTag mouse line to tag mitochondria in excitatory 
neurons of layer 5/6 via Rbp4:Cre and astrocytes via Gfap:Cre. Brain overview shows general 
expression pattern for Rbp4:Cre and details show expression patterns for both lines in mouse cortex. 
Scale bars: 1 mm (brain); 25 μm cortex. (b-c) Immunofluorescence staining of candidates in cortex 
from (b) Rbp4:Cre+/GFP-OMM and (c) Gfap:Cre+/GFP-OMM mice. Cox4i1 is a ubiquitous 
mitochondrial protein. Proteins are enriched in: neurons, Nipsnap1 and Ociad2; and astrocytes, Gldc 
and Sfxn5. All proteins localize to mitochondria. Details show the merge channel and the single 
channels for GFP-OMM (green) and the candidate (magenta). Scale bars: 25 μm (detail 10 μm). 
Modified from Fecher et al. (2019), Supplementary Figure 12. 
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Figure 41│ Cell type-specific mitochondrial markers distinguish 
neuronal and astrocytic mitochondria in cortex (see previous 
page for legend). 
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mitochondria compared to Purkinje cells and therefore, Nipsnap1 was classified as neuronal 
as previously reported by Nautiyal et al. (2010). This result was confirmed in mouse cortex and 
spinal cord, where Nipsnap1 signals colocalized with neuronal expressed GFP-OMM                    
(Figure 41b and 42b), but not with astrocytic labeling (Figure 41c and 42c).  
Among astrocytic candidates, I confirmed cell type-specific expression of Gldc and Sfxn5 in 
cortex and spinal cord (Figure 41c and 42c). Both proteins were absent in neuronal 
mitochondria (Figure 41b and 42b). While astrocytic mitochondria were evenly distributed in 
cortex – known as astrocyte tiling (Bushong et al., 2002), signals from astrocytic mitochondria 
were intense in spinal cord gray matter, but sparse in white matter (Figure 42a).  This might 
reflect astrocyte density or heterogeneity (reviewed in Lundgaard et al., 2014). 
Other cell type-enriched candidates from cerebellum were less useful to differentiate neural 
mitochondria in cortex and spinal cord. For example, Rmdn3 signals were present in neuronal 
mitochondria, but dimmer than in cerebellum and evenly distributed among neurons.                          
In contrast, Got2 signals saturated at the tissue sections surface due to its high neuronal 
abundance. Mcu was highly enriched in CA3 neurons of the hippocampus as previously 
reported (Markus et al., 2016), but discriminated less well neuronal from astrocytic 
mitochondria than in cerebellum. 
Still, the experiments in cortex and spinal cord provided use with a pan-neuronal (Nipsnap1), 
a neuronal subtype (Ociad2) and two astrocytic (Gldc, Sfxn5) markers that efficiently recognize 
cell type-specific mitochondria across tissues – in contrast to the pan-mitochondrial marker 
Cox4i1.  
Secondly, we questioned whether mitochondrial diversity as observed in mouse cerebellum 
could be conserved across species and therefore tested mitochondrial markers in cerebellum 
of other mammals. Conservation across species would be a remarkable result given its 
application for  biomedical  research that often  uses rodent animal  models to explore  human 
Figure 42│ Cell type-specific mitochondrial markers distinguish neuronal and astrocytic mitochondria 
in spinal cord. (a) Cre-driver lines crossed to the MitoTag mouse line to tag mitochondria in 
cholinergic neurons including motor neurons via ChAT:Cre and astrocytes via Gfap:Cre. Spinal cord 
overviews show general expression pattern with details of ventral horn. Scale bars: 500 μm (detail 
25 μm). (b-c) Immunofluorescence staining of candidates in spinal cord from (b) ChAT:Cre+/GFP-
OMM and (c) Gfap:Cre+/GFP-OMM mice. Cox4i1 is a ubiquitous mitochondrial protein. Proteins are 
enriched in: neurons, Nipsnap1 and Ociad2; and astrocytes, Gldc and Sfxn5. All proteins localize to 
mitochondria. Details show the merge channel and the single channels for GFP-OMM (green) and 
the candidate (magenta). Scale bars: 25 μm (detail 10 μm). Modified from Fecher et al. (2019), 
Supplementary Figure 12. 
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Figure 42│ Cell type-specific mitochondrial markers distinguish 
neuronal and astrocytic mitochondria in spinal cord (see previous 
page for legend). 
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diseases with subsequent validation in human specimen. To answer this question, I chose four 
markers to illustrate mitochondrial heterogeneity across species: Nipsnap1, Got2,                          
pan-neuronal; Rmdn3, Purkinje cell-enriched; and Gldc, Sfxn5, astrocyte-enriched. 
The cerebellum of mouse, rat and human is similarly composed in structure with individual 
lobules and the organization into layers – despite their obvious difference in scale (Figure 43a). 
Human sample were provided by Doron Merkler and immunofluorescence staining performed 
by Ingrid Wagner (Department of Pathology and Immunology, University of Geneva, 
Switzerland). I performed acquisition of human samples and immunofluorescence staining in 
mouse and rat. In all three species, cell type-specific mitochondria were visualized with the 
selected markers (Figure 43b) – except for Nipsnap1 in human cerebellum, which was not 
tested and replaced by Got2 (pan-neuronal). Remarkably, I observed identical patterns and 
distributions of mitochondria in mouse and rat with the labeling of neuronal (Nipsnap1),  
Figure 43│ Cell type-specific mitochondrial markers distinguish neuronal and astrocytic 
mitochondria in mouse, rat and human cerebellum. (a) Cerebellum overview from mouse 
(sagittal section, full), rat (coronal section, part) and human (coronal section, part) by 
visualizing nuclei with DAPI or Hoechst staining. Scale bar: 1 mm. (b) Immunofluorescence 
staining of candidates in cerebellum of different species. Cell type-specific mitochondria are 
stained against: Nipsnap1 and Got2 for neurons; Rmdn3 for Purkinje cells; and Gldc and Sfxn5 
for astrocytes. Nuc, nuclear counter stain for tissue orientation. Scale bars: 50 μm. 
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Figure 44│ Cell type-specific mitochondrial markers distinguish neuronal and astrocytic 
mitochondria in aves and amphibian. (a) Cerebellum overview (sagittal section) from 
embryonic day 19 chicken and zebra finch by visualizing nuclei with DAPI. Scale bar: 1 mm.   
(b) Immunofluorescence staining of candidates in avian cerebellum. Cell type-specific 
mitochondria are stained against: Nipsnap1 for neurons; Gldc and Sfxn5 for astrocytes. Note 
immature layering of chicken cerebellum due to developmental stage. Nuc, nuclear counter 
stain for tissue orientation. Scale bars: 25 μm. (c) Brain overview (sagittal section) and details 
of tectum and cerebellum from Cuban tree frog by visualizing nuclei with DAPI. GCL, granule 
cell layer; PCL, Purkinje cell layer; ML, molecular layer. Scale bars: 1 mm (detail 200 μm).   
(d) Immunofluorescence staining of candidates in cerebellum and tectum. Cell type-specific 
mitochondria are stained against: Got2 for neurons; Gldc and Sfxn5 for astrocytes. Nuc, nuclear 
counter stain for tissue orientation. Scale bars: 25 μm. 
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Purkinje cell (Rmdn3) and astrocytic (Gldc, Sfxn5) mitochondria. In human cerebellum,                          
I noticed similar distributions and patterns as in rodents confirming the cell type-enrichment 
of our mitochondrial markers despite differences in signal contrast. These differences are 
likely due to altered fixation and staining method of human tissue (see Chapter 3.2.14.2). 
After these exciting results in rodent and human tissue, I further questioned whether 
mitochondrial markers were also preserved in more distant species, like aves and amphibian 
(Figure 44). I performed these experiments during my fellowship at the Marine Biological 
Laboratory in Woods Hole, where I had access to these species through the generous donation 
from other Grass fellows. Among aves, I tested mitochondrial markers in adult zebra finch and 
embryonic day 19 (E19) chicken, which have a foliated cerebellum like mammals (Figure 44a). 
In all cases, the distribution of neural mitochondria was comparable to results in rodent and 
human tissue. Specifically, Gldc and Sfxn5 distinguished astrocytic mitochondria, while 
neuronal mitochondria were identified by Nipsnap1 in both species (Figure 44b); however, no 
Rmdn3 signals could be detected. Despite the advanced development of chicken cerebellum 
before hatching (Akar and Sur, 2010), I observed an immature Purkinje cell morphology and 
incomplete cell migration at E19 (Figure 44a, overview chicken). 
Next, I performed immunofluorescence staining in tissue from Cuban tree frog, an amphibian, 
with a flat sheet cerebellum (Figure 44c). Despite the lack of foliation, the amphibian 
cerebellum is layered in GCL, PCL and ML. Again, I could not detect Rmdn3 signals. However, 
I observed Gldc and Sfxn5 signals that distinguished a subset of mitochondria in frog     
cerebellum – similar to mitochondria in Bergmann glia and astrocytes of mouse cerebellum 
(Figure 44d). Additionally, Nipsnap1 was abundantly present, labeled mitochondria-like 
structures and was likely specific to neurons. Similar results were obtained from another brain 
structure, the 8-layered optic tectum. While I observed a broad labeling with Nipsnap1, Gldc 
and Sfxn5 signals were sparsely distributed among layers indicating possibly astrocytic 
mitochondria and hinting to an overall neuronal vs astrocytic pattern.  
In summary, these experiments demonstrated that cell type-specific mitochondrial candidates 
from cerebellum are conserved in their neuronal vs astrocytic distribution in mouse cortex 
and spinal cord. Hence, these proteins can be termed as cell type-specific ‘markers’ in the 
central nervous system. Furthermore, exploration of mitochondrial markers from cerebellum 
across species affirmed their presence in amphibian, aves, rodents and human. 
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4.6.2. Cell type-specific mitochondria in AD and ALS 
After establishing our cell type-specific mitochondrial markers across tissues, we decided to 
demonstrate them as tool for biomedical research to characterize neural mitochondria in 
mouse models of neurodegeneration and related patient samples. Mitochondrial dysfunction 
is implicated in many neurodegenerative diseases, such as Parkinson’s disease,                   
Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS; see Chapter 1.7). Here, 
morphological analysis of mitochondria – mostly via ultrastructure (Johnson and Blum, 1970; 
Baloyannis, 2006) – is exclusively focused on neurons and their cell soma given that this region 
can be identified in a cell type-specific manner via marker proteins (Grünewald et al., 2014; 
Lax et al., 2016). However, neuronal pathology often starts at neuronal processes with 
synaptic dysfunction and loss (reviewed in Gillingwater and Wishart, 2013); moreover,                   
the contribution of glial mitochondria is yet unknown in most contexts of neurodegeneration. 
For AD, we first decided to use a common mouse model created by overexpression of human 
APPSwe and mutant presenilin 1 (APP23/PS45; Busche et al., 2008). In these mice, cortical 
amyloid-β plaques start appearing at 3-month of age. I performed immunofluorescence 
staining of Ociad2 (neuronal mitochondria) and Sfxn5 (astrocytic mitochondria) in cortex from 
9-month-old APP23/PS45 and age-matched control animals. Uchida and Takahashi (2008) 
reported that nuclear acid dyes, such as DAPI and Hoechst, intercalate with amyloid-β plaques 
in transgenic APP mouse models; hence, I used Hoechst to visualize amyloid-β plaques. While 
transgenic APP mouse lines model the formation of amyloid-β plaque, the loss of neurons is 
less successful (reviewed in Wirths and Bayer, 2010) despite being a hallmark of human 
pathology. Hence, I observed normal distribution of neurons and astrocytes around amyloid-
β plaques. Only the plaque core region was devoid of cell bodies. Mitochondria in surrounding 
neurons and astrocytes were unchanged in morphology between conditions – as observed by 
light microscopy (Figure 45a). Within the plaque area (Figure 45b), astrocytic mitochondria 
were present in all regions, while the core region was mostly free of neuronal mitochondria 
and their density decreased in the diffuse area. I found prominent astrogliosis in APP23/PS45 
tissue by staining against glial fibrillary acidic protein (Gfap; Figure 45c). While mitochondria 
morphology was normal in reactive astrocytes, their mass seemed increased compared to 
control. 
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Figure 45│ Cell type-specific 
mitochondria in a mouse   
model of Alzheimer’s disease.   
(a) Immunofluorescence staining 
against Ociad2 (magenta, neuronal 
mitochondria) and Sfxn5 (green, 
astrocytic mitochondria) in cortex 
from 9-month-old APP23/PS45 and 
wild type mice. Amyloid-β plaque and 
nuclei (cyan) are stained by Hoechst as 
previously reported for APP mouse 
models by Uchida and Takahashi 
(2008). Details show merged and 
single channels. Scale bars: 25 μm 
(detail 10 μm). (b) Detail of amyloid-β 
plaque region from a, APP23/PS45 
showing plaque schema with dense 
core (line) and diffuse (dashed line) 
region, and single channels. Scale bar: 
25 μm. (c) Astrogliosis in APP23/PS45 
mouse cortex revealed by staining 
against Gfap (gray). Region is taken in 
9-month-old mice and in distance from 
amyloid-β plaques. Astrocytic 
mitochondria are stained via Sfxn5 
(green). Gamma was adjusted for Gfap 
staining to visualize mitochondrial 
staining in composites. Nuc, nuclear 
counter stain. Scale bars: 25 μm (detail 
10 μm). Modified from Fecher et al. 
(2019), Figure 4 and Supplementary 
Figure 13. 
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Next, we performed immunofluorescence staining in postmortem human tissue from AD 
cases. Human tissue was provided by Doron Merkler (D.M.), staining performed by Ingrid 
Wagner (I.W.; Department of Pathology and Immunology, University of Geneva, Switzerland) 
and acquisition of samples performed by me. Overall, morphology and density of neuronal as 
well as astrocytic mitochondria was unchanged between samples (Figure 46). Neuronal 
mitochondria were equally present in all parts of the plaque contrary to my observation in the 
APP23/PS45 tissue. Astrogliosis did not morphologically alter astrocytic mitochondria, but 
increased their mass in cell bodies of reactive astrocytes – similar to the observations seen in 
APP23/PS45 tissue (Gfap; Figure 46b). 
Figure 46│ Cell type-specific mitochondrial markers in human cortex from 
patients with Alzheimer’s disease. (a-b) Immunofluorescence staining 
against amyloid-β (cyan), (a) Ociad2 (magenta, neuronal mitochondria) 
and (b) Sfxn5 (green, astrocytic mitochondria) in cortex from patients with 
Alzheimer’s disease (AD) and control (Ctr). Overviews show general 
distribution in tissue and details show mitochondrial morphology around 
plaques. Rectangular details in b show staining against Gfap (gray) 
demonstrating astrogliosis in and around plaques in AD tissue. Nuc, 
nuclear counter stain. Scale bars: 25 μm (details 10 μm). Modified from 
Fecher et al. (2019), Supplementary Figure 13. 
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For ALS, we decided to use a mouse model created by overexpression of human                          
Cu,Zn superoxide dismutase mutated at G93A (SOD1G93A), which causes motor neuron 
degeneration followed by paralysis (Gurney et al., 1994). For experiments, I used non-
symptomatic mice at the age of 5-month and performed immunofluorescence staining for 
Nipsnap1 (neuronal mitochondria), Sfxn5 (astrocytic mitochondria) and ChAT (motor neuron 
marker) in spinal cord. In controls, I observed a dense mitochondrial network stained by 
Nipsnap1 in motor neurons and a surrounding network of astrocytic mitochondria (Figure 47). 
In SOD1G93A tissue, astrocytic mitochondria via Sfxn5 staining were present around motor 
Figure 47│ Cell type-specific mitochondria in a mouse model of 
amyotrophic lateral sclerosis. Immunofluorescence staining against 
Nipsnap1 (magenta, neuronal mitochondria) and Sfxn5 (green, 
astrocytic mitochondria) in spinal cord of 5-month-old SOD1G93A and 
control (Ctr) mice. Motor neurons are stained via ChAT (cyan) and cell 
body outline (white line) created from this. Details show merged and 
single channels. Nuc, nuclear counter stain. Scale bars: 25 μm (details 
10 μm). 
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neurons and unchanged in density and morphology. This was in contrast to neuronal 
mitochondria that had formed big aggregates in motor neurons. 
We then performed similar immunofluorescence stainings in human spinal cord from ALS 
cases with the help of D.M. and I.W. (Department of Pathology and Immunology, University 
of Geneva, Switzerland). While I found a comparable network distribution of neuronal and 
astrocytic mitochondria in controls as previously seen in mouse spinal cord, neuronal 
Figure 48│ Cell type-specific mitochondrial markers in human spinal cord from patients with 
amyotrophic lateral sclerosis. (a-b) Immunofluorescence staining against (a) Nipsnap1 
(magenta, neuronal mitochondria) and (b) Sfxn5 (green, astrocytic mitochondria) in spinal cord 
from patients with amyotrophic lateral sclerosis (ALS) and control (Ctr). Overviews show general 
distribution in tissue and details show mitochondrial morphology. Note images are taken with 
different magnification. Nuc, nuclear counter stain. Scale bars: 100 μm (detail 25 μm). (c) Detail 
from a, ALS with cell outline from maximum projection and higher magnification details 1-3 
showing mitochondrial morphology via Nipsnap1 staining. Scale bars: 25 μm (detail 10 μm). (d) 
Rectangular details from b showing astrogliosis in aged spinal cord. Sfxn5 staining (green) is 
merged with Gfap staining (gray). Scale bar: 10 μm. Modified from Fecher et al. (2019), Figure 4 
and Supplementary Figure 14. 
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mitochondria were prominently altered in pathological cases (Figure 48). Overall Nipsnap1 
intensity was drastically reduced with few neuronal cell bodies left (ALS; Figure 48a).                          
Co-staining against ChAT was not performed and neuronal identity could not be determined. 
The mitochondrial network was similarly disrupted as seen in the presented mouse model and 
mitochondria rounded and clustered in remaining processes (Figure 48c, details).                          
For astrocytic mitochondria, staining for Sfxn5 revealed an overall fragmented network with 
frequently rounded mitochondria in ALS and control tissue (Figure 48b). In some cases,                           
I observed more intense and clustered Sfxn5 staining in pathological cases; however, this was 
independent from astrogliosis (Gfap; Figure 48d), which was ALS-independent. 
In summary, we demonstrated the application of cell type-specific mitochondrial markers in 
the context of AD and ALS. Here, Nipsnap1 revealed neuronal mitochondria and Sfxn5 
astrocytic mitochondria. While both markers could not demonstrate prominent mitochondrial 
alterations between pathological and control tissue in the AD mouse model and human cases, 
we found pathological changes in the context of ALS (Figure 47 and 48). In both the mouse 
model and human ALS cases, density and morphology of neuronal mitochondria were changed 
in soma and neurites. Additionally in the presented human case, clustering of astrocytic 
mitochondria was observed independent of astrogliosis (Figure 48).  
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Chapter 5: Discussion 
Mitochondria are involved in many cellular functions, such as catabolism, anabolism, 
apoptosis, Ca2+ homeostasis and iron-sulphur cluster assembly; in addition, they are a 
signaling and communication hub within cells. The fine-tuning of these functions,                          
e.g. catabolism of fatty acids or anabolism of amino acids, is controlled by the cellular                 
transcriptome and translatome given that >99% of mitochondrial proteins are nuclear 
encoded. Therefore, it is important to define mitochondrial phenotypes dependent on their 
cellular context, i.e. their cell type and its physiological state. This is especially true for the 
investigation of heterogeneous tissues, such as the nervous system, where the bulk analysis 
of brain mitochondria does not inform about the individual mitochondrial population of the 
estimated ∼1,000 present cell types (Koch, 2019).  
In this thesis, I have introduced the MitoTag mouse model for the characterization of cell                
type-defined mitochondria. Further, we have demonstrated its application in cerebellum 
from the profiling of cell type-specific mitochondrial proteomes to the validation of functional 
predictions from these profiles. Specifically, this work has identified that ∼15% of 
mitochondrial annotated proteins (MitoCarta; Calvo et al., 2016) are cell type-enriched among 
Purkinje cells, granule cells and astrocytes. Of these proteins, I have validated 19 as cell                 
type-enriched ‘mitochondrial markers’ in the central nervous system. Furthermore, we 
predicted cell type-enriched mitochondrial functions and corroborated these profiling 
predictions by independent assays probing for mitochondrial beta-oxidation, Ca2+ uptake and 
organelle contact sites. Hence, the present work elucidates the cell type-specific fine-tuning 
of mitochondrial biology in these major cerebellar cell types. 
5.1. Technical advances and limitations of the MitoTag approach 
Prior to this study, neural mitochondria from defined cell types could be isolated via three 
approaches: (i) the isolation of mitochondria from primary cells in culture, e.g. cortical 
neurons and astrocytes; (ii) the dissociation of neural cells from tissue and their                    
fluorescence-activated cell sorting (FACSorting) with subsequent organelle isolation; and                   
(iii) the dissociation of neural cells from tissue, their immunopurification via surface markers 
using antibody-coated magnetic beads and subsequent isolation of mitochondria. All three 
approaches have in common that mitochondria originate mostly from early postnatal                       
tissue – even so FACSorting of adult neural cells is possible (Fischer et al., 2011) – and that a 
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limited number of cell types can be adapted to them. In addition, cell culture media influence 
cellular metabolism (Cantor et al., 2017), and a substantial amount of time is needed for 
FACSorting and immunopurification via magnetic beads, while the recovered material is small. 
In contrast, these limitations are circumvented with the MitoTag mouse model. In brief,                  
the MitoTag mouse model is based on a fluorescent GFP-tag localized to the outer 
mitochondrial membrane (GFP-OMM) and under the control of the loxP/Cre recombinase 
system for cell type specificity. Therefore, cell type-specific mitochondria are tagged in vivo 
and can be directly isolated from the tissue and the condition of interest, e.g. different ages, 
treatments or disease models. In addition, tagged mitochondria originate from all parts of the 
cell, e.g. from axon, dendrites, soma and synapses in neurons, while FACSorted and 
immunopurified cells mostly represent material from cell bodies. Of course, in cases where a 
compartment-specific subpopulation of mitochondria shall be characterized, anatomical 
features can be used, such as corticospinal projections, to separate somatodendritic from 
axonal mitochondria. 
For the introduction of this model, we evaluated several parameters to ensure faithful 
expression and localization, as well as intactness and functionality of immunocaptured 
organelles. The faithful expression is directly linked to the Cre-driver line of interest and 
should be carefully evaluated because leakiness into other cell types, e.g. by a common cell 
lineage, will contaminate the purification effort. Due to this concern, Gella et al. (2019) 
recently reported the use of an adeno-associated viral vector to exclusively deliver Tomm20-
3xHA to glutamatergic neurons of the vestibular nucleus (AAV1-DIO-mitoTag in Slc17a6:Cre 
mice). Our experiments support tag localization to the outer mitochondrial membrane in all 
tested cell types (Table A1); still, Costello et al. (2017) reported that endogenous OMP25 can 
be incorporated into peroxisomal membranes, and therefore other cell types should be 
evaluated prior to use. Based on our evaluation in motor neurons and cortical cells, we have 
demonstrated that mitochondrial function, e.g. axonal transport and oxygen consumption,              
is not influenced by tag expression or immunocapture. 
Interestingly, Ahier et al. (2018b) introduced a similar invertebrate model using 
Caenorhabditis elegans. In brief, the authors generated Mos1-mediated single copy insertions 
of a transgene consisting of the outer mitochondrial membrane protein Tomm20 tagged with 
the fluorescent protein mKate2 and a HA-tag under the control of different cell type-specific 
promoters. Similar to our work, tag localization, faithful expression and functionality of tagged 
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organelles was assessed – here in body wall muscle cells. The purification of tagged 
mitochondria was performed via magnetic beads against HA (Table 8). Additionally, the 
authors performed mixing experiments by adding mitochondria containing matrix localized 
GFP and mutant mtDNA to evaluate the performance of their affinity purification. I also 
determined our immunocapture protocol with similar mixing experiments and established 
that cell type-specific mitochondria from neural cell types can be enriched and purified from 
mouse brain. Here, the proximity of organelles influenced their separation during 
immunocapture. In fact, small amounts of mito-RFP, which represented material from 
untagged mitochondria, remained present in our isolations (Figure 16); however, this 
contamination was not influenced by the abundance of tagged mitochondria within the tissue 
(100-5% GFP-OMM+, see Figure 17). I therefore concluded that this contamination is rather 
acquired during the isolation process by incorporation of abundant mitochondrial precursor 
proteins (like the transgene mito-RFP) than by the co-isolation of untagged, whole organelles.  
Due to advantages of their model system, Ahier et al. (2018b) could show the isolation of 
mitochondria from a single cell, namely the gustatory neuron ASEL, and from individual 
animals. While this is certainly useful in the case of mtDNA heteroplasmy, the amount of 
isolated mitochondria for functional assays is limited in the Caenorhabditis elegans model,      
e.g. 70,000 animals were required for one oxygen consumption experiment with only 
antimycin A/rotenone treatment. Interestingly, an introduced mutation in mtDNA – uaDf5 
deleting a 3.1 kb segment – differed in propagation among cell types with the least 
heteroplasmy in neurons and intestine, and the highest mutation load in germline. This mosaic 
pattern correlated with an overall increased mtDNA content and mitochondrial mass in 
germline cells, which are the only mitotically active cells in adult animal. 
While the affinity protocol by Ahier et al. (2018b) and the presented immunocapture require 
approximately 2 – 2.5 hours for organelle isolation, Bayraktar et al. (2019) reported a rapid 
isolation protocol for metabolomics of cell type mitochondria of approximately 10 minutes 
(Table 8). Here, the authors generated a Rosa26 knock-in mouse model harboring Cre-
dependent 3xHA-GFP-OMM – similar to our MitoTag mouse model – and applied their mouse 
model to hepatocytes in liver under fasting/refeeding conditions. In contrast to proteins and 
DNA, metabolites are rapidly exchanged between cellular compartments and hence,                          
a prolonged isolation process will gradually alter the mitochondrial metabolome. In mouse 
hepatocytes, Bayraktar et al. (2019) confirmed enrichment of mitochondrial metabolites and  
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Table 8. Comparison of isolation protocols for cell type-specific mitochondria from tissue. 
Study Fecher et al. (2019) Ahier et al. (2018b) Bayraktar et al. (2019) 
Model organism Mus musculus Caenorhabditis elegans Mus musculus 
Cell type 
Cell type driver 
Neural cells 
Emx1: Cre 
Body wall muscle cells
myo-3p 
Hepatocytes 
Alb:Cre 
Tag GFP-OMM Tom20-mKate2-HA 3xHA-GFP-OMM 
Beads Cat. # Miltenyi Biotec. 
130-091-125 
Thermo Fisher Scientific, 
88837 
Thermo Fisher Scientific, 
88837 
Beads (diameter) paramagnetic (50 nm) paramagnetic (1 μm) paramagnetic (1 μm) 
Beads amount 50 μl 100 μg 200 μl 
Beads antibody anti-GFP, mouse IgG1 anti-HA, mouse IgG1 anti-HA, mouse IgG1 
Tissue Cortex Whole animal Liver
Tissue disruption Nitrogen decompression Mechanical disruption with 
21 pestle strokes  
Mechanical disruption with 
rotated pestle at 220 rpm 
IP input Post-nuclear lysate Crude mitochondrial 
fraction 
Post-nuclear supernatant
Amount 20 mg tissue 10,000 animals ∼50 mg tissue 
IP buffer 137 KCl, 2.5 MgCl, 3 
KH2PO4, 1 EDTA, 10 HEPES, 
pH 7.4,  1% BSA, protease 
inhibitors 
1× PBS, 2 mM EDTA, 1% 
BSA, protease inhibitors 
136 mM KCl, 10 mM 
KH2PO4, pH 7.25, in Optima 
LC/MS water 
Incubation time 60 minutes at 4C 60 minutes at 4C 3.5 minutes 
Separation Magnetic stand;  
3x wash with 3ml;  
elution with 4ml;  
spin down 12,000g 
Magnetic stand; 
2x wash with 25 ml;  
elution with 25 μl 
Magnetic stand;  
3x wash;  
no elution 
Total time,  
approx. 
∼ 2.5 hours ∼ 2 hours ∼ 10 minutes 
Recovery 4.83 μg/mg tissue 1.01% total mitochondria
(∼30% with single animal) 
n.d. 
Also see Ahier et al. (2018a) and Chen et al. (2017) for protocol details.
 
511 proteins, of which 75.9% were mitochondrial annotated. No cytosolic or lysosomal 
metabolites were detected. Interestingly, when mice were fasted overnight and not refed, 
increased levels of acetyl-CoA from beta-oxidation, GMP, and glutamine from glutaminolysis 
as well as decreased methionine and increased alanine levels were exclusively identified on 
the cell level, but not on the total tissue level. While the nature of metabolites requires a 
timely isolation, it remains to be shown how the rapid isolation workflow performs with rare 
cell types, e.g. neuronal subpopulations in brain, and whether sufficient yield and purity can 
be achieved. For example, in the control IP from wild type tissue (MITO-Tag mice without Cre 
expression) a total of 1,204 proteins were identified, of which 511 proteins were >5 times 
enriched in the targeted HA-MITO IP (MITO-Tag mice with Alb:Cre expression). While the 
authors comment on the absence of lymphocyte-enriched proteins, like Bcl2, in their 
proteome, no detailed mixing experiments were performed – in fact, the tagged 
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mitochondrial population originated from ∼70% of tissue cells (Ding et al., 2016), which 
contribute to the majority of biomass in liver. 
In conclusion, the comparison of isolation protocols across studies demonstrates that 
researchers will have to adapt and validate their purification protocol for cell type-specific 
mitochondria not only dependent on tissue and cell type, but also dependent on assay and 
final readout. For example, the here presented immunocapture protocol for neural cells 
efficiently enriches mitochondria from the targeted cell types of interest – however, the 
isolation still represents a crude mitochondrial fraction with associated proteins, i.e. cytosolic 
and other organelle proteins that interact with the outer mitochondrial membrane.                          
We deliberately chose this approach, as we were particularly interested in this group of 
proteins, such as organelle tethers, cytoskeletal motor proteins and adapters. In addition, the 
functional performance of isolated mitochondria was a central goal of our study and further 
purification steps are known to influence mitochondrial respiration (Wang et al., 2011b). 
Nevertheless, purity of cell type-specific mitochondria can be further improved after 
immunocapture, e.g. by a subsequent Percoll gradient step (Sims and Anderson, 2008) or the 
fractionation of submitochondrial compartments as performed by Morgenstern et al. (2017). 
Hence, I am anticipating further modifications and breakthroughs in the efficient isolation 
of mitochondria from in vivo settings, which will adapt purity, yield and time dependent on 
cell types in the future.  
5.2. Cell type-enriched candidates reflect metabolic coupling of neural cells 
The brain is energy demanding given that it consumes ∼20% of total body energy. In recent 
years the field of ‘neuroenergetics’ emerged pioneered by the functional imaging of brain 
oxygen consumption and glucose utilization in humans via positron emission tomography and 
functional magnetic resonance imaging (reviewed in Raichle, 1998). Long before this, Roy and 
Sherrington (1890) provided one of the first evidences that local brain activity results in blood 
vessel modification to adjust supply to demand. 
The demand in this case is oxygen and glucose (Sokoloff, 1981) with liver-derived ketone 
bodies as secondary energy source (reviewed in Fedorovich et al., 2018). Specifically, the 
computational units of the brain, neurons, rely on lactate, which is supplied by                          
glial cells – mostly astrocytes (reviewed in Weber and Barros, 2015), but also oligodendrocytes 
(Fünfschilling et al., 2012). Thus, astrocytes and neurons form a metabolic unit in terms of 
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energy supply, but also for neurotransmitter homeostasis. The catabolism of                          
glucose – glycolysis – is localized to the cytosol; hence, our mitochondrial profiling cannot 
reveal cell type-specific differences in this pathway. However, mitochondrial candidates from 
our profiling clearly showed specialization of the TCA cycle and its associated catabolic 
pathways among neural mitochondria. These relate to the neural metabolic coupling, termed 
the astrocyte-neuron lactate shuttle hypothesis (ANLS; Pellerin and Magistretti, 1994),                      
and are illustrated in Figure 49 and 50 together with cell type-enriched specializations of the 
TCA cycle, its fuel pathways and junctions, and other enriched processes. 
For example, in the ANLS, neurons are provided with L-lactate, which is converted to pyruvate 
– the main substrate of the neuronal TCA cycle. In brief, astrocytes form connections with the 
vasculature via endfeet throughout the brain (63% coverage; Mathiisen et al., 2010) and 
receive glucose. Via glycolysis (Figure 49a), glucose is oxidized to pyruvate and further 
converted to L-lactate via L-lactate dehydrogenase (Ldha/b; Bittar et al., 1996) as part of 
aerobic glycolysis, termed the Warburg effect (Warburg, 1956). Interestingly, despite the 
presence of oxygen, pyruvate respiration is prevented in astrocytes in several ways. While the 
mitochondrial pyruvate carrier (MPC) was unchanged between neural cells in our data, 
astrocytic pyruvate kinase (Pkm2) interacts with Ldha via phosphorylation (Christofk et al., 
2008) leading to direct conversion of formed pyruvate to L-lactate. Furthermore, Pellerin and 
Magistretti (1994) demonstrated that astrocytic glucose uptake and lactate release are 
stimulated by sodium-driven glutamate uptake during neurotransmission. This glutamate 
uptake acidifies the astrocytic cytosol and mitochondrial matrix leading to an altered 
mitochondrial membrane potential, and thereby decreases mitochondrial metabolism during 
activity-driven glycolysis (Azarias et al., 2011). Finally, pyruvate entry into the TCA cycle is 
blocked in astrocytes via phosphorylation of the pyruvate dehydrogenase complex (PDH) via 
pyruvate dehydrogenase kinase 4 (Pdk4, not identified in our proteomes; Halim et al., 2010). 
After generation, L-lactate is exported via monocarboxylate transporters (MCT1/4) and 
imported by neurons (MCT2; Pierre and Pellerin, 2005; Rafiki et al., 2003), where Ldhb 
converts it to pyruvate (Figure 49b). Sada et al. (2015) showed that disruption of astrocytic 
lactate supply significantly altered neuronal excitability and Machler et al. (2016) provided in 
vivo evidence for a lactate gradient from astrocytes to neurons.  
The ANLS specifically states that during neuronal activity glycolysis is preferentially performed 
in astrocytes  to  produce  L-lactate  and  supply  neurons;  however, this  does  not  mean  that  
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Figure 49│ Metabolic coupling of astrocytes and neurons. Metabolic pathways in (a) astrocytes and 
(b) neurons linked to the astrocyte-neuron lactate shuttle hypothesis. Metabolites (gray and 
green), enzymes (black or color), protein interaction (brackets) and pathway importance (line 
width) are indicated. Cell type-enriched candidates from our mitochondrial profiling are shown in 
blue (astrocytes), red (neuronal) and orange (granule cell enriched). Neuronal or granule cell 
enrichment is based on the comparison PC vs GC (FC ≥ │0.5│, q-value <0.05) and not identical to 
Figure 24a. For simplicity, not all pathways and enzymes are shown. See also complementary 
schema in Figure 50 and abbreviation index (page 217) for details. 
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glycolysis is absent in neurons. Under steady-state conditions, glucose is taken up by neurons; 
yet, it is not converted to pyruvate, but primarily used for NADPH generation in the pentose 
phosphate pathway (PPP; Bolanos and Almeida, 2010). The NADPH pool is further used to 
regenerate glutathione (GSH), which protects neurons against oxidative stress (Vaughn and 
Deshmukh, 2008). Glucose-6-phosphate can enter the PPP after the first step of glycolysis, 
where hexokinase (Hk1/2) phosphorylates glucose. Hk1 is known to localize to the outer 
mitochondrial membrane via VDAC interaction (Felgner et al., 1979; Linden et al., 1982),               
while Hk2 can additionally translocate to the cytosol, where it is involved in glycogen synthesis 
(John et al., 2011). Hk1 and Hk2 were enriched in granule cell and astrocytic mitochondria, 
respectively. Interestingly, glycogen is primarily produced in astrocytes and its machinery is 
inactive in neurons (Dringen et al., 1993; Vilchez et al., 2007). Further, Duran et al. (2012) 
showed that neuronal overexpression of muscle glycogen synthase – the main isoform 
expressed in brain – causes neurodegeneration; however, its ectopic expression protects 
neurons during hypoxia (Saez et al., 2014). 
While intermediates from the PPP could be redirected to glycolysis, this is not the case in 
experimental studies (Herrero-Mendez et al., 2009; Bolanos et al., 2010). Along with this, 
other reasons argue for a minor role of energy-producing glycolysis in neurons, namely:                       
(i) the proteasomal degradation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 
(Pfkfb3); (ii) Pkm1 disability to modulate glycolysis; and (iii) reduced detoxification of 
methylglyoxal. First, glycolysis is controlled by the master regulator 6-phosphofructo-1-kinase 
(Pfk1), which is allosterically activated by fructose-2,6-bisphosphate, which in turn is 
generated from fructose-6-phosphate via the glycolytic enzyme Pfkfb3. In neurons, Pfkfb3 is 
actively degraded via the proteasome and upregulation of Pfkfb3 levels have been shown to 
cause oxidative stress and neuronal death (Herrero-Mendez et al., 2009). Secondly,                          
Pkm metabolizes phosphoenolpyruvate (PEP) to pyruvate and ATP – the final step of 
glycolysis. The splice variants Pkm1 and Pkm2 are expressed in neurons and astrocytes, 
respectively (Zhang et al., 2014). However, only Pkm2 is regulated by posttranslational 
modifications (reviewed in Prakasam et al., 2018). For example, o-GluNAcylation at Thr405 and 
Ser406 leads to translocation of Pkm2 to the nucleus, where it stimulates the expression of 
glucose transporter type 1 (Glut1) and Ldha to increase glucose uptake and lactate production 
(Wang et al., 2017). Thus, glycolysis is activity-dependently regulated in astrocytes, while this 
feature is absent in neurons and the rate of glycolysis is fixed to a baseline (Almeida et al., 
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2001). Finally, methylglyoxal is a byproduct of glycolysis and forms neurotoxic advanced 
glycation endproducts (reviewed in Munch et al., 2012). It is produced via the stochastic 
fragmentation of glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone phosphate 
(DHAP) and detoxified to D-lactate by the glyoxalase system, Glo1 and Glo2 (Allaman et al., 
2015). This system is specifically enriched in astrocytes and repressed in neurons (Belanger et 
al., 2011). Interestingly, like L-lactate, D-lactate is transferred to neurons via MCT and here, it 
is converted to pyruvate via mitochondrial Ldhd, which I confirmed as neuronal candidate 
(Figure A1c). While debated for some time, Ldhd function was recently confirmed in humans 
(Monroe et al., 2019) and patients with D-lactic acidosis frequently present with broad 
neurological symptoms (reviewed in Uribarri et al., 1998), which however so far have been 
investigated in the context of an abnormal bacterial colon flora, but not as metabolic 
syndrome. 
Hence, neurons uniquely depend on glial lactate supply, but can also use other substrates to 
fuel their TCA cycle. For example, the neurotransmitter glutamate is recycled by astrocytes 
and re-enters neurons as glutamine (Benjamin and Quastel, 1975). In this way, astrocytes 
contribute to the spatial and temporal resolution of neurotransmission via neurotransmitter 
uptake from the synaptic cleft. While glutamate-to-glutamine conversion is cytosolic in 
astrocytes (Gs; Figure 49a), the reverse process happens in neuronal mitochondria via the 
enzyme glutaminase (Gls, Gls2; Laake et al., 1999). Glutamate can then be used as 
neurotransmitter in glutamatergic neurons, be converted to GABA in GABAergic neurons or 
enter the TCA cycle as α-ketoglutarate via glutamate oxaloacetate transaminase (Got2;               
Figure 49b). This reaction also contributes to the NADPH pool. For example, in cerebellar 
slices, de Barry et al. (1983) quantified the recycling of free glutamate into 42% glutamine, 
25% α-ketoglutarate and 1% GABA. We found Gls and Gls2 as enriched candidates in granule 
cell mitochondria according to the glutamatergic nature of these neurons. While glutaminase 
is less abundant in Purkinje cells, Got2 can generate glutamate starting from                          
oxaloacetate – hence, providing glutamate for GABA generation independent from glutamine. 
Additionally, these Got2-mediated reactions are part of the ‘mini TCA cycle’ that operates in 
the absence of acetyl-CoA (Yudkoff et al., 1994). 
Other neurotransmitter, like glycine and GABA, are also recycled in astrocytes (Gadea and 
Lopez-Colome, 2001a, b), e.g. via the glycine cleavage system (Gcs; Figure 49a). However, in 
contrast to glutamate, Chatton et al. (2003) could not detect a metabolic coupling between 
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sodium-dependent GABA uptake and glycolysis. Thus, the coupling of neurotransmitter 
uptake and lactate generation is currently believed to be exclusive for glutamate. Still, without 
glial recycling, neurotransmitters would be lost into the blood stream resulting in a net loss of 
energy substrates and the demand to replace them for neurotransmission (discussed in 
Marcaggi and Attwell, 2004). 
Additionally to glutamate-glutamine recycling in astrocytes, glutamate may be imported into 
astrocytic mitochondria via Slc25a18 and enter the TCA cycle as α-ketoglutarate via glutamate 
dehydrogenase 1 (Glud1; Figure 49a). 
In addition to the ANLS, several other interesting specializations were revealed through our 
proteomic profiling between astrocytic and neuronal mitochondria (Figure 50). 
First, as discussed before, pyruvate entry into the astrocytic TCA cycle is limited due to 
phosphorylation of PDH (Halim et al., 2010); however, we found that the major components 
of beta-oxidation are enriched in astrocytic mitochondria (see Chapter 4.3) and therefore 
acetyl-CoA can fuels the TCA cycle. Citrate synthase (CS) condensates acetyl-CoA and 
oxaloacetate to citrate, the first TCA cycle intermediate; hence, oxaloacetate levels are crucial 
in astrocytes. While this intermediate is provided in a ‘running’ TCA cycle, it can also be 
replenished via pyruvate carboxylase (PC), which is enriched in astrocytes (Yu et al., 1983; 
Shank et al., 1985). 
Secondly, three reactions of the TCA cycle generate NADH, which is transferred to complex I. 
Interestingly, in astrocytes, one of these reactions is modified to generate NADPH via 
isocitrate dehydrogenase 2 (Idh2; Figure 50a). Idh2 can operate bidirectional and either 
generate isocitrate from α-ketoglutarate consuming NADPH, termed reductive carboxylation 
(Comte et al., 2002); or generate α-ketoglutarate and NADPH, which is used to recycle GSH by 
glutathione reductase (Vogel et al., 1999). As previously discussed, neuronal NADPH is 
generate via the PPP from glucose, but can also be formed via Got2 and malic enzymes (Me2) 
in mitochondria; hence, providing two local pools of GSH recycling. In addition to Idh2, 
nicotinamide nucleotide transhydrogenase (Nnt) was enriched in astrocytic mitochondria, 
which also generates NADPH via the proton motive force across the inner mitochondrial 
membrane (Earle et al., 1978; Leung et al., 2015). Thus, NADPH generation via Nnt is directly 
linked to the ETC activity unlike its generation via Got2, Me2 or Idh2. Sazanov and Jackson 
(1994) proposed that Nnt works synergistically with an Idh2-Idh3 cycle to control flux through 
the  TCA  cycle  depending  on  demand.  Here,  Idh3  works  in  forward  direction  generation  
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Figure 50│ Neural specialization of TCA cycle, adjacent fuel and other pathways. Overview of 
enriched candidates in (a) astrocytes and (b) neurons linked to the TCA cycle, its fuel pathways and 
junctions. Metabolites (gray and green), enzymes (black or color), protein interaction (brackets) 
and pathway importance (line width) are indicated. Cell type-enriched candidates from our 
mitochondrial profiling are shown in blue (astrocytes), red (neuronal), orange (granule cell 
enriched) and magenta (Purkinje cell enriched). Neuronal, GC and PC enrichment is based on the 
comparison PC vs GC (FC ≥ │0.5│, q-value <0.05) and not identical to Figure 24a. [PC, Pdk4] were 
not identified in mass spectrometry, but their enrichment is supported via literature. For simplicity, 
not all pathways and enzymes are shown. See also complementary schema in Figure 49 and 
abbreviation index (page 217) for details. 
147 
 
α-ketoglutarate, while Idh2 works in reverse consuming NADPH provided by Nnt. Dependent 
on redox state and ETC activity, these reactions are adjusted. Under which conditions 
astrocytes depend on this regulatory mechanism is unknown; however, this cycle is disrupted 
in glioma due to Idh2 mutations causing a rewiring of the flux towards 2-hydroxyglutaric acid 
generation (Huang et al., 2019). NADPH generation in astrocytes strengthen their antioxidant 
defense in mitochondria, which for example is necessary for the breakdown of biogenic 
amines like dopamine via monoamine oxidase B (MaoB; Waldmeier, 1987) – a process 
generating H2O2. Recently, however, Graves et al. (2020) reported that dopamine clearance 
via MaoB does not necessarily increase local H2O2 levels. The authors discovered a transfer of 
free electrons to complex IV of the ETC, which fueled ATP production in neurons. 
Thirdly and to our surprise, we found catalase (Cat) enriched in astrocytic mitochondria and              
I confirmed this observation independently (Figure 33b). This peroxisomal protein was 
previously reported in mitochondria (Radi et al., 1991), like several other proteins that are 
dually localized to these organelles (Costello et al., 2017). Furthermore, Petrova et al. (2004) 
showed that under stress conditions, Cat relocalizes to mitochondria by unknown import 
mechanisms. We also observed an enrichment of other peroxisomal proteins in astrocytic 
mitochondria (see Chapter 4.2.5), most of which are unlikely to relocate as proposed for Cat. 
Still, peroxisomes and mitochondria have an intimate relationship via interconnected 
functions and peroxisome de-novo biogenesis from mitochondrial vesicles (Sugiura et al., 
2017). In particular, FA catabolism is shared between these organelles and  FA are degraded 
dependent on chain length (Lazarow and De Duve, 1976). While mitochondria fully oxidize FA, 
peroxisomes cannot and shuttle acylcarnitine (C2, C3, C11) to mitochondria (Verhoeven et al., 
1998). 
Finally, while ATP is mostly generated on complex V within mitochondria, one reaction of the 
TCA cycle generates nucleoside triphosphates, known as substrate level phosphorylation 
(reviewed in Tretter et al., 2016). This reaction is mediate by succinyl-CoA ligase (Sucl; Johnson 
et al., 1998), which is a heterodimer of Suclg1 and either Sucla2 (ATP generating) or Suclg2 
(GTP generating). In astrocytes, we found GTP generating Suclg2 enriched. Interestingly,                
GTP is not exported from mammalian mitochondria (Heldt and Schwalbach, 1967), while 
Saccharomyces cerevisiae lacks Suclg2 and expresses the GDP/GTP exchanger, Ggc1p (Vozza 
et al., 2004). GTP is essential for mtDNA maintenance (Kadrmas et al., 1991; Tokarska-
Schlattner et al., 2008) and can be interconverted to other nucleotides via adenylate kinases 
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(Ak). In astrocytes, Ak3 is enriched, which scavenges GTP and uses this for mitochondrial AMP 
recycling to ADP (GTP + AMP --> GDP + ADP; Heldt and Schwalbach, 1967). 
The neuronal TCA cycle (Figure 50b) is fueled via pyruvate, which originates from astrocytic 
lactate. In particular, Ldhd was found enriched in neuronal mitochondria and independently 
validated (Figure A1c). PDH is controlled via pyruvate dehydrogenase kinases (Pdk1-4) and 
pyruvate dehydrogenase phosphatases (Pdp1/2), which we found both enriched in neuronal 
mitochondria. Also, glutamate can fuel the neuronal TCA via Got2 activity. Defense against 
oxidative stress is essential for neurons (reviewed in Cenini et al., 2019) and thus, NADPH 
generation is present in cytosol via the PPP and in mitochondria via Got2 and Me2 – both 
enriched in our neuronal proteomes. Several studies link neuronal Got2 expression to ATP 
production and neuronal survival, for example during ischemia (Xu et al., 2019), traumatic 
brain injury (Arun et al., 2013) and experimental autoimmune encephalomyelitis (Honorat et 
al., 2017). 
As described in Chapter 1.4.1, Nipsnap1 is a mitochondrial protein enriched in neurons 
(Nautiyal et al., 2010) and our experiments corroborate these previous reports. Despite this 
clear cell type annotation, Nipsnap1 function is unclear with reports documenting its 
interaction with amyloid precursor protein (APP; Tummala et al., 2010) or the branched-chain 
α-keto acid dehydrogenase enzyme complex (Nautiyal et al., 2010). Recently, Princely Abudu 
et al. (2019) showed that Nipsnap1 deletion causes neuronal death indicating its importance 
for certain neuronal populations. Still, these reports do not offer a clear molecular function of 
Nispnap1 in the context of neuronal physiology. 
We also found striking differences between mitochondria from granule cells and Purkinje 
cells, for example, the enrichment of the mitochondrial calcium uniporter complex or the 
enrichment of contact sites between mitochondria and the endoplasmic reticulum (ER).                
Both findings contribute to the cellular Ca2+ homeostasis and are further discussed in Chapter 
5.4.  
Particularly enriched in granule cell mitochondria was phosphoenolpyruvate carboxykinase 2 
(Pck2), which converts oxaloacetate to PEP using GTP (Stark et al., 2014). In contrast to 
astrocytes, GTP is not formed via Sucl in the TCA cycle, but can be generated via mitochondrial 
nucleoside diphosphate kinase (Nme3), which was not enriched in a cell type-specific manner 
(Figure 50b). PEP is then exported from mitochondria and can be used to fuel NADPH 
generation in the PPP. In fact, generation of PEP from oxaloacetate is energetically more 
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efficient than PEP generation from lactate given that fewer enzymes and transporters are 
necessary (see discussion in Stark et al., 2014). Interestingly, granule cell mitochondria were 
enriched in Ak4, another GTP-dependent adenylate kinase. In contrast to astrocytic Ak3, 
neuronal Ak4 binds GTP but lacks phosphotransferase activity (Noma et al., 2001). Liu et al. 
(2009) reported that Ak4 acts as a stress sensor in cells by interacting with the ADP/ATP 
translocase (ANT1/2) and modulating ANT1/2 activity dependent on TCA cycle activity.                          
Furthermore, this interaction was increased under oxidative stress and repressed cytochrome 
c release and apoptosis in neuronal SH-SY5Y cells. 
Paradoxically, granule cells are more susceptible to oxidative stress than other neurons                 
(Wang et al., 2009). In fact, neuronal vulnerability to oxidative stress correlates with 
increased levels of endogenous reactive oxygen species (ROS) and an increased defense 
against ROS at baseline (reviewed in Wang and Michaelis, 2010). It is therefore argued that 
the cellular ROS defense mechanisms cannot be further increased under a stress impact and 
hence, neuronal death is the consequence. Nevertheless, why do certain neuronal 
populations maintain this elevated ROS environment under steady-state conditions? 
Compelling evidence hints to a critical involvement of ROS as a signaling molecule (reviewed 
in Borquez et al., 2016). For example, Accardi et al. (2015) demonstrated in cerebellar granule 
cells that inhibitory synapses are strengthened in a mitochondrial ROS-dependent manner via 
the specific recruitment of α6-GABAA receptors to postsynaptic sites. This receptor 
recruitment happened independently from existing α1-GABAA receptors at distinct synapses 
and hence, complemented the already existing network. Similar results were obtained in 
inhibitory stellate cells with the recruitment of α3-GABAA receptors (Accardi et al., 2014). 
Therefore, Ak4 expression in granule cells may represent a significant mitochondrial fine-
tuning under elevated ROS levels to preserve the physiology of these inhibitory neurons. 
In summary, our cell type-specific profiling of mitochondria illustrates that a common cellular 
goal can be achieve via multiple pathways and hence is uniquely adapted to the sum of cellular 
processes. For example, mitochondria provide cells with ATP – however, ATP generation can 
be based on different fuels, like lactate, FA or glutamate, and furthermore can be provide by 
the blood stream and general body metabolism or the local supply via adjacent cell types. 
Similarly, the cellular redox defense via GSH can be maintained via the PPP, Got2 or Me2 
activity in neurons, or via Nnt and Idh2 activity in astrocytes. While at a first glance these 
pathways seem parallel and possibly redundant, it is clear from the here presented overview 
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in Figure 49 and 50 that certain preconditions argue against redundancy. For example, while 
astrocytes provide neurons with lactate and hence neuronal glucose uptake is not essential 
for ATP generation, glucose is an essential source for the generation of NADPH in the PPP. 
Furthermore, in granule cells, the supply of the PPP is further secured via conversion of 
oxaloacetate to PEP through Pck2. Hence, the active blockade of glycolysis in neurons is 
essential for their supply of NADPH and subsequent GSH recycling as demonstrated by 
increased oxidative stress under forced neuronal Pfkfb3 expression                          
(Herrero-Mendez et al., 2009). 
5.3. Fatty acid oxidation in the brain – local ‘hotpots’ in astrocytes 
Fatty acids (FA) are the richest substrate available for energy production via oxidative 
phosphorylation. For example, one mole palmitic acid (C16:0) yields 106 mole ATP in contrast 
to 32 mole ATP per mole glucose (Schonfeld and Reiser, 2013). Palmitic acid oxidation also 
requires ∼15% more oxygen and creates a FADH2/NADH ratio of 0.48 in contrast to 0.2 with 
glucose. These differences – among several other arguments – contributed to a long debate 
regarding FA oxidation in the nervous system and in neurons (reviewed in Schonfeld and 
Reiser, 2013; Panov et al., 2014; Schonfeld and Reiser, 2017).  
Initial arguments against FA oxidation in brain were: (i) the limited uptake of non-esterified FA 
over the blood-brain-barrier, which was experimentally refuted (Smith and Nagura, 2001; 
Ouellet et al., 2009); (ii) the low activation of FA via CoA conjugation and hence, toxic effect 
of free FA on mitochondrial membrane potential, ETC and permeability transition pore.                
While these hold true for long-chain FA, medium- and short-chain FA are rapidly activated 
(Ebert et al., 2003), and in particular, neurons are protected against free long-chain FA via the 
high expression of long-chain acyl-CoA thioesterase 7 (Acot7; Ellis et al., 2013); and                          
(iii) the additional side effects such as hypoxic conditioning due to higher oxygen demand, 
enhanced ROS production and overall slow oxidation compared to neuronal demand. In fact, 
neural FA oxidation is slow compared to heart or kidney mitochondria (Bird et al., 1985; Yang 
et al., 1987), requires more oxygen due to a higher FADH2/NADH ratio and hence, is not ideal 
to supply neurons with ATP under neurotransmission. However, glucose is neither an ideal 
substrate within this context and thus, neurons depend on glial lactate during 
neurotransmission and on ketone bodies during periods of fasting (reviewed in Morris, 2005).  
Further arguments for FA oxidation in neural cells come from transcriptome studies of 
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cultured and FACSorted astrocytes, which quantified the machinery of mitochondrial beta-
oxidation on the transcript level (Eraso-Pichot et al., 2018). Additionally, FA oxidation has been 
demonstrated in cultured astrocytes (Edmond et al., 1987; Sayre et al., 2017) and 
hypothalamic neurons (McFadden et al., 2014). Furthermore, Cpt2 deletion in Drosophila 
melanogaster let to the accumulation of triglycerides in neural cells (Schulz et al., 2015). 
Therefore, the presence of beta-oxidation in neural cells cannot be questioned anymore, 
while its distribution among neural cell types is unclear. For example, neural stem cells depend 
on FA oxidation during their quiescent state and modulate beta-oxidation for proliferation and 
differentiation (Knobloch et al., 2017; see Chapter 1.4.2). 
Our proteomic profiling of immunocaptured mitochondria from the adult mouse cerebellum 
corroborate in vitro and transcriptome data by quantifying the majority of proteins involved 
in mitochondrial beta-oxidation and their enrichment in astrocytic mitochondria (Figure 34). 
We furthermore performed oxygen consumption assays on cell type-specific mitochondria 
from astrocytes and Purkinje cells. While these mitochondrial populations did not differ in 
their respiration on pyruvate/malate or succinate/rotenone, L-palmitoylcarnitine/malate 
oxidation was significantly reduced in neuronal mitochondria (Figure 36); hence, our 
experiments provide the so-far closest in vivo examination of long-chain FA oxidation in 
defined neural cell types. Still, the comparison across substrates confirmed the notion that 
even astrocytic beta-oxidation is slow and less efficient than respiration on pyruvate or 
succinate (reviewed in Schonfeld and Reiser, 2013). However, Panov et al. (2014) pointed out 
that in situ mitochondria are exposed to a mixture of substrates and that the in vitro analysis 
via one isolated substrate represents a rather artificial situation. In fact, when the authors 
combined long-chain FA with other substrates, an additive effect on mitochondrial respiration 
was observed with brain mitochondria.  
In addition, astrocytic beta-oxidation in vivo might be further improved via the synergistic 
action of mitochondria and peroxisomes. While long-chain FA need to be imported via the 
carnitine shuttle system for mitochondrial beta-oxidation, these steps are absent in 
peroxisomes for the degradation of very long-chain FA. After initial breakdown, acylcarnitine 
is transferred from peroxisomes to mitochondria and here fully oxidized. We observed an 
enrichment of peroxisomal proteins in our proteome from astrocytic mitochondria                          
(see Chapter 4.2.5). Further evaluation of peroxisome density in Purkinje cells and astrocytes 
did not confirm a differential abundance of this organelle (Figure A1d); thereby ruling out pure 
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contamination as a possible explanation. Additionally, Pex11β and Eci2 have been described 
to tether mitochondria and peroxisomes (Shai et al., 2018; Fan et al., 2016) and Eci2 was 
significantly enriched in our proteome from astrocytic mitochondria (Table A2). Therefore, I 
hypothesize that in astrocytes, mitochondria and peroxisomes form a metabolic unit for the 
efficient oxidation of FA under steady-state in vivo conditions (Figure 51a). This unit not only 
improves the processing of FA, but also minimizes the exposure of mitochondria to free FA 
and reduces the generation of ROS via the synergistic clearance by peroxisomes and 
mitochondria.  
Interestingly, Liu et al. (2017) showed that neuronal lipids are transferred to astrocytes in a 
ROS-dependent manner. This transfer was mediated via fatty acid transport proteins and 
apolipoproteins, and induced the formation of lipid droplets in astrocytes. FA transfer to 
astrocytes was neuroprotective and scavenged, peroxidized lipids, which are neurotoxic 
(Bailey et al., 2015).  Presumably, under normal conditions, astrocytic lipid droplets are 
metabolized via beta-oxidation. Recently, Ioannou et al. (2019) further confirmed these 
results by demonstrating that also hyperactive neurons generate FA and expel them as 
apolipoprotein E-positive vesicles. These were taken up by astrocytes and either stored as lipid 
droplets or metabolized in mitochondria. The overall process was stimulated via neuronal 
activity and activated astrocytic programs to enhance beta-oxidation and antioxidant defense 
mechanisms.   Furthermore,  the  authors   confirmed  lipid  droplet  formation  in  vivo  in  the 
Figure 51│Functional specialization of cerebellar mitochondria. Proteomic profiling of cell type-
specific mitochondria revealed fine-tuning of central mitochondrial functions among neural cells. 
(a) Astrocytic mitochondria (Mito) are specialized in beta-oxidation with possible cooperation of 
peroxisomes (Pex); while (b) neuronal mitochondria differentially regulate their Ca2+ homeostasis: 
in granule cells (orange) via enhanced Mcu expression and in Purkinje cells (magenta) via 
parvalbumin (PV) and increased contact sites to the endoplasmic reticulum (ER) mediated by 
Rmdn3 and its interactors (e.g. VAPB). ER-mitochondria contact sites are also known to mediate 
lipid exchange and signaling. ML, molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer. 
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context of stroke. Hence, both reports provide evidence for a coupled FA metabolism between 
astrocytes and neurons.  
In summary, while the evidence for FA oxidation in neurons is limited to certain neuronal 
subtypes, e.g. hypothalamic neurons, ample evidence exists that neural cells are able to 
oxidize long-chain FA. While this oxidation is not comparable to other tissues with high-energy 
demands and FA oxidation (e.g. heart and kidney), its neural form serves neuronal protection 
and cell survival. Hence, further deciphering of its regulation and cell type enrichment will 
advance our understanding of neurodegeneration. 
5.4. Mitochondrial calcium signaling in cerebellar neurons – One signal, many goals 
In cells, calcium (Ca2+) is a ubiquitous signaling molecule. Dependent on speed, amplitude, 
spatial and temporal resolution, Ca2+ signals evoke a plethora of cellular functions aided by 
the action of channels, pumps, intracellular stores and buffer proteins (reviewed in Berridge 
et al., 2000). For example, in neurons, Ca2+ triggers exocytosis at the presynapse,                        
activity-dependent synaptic plasticity at the postsynapse and gene expression in the nucleus 
(reviewed in Neher and Sakaba, 2008; Mateos-Aparicio and Rodríguez-Moreno, 2020; 
Tyssowski and Gray, 2019). While cytosolic free Ca2+ concentrations are kept low at rest                  
(100 nM), the endoplasmic reticulum (ER) stores Ca2+ at a concentration ∼100 μM. 
Mitochondria participate in the cellular Ca2+ homeostasis by acting as an additional buffer 
system in the cytosol and at privileged contact sites to the ER and plasma membrane 
(reviewed in Szymanski et al., 2017). These contact sites are established via tether and spacer 
proteins, which allow for the close apposition of membranes and the formation of Ca2+ 
microdomains with Ca2+ concentrations >10 μM during signaling events (Rizzuto et al., 1998; 
Csordas et al., 2010). Furthermore, mitochondrial Ca2+ activates the TCA cycle via modulation 
of PDH, Idh and α-Kgdh, the F0F1ATPase and controls apoptosis. In addition, mitochondria can 
store large amounts of bound Ca2+ as calcium-phosphate complexes, which is generated at 
free matrix Ca2+ concentrations of 0.2 – 2 μM (Chalmers and Nicholls, 2003). 
Ca2+ enters mitochondria via the mitochondrial calcium uniporter (Mcu) complex in the inner 
mitochondrial membrane, which we found strikingly enriched in granule cell mitochondria 
(Figure 37a and b). Regulation of Mcu function has been described on the expression level of 
Mcu/McuB ratio, Mcu/Micu1 ratio and via posttranslational modifications (see Chapter 1.2.3). 
Given that mitochondrial Ca2+ handling is essential for proper neurotransmission                          
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(Shutov et al., 2013; Marland et al., 2016), we were surprised to find Mcu differentially 
expressed between neuronal subtypes. In granule cells, I quantified a 3.2-fold enrichment of 
Mcu in comparison to Purkinje cells, which correlated with a drastic functional reduction of ex 
vivo Ca2+ uptake in Purkinje cell mitochondria (Figure 37c). Also in astrocytes, we observed a 
trend towards reduced Mcu levels and correlating diminished Ca2+ uptake compared to 
granule cell mitochondria. Boitier et al. (1999) showed that mitochondrial Ca2+ uptake reduces 
the propagation of astrocytic Ca2+ waves. Interestingly, Markus et al. (2016) previously showed 
differential Mcu expression between the hippocampal subregion, CA1 and CA2. Granule cell-
specific ablation of Mcu completely abolished mitochondrial Ca2+ uptake in immunocaptured 
organelles from these cells (Figure 38), which is in contrast to a report by Hamilton et al. (2018) 
claiming that brain mitochondria uptake Ca2+ in a Mcu-independent way. Furthermore, Henzi 
and Schwaller (2015) reported that loss of parvalbumin increases Mcu, McuR1 and Micu1 
expression levels as well as mitochondrial mass. Parvalbumin is a slow-onset, cytosolic Ca2+-
binding protein and highly expressed in Purkinje cells, where it prevents paired-pulse 
facilitation and contributes to short-term plasticity (Caillard et al., 2000). Mitochondrial mass 
was also increased in parvalbumin-deficient Purkinje cells, while calbindin deficiency did not 
alter mitochondrial abundance (Chen et al., 2006). Therefore, the authors hypothesized that 
parvalbumin deficiency is compensated via mitochondrial Ca2+ handling by restoring a similar 
spatiotemporal Ca2+ signaling. Hence, Mcu downregulation in Purkinje cells could be related 
to the abundant presence of parvalbumin. In contrast, granule cells do not contain 
parvalbumin but have calretinin as cytosolic buffer and Ca2+ sensor                           
(Resibois and Rogers, 1992). 
In Purkinje cells, we found the ER-mitochondrial tether regulator of microtubule dynamics 
protein 3 (Rmdn3) ≥3.5-fold enriched compared to mitochondria from granule cells and 
astrocytes (Figure 39a). De Vos et al. (2012) showed that Rmdn3 interacts with the ER-resident 
protein vesicle-associated membrane protein-associated protein B (VAPB). In vitro,                        
the interaction of VAPB and Rmdn3 facilitates close contact sites between the ER and 
mitochondria and increases Ca2+ transfer between the organelles (Stoica et al., 2014). This 
interaction is increased with the ALS-associated mutant VAPBP56S (Nishimura et al., 2004) and 
disrupted by mutations in TDP-43 (Stoica et al., 2014), FUS (Stoica et al., 2016) and                     α-
synuclein (Paillusson et al., 2017). In addition, Rmdn3 has been shown to be involved in 
mitochondrial phosphatidylserine synthesis via the interact with oxysterol-binding protein-
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related protein 5 and 8 (ORP5/8), which are also ER membrane proteins (Galmes et al., 2016). 
Correlating with the high abundance of Rmdn3 in Purkinje cell mitochondria, we observed 
increased ER-mitochondria contact sites (distance ≤30 nm) in these neurons in contrast to a 
low organelle contact frequency in granule cells and astrocytes (Figure 39c). Through the 
ablation of Rmdn3 (Figure 40), we further showed that approximately half of these contact 
sites are mediated via Rmdn3 in Purkinje cells. To our surprise, these animals do not develop 
behavioral alterations or Purkinje cell loss despite the observed structural phenotype, and 
further experiments will have to reveal the underlying compensatory mechanisms in Ca2+ 
homeostasis and/or lipid metabolism.  
In summary, the inverse presence of Mcu complex and ER-mitochondria contact sites is a 
compelling difference between granule cell and Purkinje cell mitochondria. On the one hand, 
granule cell mitochondria have high Mcu, Micu1 and Micu3 levels, while they are rarely in 
contact with the ER. Recently, Patron et al. (2019) showed that Micu3 acts as Mcu activator in 
close contrast to the gatekeeping function of Micu2. Additionally, Ashrafi et al. (2020) 
demonstrated that neuronal mitochondria are able to uptake Ca2+ at a lower threshold and in 
the absence of ER contacts due to Micu3 properties. On the other hand, ∼37% of 
mitochondrial surface is in close contact with the ER in Purkinje cells, while these organelles 
present with low levels of Mcu complex. A similar phenotype was observed upon Mfn2 
deletion. Here, Filadi et al. (2015) observed – in contrast to an earlier report (de Brito and 
Scorrano, 2008) – an increase in ER-mitochondria contact sites and a reduction in Ca2+ uptake 
in Mfn2-deficient cells. Here, the authors argued that the loss of proper spacing between the 
organelles results in compensatory repression of Mcu expression to avoid mitochondrial Ca2+ 
overload. Hence, I speculate that non-compensatory close ER-mitochondrial contact sites, i.e. 
contacts under stead-state in vivo conditions as seen in Purkinje cells, might have a prominent 
role in signaling, lipid transfer and metabolic adaptation – rather than in enhanced Ca2+ 
transfer and buffering as commonly assumed. I therefore hypothesizes that in granule cells, 
cytosolic Ca2+ buffering is achieved via mitochondria and their increased level of the Mcu 
complex (Figure 51b, left side). Due to Micu3 properties, mitochondrial Ca2+ is taken up at 
lower cytosolic concentrations than with Micu2 and structural microdomains with the ER are 
not necessary. In contrast, Ca2+ buffering in Purkinje cells is achieved via cytosolic 
parvalbumin and hence, mitochondria are fine-tuned for other functions associated with 
close ER juxtaposition, e.g. for lipid synthesis and signaling (Figure 51b, right side). Still, even 
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with low Mcu expression levels in vivo, mitochondrial Ca2+ signaling is probably accomplished 
via these enhanced organelle contact sites, even though ex vivo Ca2+ uptake cannot be 
recapitulated in isolated Purkinje cell organelles. 
5.5. Future perspectives of cell type-specific mitochondria 
Our profiling of cerebellar mitochondria has revealed the fine-tuning and cell type-specific 
enrichment of mitochondrial functions that so far could not be uncovered in this complexity 
due to the lack of a sufficient in vivo tool. The MitoTag mouse model provides us with such a 
tool to answer many questions covering mitochondrial biology across development, aging, 
under specific metabolic restrictions or disease models, and this in a cell type-resolved 
manner. 
Interestingly, mitochondrial diversity as observed in cerebellar neurons and astrocytes 
seems to be conserved during evolution, given that I was able to differentiate mitochondrial 
populations from neurons and astrocytes in rodents, human, aves and amphibians                        
(Figure 43 and 44). The conservation of mitochondrial diversity in the nervous system also 
allowed us to transfer our set of mitochondrial ‘markers’ from the cerebellum to other 
neuronal tissues. These cell type-resolved, mitochondrial ‘markers’ represent another 
important finding of this thesis, because they allow for the in situ probing of mitochondrial 
alterations in disease models and pathological tissue from human cases. This is possible 
without the need of additional transgene expression, e.g. mito-GFP, or the identification of 
neural cells by marker proteins. We here chose to demonstrate this possibility for Alzheimer’s 
disease and amyotrophic lateral sclerosis, given that mitochondrial pathology has been 
reported in both diseases (see Chapter 1.7). While traditionally in neurodegeneration, the 
analysis of mitochondrial alterations is restricted to neuronal cell bodies due to the need of 
cell type markers (Grünewald et al., 2014; Lax et al., 2016), this limitation is eliminated with 
the introduced mitochondrial ‘markers’ and even axonal and synaptic organelles can now be 
included in the analysis. 
Additionally, I anticipate that in the future, cell type-specific mitochondria will be examined 
with many more functional assays and omics-based screening, such as lipidomics, 
phosphoproteomics or metabolomics, than demonstrated in this thesis. These results will 
further elucidate mitochondria biology and intertwine it with the many possible cellular 
contexts that are present in vivo. 
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Chapter 7: Appendix 
7.1. MitoTag expression in different Cre-driver lines 
Table A1. MitoTag expression in tested Cre-driver lines. 
Cre-driver line Reported cell type/ lineage 
Emx1:Cre 
(Gorski et al., 
2002) 
B6.129S2-Emx1tm1(cre)Krj/J (JAX#005628) MGI:2684610 
∼88% of neurons in neocortex and hippocampus, and in glial cells of the 
pallium 
Expression with MitoTag: 
reported expression 
Actin:Cre 
(Lewandoski et al., 
1997) 
B6N.FVB-Tmem163Tg(ACTB-cre)2Mrt/CjDswJ (JAX#019099) MGI:2176050 
Cre recombinase activity is widespread in the embryo by the blastocyst stage 
of development. 
Expression with MitoTag: 
reported expression 
Gfap:Cre  
(Gregorian et al., 
2009) 
B6.Gc-Tg(Gfap-cre)77.6Mvs/2J (JAX#024098) MGI:3838840 
most astrocytes in brain and spinal cord tissues, and all astrocytes following 
CNS injury; no Cre recombinase activity in postnatal or adult neural stem 
cells (or their progeny) from the hippocampus or other brain regions 
Expression with MitoTag:
reported expression 
L7:Cre 
(Barski et al., 2000) 
B6.129-Tg(Pcp2-cre)2Mpin/J (JAX#004146) MGI:2174502 
most Purkinje cells (>P6) and some retinal bipolar neurons 
Expression with MitoTag: 
reported expression 
Gabra6:Cre 
(Fünfschilling and 
Reichardt, 2002) 
Tg(mα6-cre)B1LFR MGI:4358481 
postnatally in granule cells of the cerebellum and dorsal cochlear nucleus, as 
well as in a subset of precerebellar nuclei in the brainstem 
Expression with MitoTag: 
reported expression 
Mog:iCre 
(Hovelmeyer et al., 
2005) 
Mogtm1(cre)Gkl MGI:3689957 
mature oligodendrocytes in the central nervous system without expression 
in neurons, astrocytes or oligodendrocyte precursor cells 
Expression with MitoTag: 
reported expression 
Plp:CreERT 
(Doerflinger et al., 
2003) 
B6.Cg-Tg(Plp1-cre/ERT)3Pop/J (JAX#005975) MGI:3695909 
after tamoxifen administration in oligodendrocytes and Schwann cells 
Expression with MitoTag: 
reported expression, but inefficient recombination in CNS 
Cx3Cr1:CreERT 
(Yona et al., 2013) 
B6.129P2(C)-Cx3cr1tm2.1(cre/ERT2)Jung/J (JAX#020940) MGI:5568569 
after tamoxifen administration in monocytes, macrophages and microglia 
Expression with MitoTag: 
reported expression, but inefficient recombination 
Pvalb:Cre 
(Madisen et al., 
2010) 
B6.Cg-Pvalbtm1.1(cre)Aibs/J (JAX#012358) MGI:4440464 
in scattered interneuron populations in the cortex and hippocampus, as well 
as neuronal populations in other brain regions; additional layer 5 neurons 
Expression with MitoTag: 
reported expression 
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Cre-driver line Reported cell type/ lineage 
Sst:Cre 
(Taniguchi et al., 
2011) 
B6J.Cg-Ssttm2.1(cre)Zjh/MwarJ (JAX#028864) MGI:4838416 
in somatostatin positive neurons including Martinotti cells and Oriens-
Lacunosum-Moleculare cells 
Expression with MitoTag: 
reported expression 
Vip:Cre 
(Taniguchi et al., 
2011) 
STOCK Viptm1(cre)Zjh/J (JAX#010908) MGI:4437225 
in GABAergic neurons in neocortex, hippocampus, olfactory bulb, 
suprachiasmatic nuclei, and other discrete midbrain and brainstem regions 
Expression with MitoTag: 
reported expression 
CAG:CreERT 
(Hayashi and 
McMahon, 2002) 
B6.Tg(CAG-cre/Esr1*)5Amc/J (JAX#004682) MGI:2680708 
after tamoxifen administration in widespread cells or tissues 
Expression with MitoTag: 
reported expression with efficient recombination 
Aldh:Cre 
(Tien et al., 2012) 
B6;FVB-Tg(Aldh1l1-cre)JD1884Htz/J (JAX#023748) MGI:5514359 
glial cells of the spinal cord; 75% of labeled cells also express GFAP, 15% co-
express OLIG2 and 10% express NeuN. 
Expression with MitoTag: 
reported expression in astrocytes and subset of neurons 
hGfap:CreERT 
(Ganat et al., 2006) 
B6.Cg-Tg(GFAP-cre/ERT2)505Fmv/J (JAX#012849) MGI:4458023 
after tamoxifen administration in subventricular zone, dentate gyrus, 
celebellum, mesencephalon, diencephalon, and cerebral cortex 
Expression with MitoTag: 
reported expression, but inefficient recombination in CNS 
Sept4:Cre 
(Gong et al., 2003; 
Kinoshita et al., 
2000) 
Tg(Sept4-cre)OX54Gsat/Mmucd MGI:5519914 
intense expression in Bergmann glia, moderate expression in other brain 
regions – presumably astrocytes 
Expression with MitoTag: 
expression in all astrocytes throughout the brain and spinal cord 
Rbp4:Cre 
(Gerfen et al., 
2013) 
STOCK Tg(Rbp4-cre)KL100Gsat (#031125-UCD) MGI:4367068 
restricted to most layer 5 neurons throughout neocortical and 
periallocortical areas with expression in pyramidal tract and 
intertelencephalic corticostriatal neurons; hippocampal granule cells 
Expression with MitoTag: 
reported expression 
ChAT:Cre 
(Rossi et al., 2011) 
B6;129S6-Chattm2(cre)Lowl/J (JAX#006410) MGI:3699161 
in all cholinergic neurons 
Expression with MitoTag: 
reported expression 
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7.2. Cell type-enriched candidates in Purkinje cells, granule cells and astrocytes 
Table A2. Candidates predicted to be enriched in cerebellar cell type. 
Taken from Fecher et al. (2019), Supplementary Data. 
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* FC -log10(P) * FC -log10(P) * FC -log10(P) 
Aass A * -3.270 6.600 * -3.124 4.728 -0.147 0.105 + mito 
Abat A * -0.932 4.626 * -1.335 7.068 0.404 1.782 + mito 
Abcd3 A * -1.645 7.596 * -2.054 7.839 0.409 2.142 + peroxi MEM 
Acaa1a A * -2.007 7.839 * -1.535 6.669 * -0.472 2.939 + peroxi 
Acaa2 A * -2.228 7.923 * -2.306 9.980 0.078 0.214 + mito 
Acad10 A * -2.357 7.403 * -2.630 8.089 0.273 0.693 + mito 
Acad11 A * -3.097 4.842 * -3.673 5.160 0.576 1.001 +  
Acadm A * -2.588 8.720 * -2.283 8.227 -0.305 1.045 + mito 
Acadl A * -2.378 10.341 * -2.081 8.166  -0.297 1.756 +  
Acads A * -2.814 7.788 * -2.639 9.550 -0.175 0.384 + mito 
Acadsb A * -0.889 4.288 * -1.294 5.004 0.405 1.658 + mito 
Acadvl A * -1.439 6.551 * -1.295 6.866 -0.144 0.504 + mito 
Acbd5 A * -1.845 5.677 * -2.141 6.874 0.296 0.754  peroxi MEM 
Acot2 A * -2.753 5.772 * -2.143 7.333 -0.610 1.141 + mito 
Acot8 A * -1.575 6.156 * -1.459 5.174 -0.116 0.289  peroxi 
Acox1 A * -2.322 8.297 * -2.422 7.275 0.101 0.532 + peroxi 
Acox3 A * -0.980 4.541 * -1.348 5.092 0.369 1.263 + peroxi 
Acsf2 A * -2.726 12.126 * -2.792 10.402 0.067 0.352 + mito 
Acsm5 A  0.000 0.000 * -1.535 3.278 0.000 0.000 + mito 
Acss1 A * -2.796 10.005 * -2.698 7.303 -0.099 0.291 + mito 
Acss3 A * -2.197 5.613 nd nd nd nd + cytoplasm 
Adck1 A * -1.138 4.261 * -0.941 3.516 -0.197 0.373 + chloro  
Adhfe1 A * -2.046 5.614 * -2.147 5.476 0.101 0.132 + mito 
Agpat5 A * -1.555 5.651 * -1.238 4.051 -0.317 0.721 + ER MEM 
Agps A * -1.397 2.708 -1.037 1.907 -0.360 0.808  peroxi 
Ak3 A * -2.100 7.645 * -1.335 6.507 * -0.766 3.213 + mito 
Aldh2 A * -1.984 7.425 * -2.074 6.633 0.090 0.291 + mito 
Aldh4a1 A * -2.169 8.724 * -2.075 7.979 -0.094 0.286 + mito 
Aldh6a1 A * -2.471 10.001 * -1.941 7.349 * -0.529 2.992 + mito 
Aldh7a1 A * -1.669 9.680 * -1.760 8.467 0.091 0.669 + cytoplasm 
Aldh9a1 A * -1.153 5.141 * -0.847 3.746 -0.306 1.561 + cytoplasm 
Amt A * -2.084 6.833 * -1.894 5.515 -0.190 0.515 + mito 
Bcat2 A * -0.501 2.073 * -1.029 4.755 0.528 1.639 + mito 
Cat A * -2.255 8.368 * -2.237 7.580 -0.019 0.046 + peroxi 
Cbr4 A * -0.482 2.552 * -1.387 5.674 * 0.905 3.855 + mito 
Ccbl2 A * -0.563 2.212 * -1.507 6.532 * 0.944 3.023 + cytoplasm 
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* FC -log10(P) * FC -log10(P) * FC -log10(P) 
Ccdc90b A * -2.008 4.883 * -1.902 4.513 -0.106 0.167 + mito MEM 
Chdh A * -1.942 6.478 nd nd nd nd + secreted 
Cpt1a A * -2.225 8.630 * -2.351 8.351 0.126 0.380 + mito MEM 
Cpt2 A * -1.401 5.872 * -0.864 5.571 -0.536 2.333 + mito MEM 
Crot A  nd nd * -3.917 3.680 nd nd + mito MEM 
Dao A * -2.968 9.938 * -2.916 11.119 -0.052 0.175  peroxi 
Dbt A * -0.995 4.087 * -1.298 5.411 0.303 0.840 + mito 
Ddo A  nd nd * -3.530 6.506 nd nd  peroxi 
Decr1 A * -2.178 7.054 * -1.711 6.148 -0.467 2.416 + mito 
Dhrs4 A * -2.247 6.948 * -1.620 5.502 -0.627 2.407 + peroxi 
Ech1 A * -2.204 8.149 * -2.305 7.874 0.101 0.311 + mito 
Echdc2 A * -2.131 4.321 * -1.432 4.098 -0.699 0.952 + mito 
Echdc3 A * -2.046 5.710 nd nd nd nd + mito 
Echs1 A * -1.003 5.340 * -0.959 3.833 -0.044 0.097 + mito 
Eci1 A * -1.728 7.366 * -1.319 5.188 -0.409 1.677 + mito 
Eci2 A * -1.501 8.179 * -1.544 8.391 0.043 0.205 + peroxi MEM 
Ephx2 A * -1.455 3.620 * -1.263 5.275 -0.192 0.406 + mito 
Etfa A * -0.849 3.693 * -1.084 4.080 0.235 0.585 + mito 
Fam213a A * -1.467 8.952 * -1.382 5.639 -0.085 0.259 + cytoplasm 
Gatm A * -1.418 6.900 * -0.968 4.308 -0.450 1.589 + cytoplasm 
Gcdh A * -1.466 7.571 * -1.412 6.335 -0.054 0.144 + mito 
Gldc A * -4.443 5.890 * -2.625 7.940 -1.818 2.289 + mito 
Glud1 A * -1.743 8.194 * -1.615 7.632 -0.128 0.525 + mito 
Gnpat A * -1.296 2.497 * -1.625 2.395 0.329 0.457  mito MEM 
Gpam A  nd nd * -1.012 2.967 nd nd + mito MEM 
Gpt2 A * -2.185 8.529 * -2.259 7.814 0.074 0.182 + cytoplasm 
Gstk1 A * -2.614 9.721 * -2.316 8.777 -0.298 1.370 + mito 
Hsd17b8 A  -0.426 1.723 * -1.067 4.908 0.641 2.357 + mito 
Hacl1 A * -2.620 7.825 * -2.589 7.043 -0.031 0.087  peroxi 
Hadh A * -2.258 7.347 * -2.359 8.861 0.101 0.297 + mito 
Hadha A * -1.846 7.858 * -1.718 8.392 -0.128 0.458 + mito 
Hadhb A * -1.938 7.654 * -1.981 8.065 0.043 0.104 + peroxi 
Hk2 A  nd nd * -1.827 3.474 nd nd + chloro MEM 
Hsd17b10 A * -1.133 3.715 * -0.427 2.197 -0.706 1.760 + mito 
Hsd17b4 A * -1.908 8.329 * -2.012 7.607 0.104 0.978 + peroxi 
Idh2 A * -2.208 8.973 * -1.440 6.640 * -0.768 3.961 + mito 
Isoc2a A * -1.428 3.893 * -1.055 2.377 -0.373 0.669 + cytoplasm 
Isoc2b A  -0.856 2.040 * -1.004 2.137 0.148 0.248  cytoplasm 
Ivd A * -1.642 6.715 * -1.594 7.015 -0.048 0.139 + mito 
Lonp2 A * -2.785 2.770 * -2.885 3.166 0.100 0.118 + peroxi 
MaoB A * -2.750 11.720 * -2.698 7.235 -0.052 0.117 + cytoplasm 
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* FC -log10(P) * FC -log10(P) * FC -log10(P) 
Marc2 A * -1.877 7.190 * -1.966 6.053 0.088 0.178 + mito MEM 
March5 A * -0.321 2.682 * 0.531 3.857 * -0.853 4.520 + golgi MEM 
Mavs A * -2.769 5.844 * -2.337 7.397 -0.431 0.731 + plasma MEM 
Mccc1 A * -1.011 4.940 * -1.278 6.815 0.267 1.045 + mito 
Mcee A * -1.543 4.128 -0.449 1.155 -1.095 2.310 + mito 
Mcur1 A * -2.260 7.736 * -2.305 8.823 0.045 0.112 + mito MEM 
Mgst1 A * -1.067 2.179 * -1.299 4.619 0.232 0.271 + ER MEM 
Mpv17 A * -2.110 3.279 * -0.996 2.606 -1.114 1.345 + mito MEM 
Mpv17l2 A * -0.745 2.095 * -1.699 6.122 0.954 2.202 + mito MEM 
Mut A * -0.894 3.745 * -1.305 6.421 0.411 1.231 + mito 
Nadk2 A * -2.107 9.397 * -1.233 6.661 * -0.873 4.848 + mito 
Nnt A * -1.062 4.283 * -1.151 5.132 0.089 0.187 + plasma MEM 
Nudt7 A * -2.240 2.217 nd nd nd nd  peroxi 
Oat A * -2.419 7.821 * -1.921 6.968 -0.498 1.562 + mito 
Pex14 A * -1.359 3.820 -0.874 1.955 -0.485 1.110  peroxi MEM 
Phyh A * -3.032 5.900 * -2.912 4.343 -0.120 0.237 + peroxi 
Prodh A * -2.602 9.468 * -2.541 7.070 -0.061 0.137 + mito 
Pxmp2 A * -1.918 2.895 * -3.033 5.646 1.115 1.584 + peroxi MEM 
Rexo2 A * -1.108 5.169 * -0.538 3.176 * -0.571 2.911 + mito 
Sardh A * -2.868 12.386 * -2.691 9.581 -0.177 0.985 + mito 
Scp2 A * -2.154 9.152 * -1.942 8.238 -0.212 1.186 + peroxi 
Serhl A * -1.967 5.999 nd nd nd nd  mito 
Sfxn5 A * -1.910 7.230 * -2.054 5.915 0.144 0.350 + mito MEM 
Slc25a1 A * -1.016 3.634 * -0.562 3.212 -0.453 1.265 + mito MEM 
Slc25a18 A * -2.541 8.082 * -2.603 6.636 0.063 0.185 + mito MEM 
Slc25a20 A * -0.993 4.536 * -1.297 6.565 0.304 1.099 + mito MEM 
Slc25a21 A * -2.258 4.883 nd nd nd nd + mito MEM 
Slc25a33 A * -1.351 3.018 nd nd nd nd + mito MEM 
Slc27a1 A * -1.102 6.314 * -0.946 4.715 -0.156 0.603  ER MEM 
Sqrdl A * -2.160 7.262 * -1.566 6.560 -0.594 2.436 + mito 
Suclg2 A * -2.665 8.527 * -2.707 8.221 0.042 0.089 + mito 
Sugct A * -2.377 4.520 * -2.460 8.144 0.082 0.086 + mito 
Suox A * -2.033 8.091 * -1.746 7.901 -0.287 1.118 + mito 
Them4 A * -1.838 6.298 * -1.809 6.000 -0.029 0.051 + mito 
Tspo A  -0.145 0.165 * -1.134 2.134 0.989 1.969 + mito MEM 
Tst A * -2.595 9.305 * -2.589 7.741 -0.006 0.014 + mito 
Ucp3 A * -2.442 4.618 nd nd nd nd + mito MEM 
Zadh2 A * -1.578 5.877 * -0.685 3.038 * -0.893 4.109 + peroxi 
Aars2 GC * 0.688 4.127 * 1.049 5.798 -0.361 1.989 + mito 
Abcb10 GC  -0.883 1.901 * 0.722 2.863 * -1.605 2.998 + mito MEM 
Abhd10 GC  0.185 0.420 * 1.337 4.844 * -1.151 3.284 + mito 
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* FC -log10(P) * FC -log10(P) * FC -log10(P) 
Acot9 GC * 0.753 4.696 * 1.559 6.075 * -0.805 3.400 + cytoplasm 
Ak4 GC * -1.127 4.566 * 1.214 4.412 * -2.341 5.807 + mito 
Angel2 GC  0.287 0.978 * 1.056 4.055 * -0.769 3.680 + secreted 
Auh GC * 0.759 3.819 * 1.198 4.647 -0.438 1.471 +  
Cend1 GC * 0.711 2.191 * 1.112 3.397 -0.401 1.385  nucleus 
Ckmt1 GC * 0.744 3.869 * 1.471 6.920 * -0.727 3.240 + cytoplasm 
Cpox GC * 0.812 3.258 * 1.279 4.433 -0.466 2.028 + mito 
Ethe1 GC  -0.306 0.769 * 1.074 3.188 * -1.379 4.681 + mito 
Exog GC  0.212 1.731 * 1.304 5.340 * -1.092 4.833 + secreted 
Fastkd2 GC  1.013 2.044 * 1.506 2.473 -0.493 1.018 + nucleus 
Gdap1 GC * 0.731 4.686 * 1.246 6.078 * -0.516 3.377 + cytoplasm 
Gdap1l1 GC  0.172 1.012 * 1.366 5.175 * -1.194 4.201  mito MEM 
Gls GC  0.328 1.777 * 1.823 7.319 * -1.496 6.020 + mito 
Gls2 GC  0.385 1.039 * 2.191 5.587 * -1.806 5.058 + mito 
Synj2bp GC  -0.090 0.206 * 0.503 1.453 * -0.593 2.051 + cytoplasm 
Gtpbp8 GC  nd nd nd nd * -1.006 4.442  chloro 
Guf1 GC  0.425 1.283 * 1.246 4.414 -0.822 2.393 + plastid 
Hist2h2aa1 GC  -0.730 1.089 0.850 1.196 * -1.580 2.786  nucleus 
Hist2h2ac GC  -0.730 1.089 0.850 1.196 * -1.580 2.786  nucleus 
Hk1 GC * -0.412 2.879 * 1.163 8.033 * -1.575 7.065 + chloro MEM 
Hmgcl GC  -0.337 1.491 * 0.691 3.035 * -1.028 3.804 + mito 
Isca1 GC * 0.614 2.302 * 1.005 3.027 -0.391 0.930 + mito 
Macrod1 GC * -0.926 3.892 0.261 0.500 * -1.187 3.542 + nucleus 
Mcu GC * -0.602 2.260 * 1.404 5.791 * -2.006 5.472 + mito MEM 
Mfn2 GC * 0.408 3.154 * 1.074 6.352 * -0.666 3.816 + mito MEM 
Mgst3 GC * 0.868 5.058 * 1.239 5.505 -0.371 2.450 + ER MEM 
Micu1 GC  -0.137 0.578 * 1.387 5.490 * -1.524 5.483 + mito MEM 
Micu3 GC  -0.216 1.106 * 1.406 5.780 * -1.622 7.067  mito 
Mtch2 GC  -0.001 0.002 * 1.067 5.702 * -1.068 5.409 + mito MEM 
Mthfd1l GC  0.130 1.047 * 1.547 8.227 * -1.417 9.765 + mito 
Nipsnap1 GC * 0.790 3.620 * 1.168 5.249 -0.378 1.936 + cytoplasm 
Pck2 GC * -0.443 2.408 * 1.189 6.242 * -1.632 6.394 +  
Pdk2 GC * -0.501 2.667 * 0.576 3.077 * -1.077 4.591 + mito 
Pdk3 GC * 0.973 5.305 * 1.219 5.491 -0.246 1.301 + mito 
Pdp1 GC * 0.712 3.522 * 1.110 5.023 -0.398 1.807 + mito 
Pdpr GC * 0.442 3.035 * 1.057 5.814 * -0.615 2.957 + mito 
Pgam5 GC  0.108 0.431 * 1.562 5.866 * -1.454 7.142 + mito MEM 
Pgs1 GC  0.315 1.664 * 1.174 6.136 * -0.859 4.518 + mito 
Polg2 GC  -0.802 1.628 0.423 1.637 * -1.225 2.705 + mito 
Pycr2 GC  0.196 0.536 * 1.153 3.405 * -0.957 4.010 + cytoplasm 
Rcc1 GC  0.257 0.471 * 1.249 2.183 -0.993 1.947  nucleus 
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* FC -log10(P) * FC -log10(P) * FC -log10(P) 
Sdr39u1 GC * 0.627 4.853 * 1.223 4.755 -0.596 2.410 + mito 
Sfxn3 GC * 0.614 2.940 * 1.086 4.949 -0.472 2.016 + mito MEM 
Slc25a12 GC * 0.634 3.492 * 1.191 4.978 * -0.558 2.542 + mito MEM 
Tmem65 GC * 0.666 2.324 * 1.170 4.522 -0.504 1.336 + mito MEM 
Tomm70a GC * 0.452 2.389 * 1.258 5.623 * -0.806 4.174 + mito MEM 
Trabd GC  -0.171 0.416 * 0.940 3.461 * -1.110 3.494  plasma MEM 
Trmu GC  -0.589 1.712 * 0.543 2.697 * -1.132 3.160 + mito 
Yars2 GC * 0.593 3.151 * 1.087 4.590 * -0.494 2.688 + mito 
Adck3 PC * 1.002 3.522 * 0.681 2.340 0.320 0.634 + mito 
Bcat1 PC * 1.144 3.938 * 0.670 3.300 0.474 1.608 + cytoplasm 
Coq3 PC * 1.401 4.432 * 0.953 3.359 0.448 1.162 + mito 
Coq6 PC * 1.103 4.868 * 0.919 4.728 0.184 0.490 + mito 
Cyp27a1 PC * 1.285 5.482 -0.308 0.713 * 1.593 4.222 + mito 
Dhx30 PC * 1.031 2.612 0.682 1.542 0.349 1.024 + nucleus 
Elmod1 PC * 1.545 5.425 * 0.697 4.615 * 0.848 2.876  mito 
Lyrm9 PC * 1.312 3.219 * 0.962 2.168 0.350 1.171  mito 
Me2 PC * 1.167 6.415 * 0.995 4.524 0.172 0.693 + mito 
Mrs2 PC * 1.245 6.098 * 0.692 2.368 0.554 1.849 + plasma MEM 
Nt5m PC * 1.246 5.165 * 0.428 2.731 * 0.817 2.871 + mito 
Ociad2 PC * 2.413 6.615 0.588 1.746 * 1.825 4.527  secreted 
Pam16 PC * 1.199 3.151 * 0.590 2.697 0.608 1.428 + mito 
Pptc7 PC * 1.571 5.560 * 0.984 2.923 0.587 1.671 + mito 
Ptpn4 PC * 1.098 5.023 0.135 0.498 * 0.963 4.215 + cytoplasm 
Pvalb PC * 1.104 2.806 0.401 0.992 0.703 1.421  cytoplasm 
Rmdn3 PC * 2.042 5.868 0.238 0.817 * 1.803 4.172 + cytoplasm 
Tmem70 PC * 0.946 5.193 -0.062 0.258 * 1.008 5.011 + mito MEM 
Gpd2 GC-A * -1.533 7.574 -0.058 0.261 * -1.475 6.142 + mito 
Maoa GC-A * -2.093 8.254 * -0.931 4.039 * -1.162 4.377 + chloro 
Mfn1 GC-A * -2.216 8.083 * -0.967 3.939 * -1.249 4.798 + mito MEM 
Nlrx1 GC-A * -1.429 5.429 -0.306 1.382 * -1.124 4.479 + nucleus 
Acad8 PC-A  -0.574 2.009 * -1.740 9.211 * 1.166 3.583 +  
Cryzl1 PC-A  0.357 0.294 * -1.856 4.766 * 2.213 2.766  mito 
Lama1 PC-A  -0.140 0.213 * -1.764 2.692 * 1.624 3.101  secreted 
Tpp1 PC-A  0.041 0.110 * -1.165 2.582 * 1.207 2.658  secreted 
Aldh18a1 Neuro * 1.098 4.676 * 1.287 5.161 -0.189 0.547 + cytoplasm 
Got2 Neuro * 1.093 5.321 * 1.109 5.606 -0.017 0.043 + mito 
Ldhd Neuro * 2.571 4.208 * 1.633 3.446 0.938 1.431 + mito 
Nt5dc3 Neuro * 1.483 6.237 * 1.160 4.235 0.323 0.820 + cytoplasm 
Slc25a22 Neuro * 1.126 4.841 * 1.304 5.725 -0.177 0.796 + mito MEM 
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7.3. Immunofluorescence staining of mitochondrial candidates in cerebellum 
Figure A1│ Immunofluorescence staining of candidates in mouse cerebellum. Staining in cerebellum 
from wild type (Cre−), L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM mice. 
Ctr, control for secondary antibody by omission of primary antibody; Nuc, nuclear counter stain.  
(a) Acads, Ak3 and Ak4, Cat. Scale bar: 25 μm. Modified from Fecher et al. (2019), Supplementary 
Figure 9. 
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Figure A1│ Immunofluorescence staining of candidates in mouse 
cerebellum (continued). Staining in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM 
mice. Ctr, control for secondary antibody by omission of primary 
antibody; Nuc, nuclear counter stain. (b) Cox4i1, Cpt1a, Gldc and Gls. 
Scale bar: 25 μm. Modified from Fecher et al. (2019), Supplementary 
Figure 9. 
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Figure A1│ Immunofluorescence staining of candidates in mouse 
cerebellum (continued). Staining in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM 
mice. Ctr, control for secondary antibody by omission of primary 
antibody; Nuc, nuclear counter stain. (c) Gls2, Got2, Ldhd and MaoB. 
Scale bar: 25 μm. Modified from Fecher et al. (2019), Supplementary 
Figure 9. 
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Figure A1│ Immunofluorescence staining of candidates in mouse 
cerebellum (continued). Staining in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM 
mice. Ctr, control for secondary antibody by omission of primary 
antibody; Nuc, nuclear counter stain. (d) Mavs, Mcu, Nispnap1 and 
Ociad2. Scale bar: 25 μm. Modified from Fecher et al. (2019), 
Supplementary Figure 9. 
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Figure A1│ Immunofluorescence staining of candidates in mouse 
cerebellum (continued). Staining in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM 
mice. Ctr, control for secondary antibody by omission of primary 
antibody; Nuc, nuclear counter stain. (e) Pex14, Pptc7, Rmdn3 and Sfxn5.   
Scale bar: 25 μm. Modified from Fecher et al. (2019), Supplementary 
Figure 9. 
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Figure A1│ Immunofluorescence staining of candidates in mouse 
cerebellum (continued). Staining in cerebellum from wild type (Cre−), 
L7:Cre+/GFP-OMM, Gabra6:Cre+/GFP-OMM and Gfap:Cre+/GFP-OMM 
mice. Ctr, control for secondary antibody by omission of primary 
antibody; Nuc, nuclear counter stain. (f) Slc25a20, Snph and Tst. Scale bar: 
25 μm. Modified from Fecher et al. (2019), Supplementary Figure 9. 
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Due to antibody performance, Elmod1, MaoA, Mfn1, Mfn2, Micu1, Micu3, and Pgam5 could 
not be validated by immunofluorescence staining. 
Table A3. Candidates without validation due to antibody performance. 
Candidate Epitope # Species Tested conditions 
Elmod1 
human ELMOD1, full length 12761-1-AP Rabbit 
Triton X100, 
methanol, 
acetone, 
HIER 1-7 
human ELMOD1, AA 105-135 ab173691 Rabbit 
MaoA human MaoA, AA 458-527 sc-271123 Mouse IgG1 
Mfn1 human Mfn1, AA 683-732 ab57602 Rabbit 
Mfn2 
human Mfn2, AA 461-528 sc-515647 Mouse IgG1 
human Mfn2, AA 38-55 M6319 Rabbit 
Micu1 
- StJ-97447 Mouse IgG1 
human Micu1, AA 287-371 HPA037480 Rabbit 
Micu3 
human Micu3, AA 238-309 HPA024771 Rabbit 
human Micu3, AA 410-479 HPA024048 Rabbit 
Pgam5 human PGAM5, AA 61-146 ab126534 Rabbit 
  
Figure A2│ Ak3 and Ak4 an bodies are paralog specific. Alignment of mouse Ak3 
and Ak4 isoforms with the human epitopes for αAk3 (AA 209-227, orange) and 
αAk4 (AA 58-83, blue) antibodies. Conserved amino acids between epitopes and 
isoforms are color-coded. AA, amino acid. 
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7.4. Overrepresentation analysis of candidate-enriched pathways 
ORA was performed with WebGestalt (Liao et al., 2019) and Figure 31b displays the top10 
significant GOTerm and KEGG pathways with the highest enrichment ratio. 
Table A4. ORA analysis of neuronal candidates. 
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mmu00130 Ubiquinone and other terpenoid-quinone biosynthesis 11 2 48.9394 0.0385 
mmu00220 Arginine biosynthesis 19 3 42.5000 0.0046 
mmu00250 Alanine, aspartate and glutamate metabolism 37 3 21.8243 0.0212 
mmu00330 Arginine and proline metabolism 50 4 21.5333 0.0046 
GO:0043648 Dicarboxylic acid metabolic process 99 8 17.5556 0.0000 
mmu01230 Biosynthesis of amino acids 78 4 13.8034 0.0146 
GO:0006090 Pyruvate metabolic process 102 6 12.7794 0.0010 
GO:0070585 Protein localization to mitochondrion 89 5 12.2051 0.0049 
GO:0006839 Mitochondrial transport 165 9 11.8500 0.0000 
GO:0006520 Cellular amino acid metabolic process 260 12 10.0269 0.0000 
GO:0016053 Organic acid biosynthetic process 349 11 6.8474 0.0001 
GO:0051186 Cofactor metabolic process 488 15 6.6778 0.0000 
GO:0044282 Small molecule catabolic process 328 9 5.9611 0.0018 
GO:0044262 Cellular carbohydrate metabolic process 285 7 5.3360 0.0239 
GO:0072521 Purine-containing compound metabolic process 481 11 4.9683 0.0012 
GO:0019693 Ribose phosphate metabolic process 443 9 4.4137 0.0147 
GO:0007005 Mitochondrion organization 433 8 4.0139 0.0498 
GO:0044270 Cellular nitrogen compound catabolic process 434 8 4.0046 0.0498 
GO:0046700 Heterocycle catabolic process 438 8 3.9680 0.0498 
mmu01100 Metabolic pathways 1351 18 3.5862 0.0000 
 
Table A5. ORA analysis of astrocytic candidates. 
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mmu00071 Fatty acid degradation 50 20 38.9157 0.0000 
mmu00280 Valine, leucine and isoleucine degradation 56 21 36.4834 0.0000 
mmu00640 Propanoate metabolism 31 11 34.5220 0.0000 
mmu04146 Peroxisome 84 26 30.1133 0.0000 
GO:0007031 Peroxisome organization 33 7 29.7912 0.0000 
mmu01212 Fatty acid metabolism 52 14 26.1932 0.0000 
mmu00410 β-Alanine metabolism 32 8 24.3223 0.0000 
mmu00650 Butanoate metabolism 27 6 21.6198 0.0000 
mmu00920 Sulfur metabolism 9 2 21.6198 0.0426 
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GO:0042398 Cellular modified amino acid biosynthetic process 39 6 21.6068 0.0000 
mmu00062 Fatty acid elongation 32 7 21.2820 0.0000 
GO:0018904 Ether metabolic process 20 3 21.0667 0.0148 
GO:0044282 Small molecule catabolic process 328 47 20.1247 0.0000 
GO:0033865 Nucleoside bisphosphate metabolic process 106 15 19.8742 0.0000 
mmu00260 Glycine, serine and threonine metabolism 40 8 19.4578 0.0000 
mmu00380 Tryptophan metabolism 46 9 19.0348 0.0000 
mmu00630 Glyoxylate and dicarboxylate metabolism 31 6 18.8302 0.0000 
mmu01040 Biosynthesis of unsaturated fatty acids 32 6 18.2417 0.0000 
mmu00120 Primary bile acid biosynthesis 16 3 18.2417 0.0081 
GO:0030258 Lipid modification 224 29 18.1825 0.0000 
mmu00330 Arginine and proline metabolism 50 9 17.5120 0.0000 
GO:0006631 Fatty acid metabolic process 372 43 16.2342 0.0000 
mmu00340 Histidine metabolism 24 4 16.2149 0.0016 
GO:0043648 Dicarboxylic acid metabolic process 99 11 15.6049 0.0000 
mmu01210 2-Oxocarboxylic acid metabolism 19 3 15.3614 0.0121 
GO:0016042 Lipid catabolic process 293 30 14.3800 0.0000 
mmu00310 Lysine degradation 59 8 13.1918 0.0000 
mmu00250 Alanine, aspartate and glutamate metabolism 37 5 13.1472 0.0006 
mmu01200 Carbon metabolism 120 16 12.9719 0.0000 
mmu00592 α-Linolenic acid metabolism 25 3 11.6747 0.0263 
mmu00053 Ascorbate and aldarate metabolism 27 3 10.8099 0.0316 
GO:0006520 Cellular amino acid metabolic process 260 20 10.8034 0.0000 
mmu00620 Pyruvate metabolism 38 4 10.2410 0.0083 
GO:0006575 Cellular modified amino acid metabolic process 161 11 9.5956 0.0000 
GO:0097164 Ammonium ion metabolic process 167 11 9.2508 0.0000 
GO:0006790 Sulfur compound metabolic process 275 18 9.1927 0.0000 
mmu03320 PPAR signaling pathway 85 8 9.1566 0.0000 
GO:0072527 Pyrimidine-containing compound metabolic process 68 4 8.2614 0.0389 
GO:0014823 Response to activity 70 4 8.0254 0.0419 
mmu00561 Glycerolipid metabolism 61 5 7.9745 0.0062 
GO:0006839 Mitochondrial transport 165 9 7.6606 0.0001 
GO:0051186 Cofactor metabolic process 488 26 7.4827 0.0000 
mmu00010 Glycolysis / Gluconeogenesis 67 5 7.2604 0.0083 
GO:0051262 Protein tetramerization 149 7 6.5981 0.0039 
GO:0098754 Detoxification 108 5 6.5021 0.0311 
GO:0019693 Ribose phosphate metabolic process 443 19 6.0236 0.0000 
GO:0016999 Antibiotic metabolic process 140 6 6.0190 0.0180 
GO:0006638 Neutral lipid metabolic process 121 5 5.8035 0.0435 
GO:0042737 Drug catabolic process 151 6 5.5806 0.0246 
GO:0072521 Purine-containing compound metabolic process 481 19 5.5477 0.0000 
GO:0016053 Organic acid biosynthetic process 349 13 5.2315 0.0001 
GO:0042180 Cellular ketone metabolic process 182 6 4.6300 0.0467 
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GO:0006091 Generation of precursor metabolites and energy 389 12 4.3325 0.0009 
mmu01100 Metabolic pathways 1351 57 4.1047 0.0000 
GO:0008202 Steroid metabolic process 276 8 4.0709 0.0255 
GO:0015849 Organic acid transport 310 8 3.6244 0.0432 
GO:0051260 Protein homooligomerization 358 9 3.5307 0.0311 
GO:0001505 Regulation of neurotransmitter levels 361 9 3.5014 0.0312 
GO:1901615 Organic hydroxy compound metabolic process 457 11 3.3805 0.0154 
GO:0090407 Organophosphate biosynthetic process 484 11 3.1919 0.0228 
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7.5. Patient information related to human specimens 
Human tissue samples were selected by Doron Merkler (University of Geneva and Geneva 
University Hospital, Switzerland) and immunofluorescence staining performed by Ingrid 
Wagner (University of Geneva, Switzerland) with assistance from me regarding mitochondrial 
markers (Chapter 3.2.14.2). 
Table A6. Information on human tissue samples used in this study. Modified from Fecher et 
al. (2019), Supplementary Table 3. 
Case 
# 
Age 
(years) Sex Histological specimen Tissue 
1 56 m Spinal cord without lesion Spinal cord 
2 52 m Spinal cord without lesion Spinal cord 
4 77 f Spinal cord with ALS pathology Spinal cord 
6 66 m Spinal cord with ALS pathology Spinal cord 
9 52 m Normal temporal lobe (hippocampus) Cortex 
10 67 m Normal temporal lobe (hippocampus) Cortex
11 58 m Normal temporal lobe (hippocampus) Cortex 
14 88 f Temporal lobe with AD type degenerative encephalopathy Cortex 
15 91 f Temporal lobe with AD type degenerative encephalopathy Cortex 
16 82 f Temporal lobe with AD type degenerative encephalopathy Cortex 
 
Table A7. Information on handling of human tissue samples according to BRISQ. Modified 
from Fecher et al. (2019), Supplementary Table 3. 
Criterion AD ALS 
Biospecimen type Solid tissue 
Anatomical site Brain Spinal cord 
Disease status of 
patients 
Non-neurological diseased tissue; 
Alzheimer’s disease  
Non-neurological disease (control); 
amyotrophic lateral sclerosis 
Clinical characteristics Dementia Tetraparesis 
State of patient Postmortem 
Clinical diagnosis 
Non-neurological diseased tissue;  
Alzheimer’s disease 
Normal tissue; 
amyotrophic lateral sclerosis type 
degeneration of motor neurons 
Pathology AD type degenerative encephalopathy 
ALS type degeneration of motor 
neurons 
Collection mechanism Autopsy 
Type of stabilization 4°C 
Type of preservation 10% neutral-buffered formalin fixative 
Storage 20-25°C; duration unknown 
Shipping temperature 20-25°C 
Composition 
assessment and 
selection 
Control: no microscopic 
alterations; 
AD: pathological neurotic plaques 
and neurofibrillary degeneration 
Control: no microscopic 
alterations; 
ALS: motor neuron loss with TDP43 
inclusions 
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7.6. Uncropped western blots used in figures of this study 
Figure A3│ Uncropped western blots related to (a) Figure 14c, (b) Figure 16c and      
(c) Figure 17b. Modified from Fecher et al. (2019), Supplementary Figure 18. 
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Figure A4│ Uncropped western blots related to Figure 28a. Modified from Fecher et al. 
(2019), Supplementary Figure 10. 
Figure A5│ Uncropped western blots related to (a) Figure 37b and 38b, and (b) Figure 40b. 
Modified from Fecher et al. (2019), Figure 6 and Figure 7. 
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7.7. Comprehensive statistical information on experiments of this study 
Table A8. Statistical information. Modified from Fecher et al. (2019), Supplementary Table 4. 
Figure Exp. 
# 
Conditions Testing 
1a 2 Electron microscopy - 
1b - Schema - 
 
2 - Schemata - 
 
3a - Pagliarini et al. (2008) Figure 1 
3b - Pagliarini et al. (2008) Figure 4c 
3c - Pagliarini et al. (2008) Figure 4d 
 
4 - Schemata - 
 
5a - Schema - 
5b - Plasmid map - 
5c 3 Expression in cells -
5d - Plasmid map - 
 
6 - Schemata - 
 
7 - Schemata - 
 
8 - See Chapter 3.2.12 - 
 
9 - Schemata - 
 
10a 1 Tissue sections after treatment - 
10b 2 Immunofluorescence staining - 
 
11b ≥5 Expression pattern - 
11c ≥5 Expression pattern -
11d ≥3 Immunofluorescence staining -
11e 2 Expansion microcopy - 
 
12a 10 Mitochondrial transport: 
Anterograde: Cre− (29) vs Cre+ (30); 
Retrograde: Cre− (29) vs Cre+ (30) 
Two-tailed, unpaired Welch’s test: 
t(54.14)=0.2044, P=0.8388; 
t(53.03)=1.288, P=0.2034 
12b 10 Mitochondrial shape: 
Length: Cre− (171) vs Cre+ (222); 
Width: Cre− (170) vs Cre+ (222) 
Two-tailed, unpaired Welch’s test: 
t(353.9)=0.5751, P=0.5658; 
t(353.9)=0.5751, P=0.5658 
12c ≥3 Immunofluorescence staining - 
12d 8  
NMJ size: Cre− (88) vs Cre+ (83); 
AChR density: Cre− (56) vs Cre+ (54); 
Two-tailed, unpaired Welch’s test: 
t(168.9)=0.9931, P=0.3221; 
t(98.37)=0.845, P=0.4002 
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Figure Exp. 
# 
Conditions Testing 
13a - Schema - 
13b 3 Complex I  
CE 
RCR 
SRC 
Two-tailed, unpaired Welch’s test: 
t(7.449)=0.3236, P=0.7551; 
t(6.403)=0.1959, P=0.8507; 
t(6.348)=0.5323, P=0.6126 
13c 3 Complex II CE 
RCR 
SRC 
t(4.336)=0.5852, P=0.5875; 
t(6.431)=0.4233, P=0.6859; 
t(5.644)=0.03813, P=0.9709 
 
14a - Schema - 
14b 2 Electron microscopy - 
14c 1 Western blot - 
 
15a - Schema - 
15b ≥3 Complex I  
CE 
RCR 
SRC 
One-way ANOVA, Tukey’s post hoc: 
F(2, 12)=0.0836, P=0.9203; 
F(2, 12)=0.5447, P=0.5937; 
F(2,15)=0.62, P=0.5512 
Complex II CE 
RCR 
SRC 
F(2, 13)=0.4186, P=0.6665; 
F(2, 13)=0.9171, P=0.4241; 
F(2, 15)=0.3878, P=0.6851 
 
16a - Schema - 
16b ≥5 
5 
Confocal images 
Flow cytometry data 
- 
- 
16c 1 Representative western blot - 
16d 5 Western blot quantification: 
GFP-OMM: IC Tom (5) vs IC GFP (5); 
mito-RFP: IC Tom (5) vs IC GFP (5) 
One-tailed, ratio-paired t-test: 
t(4)=11.03, P=0.0002; 
t(4)=2.411, P=0.0368 
 
17a - Schema - 
17b 4 Representative western blot - 
17c 4 Western blot quantification: 
GFP-OMM: IC GFP 100-50-25-13-5; 
IC GFP 100 vs 50 
IC GFP 100 vs 25 
IC GFP 100 vs 13 
IC GFP 100 vs 5 
mito-RFP: IC GFP 100-50-25-13-5; 
IC GFP 100 vs 50 
IC GFP 100 vs 25 
IC GFP 100 vs 13 
IC GFP 100 vs 5 
One-way Friedman test, Dunn’s post hoc: 
F(4)=8.2, P=0.0720; 
P>0.9999; 
P>0.9999; 
P>0.9999; 
P>0.1014; 
F(4)=7.158, P=0.1211; 
P=0.2946; 
P=0.2946; 
P=0.2946; 
P=0.0556 
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Figure Exp. 
# 
Conditions Testing 
18a ≥5 
≥4 
Confocal images 
Flow cytometry data 
- 
- 
18b 5 Western blot quantification: 
GFP-OMM: IC Tom (5) vs IC GFP (5); 
mito-RFP: IC Tom (5) vs IC GFP (5) 
One-tailed, ratio-paired t-test: 
t(4)=10.33, P=0.0002; 
t(4)=1.867, P=0.0677 
 
19a-c ≥5 
≥3 
Expression pattern; 
Immunofluorescence staining 
- 
- 
 
20-24 - See Chapter 3.2.12.4 
 
25a - See Chapter 3.2.12.4 
25b ≥3 Immunofluorescence staining - 
 
26a 2 Immunofluorescence staining -
26b - Protein sequence alignment 
 
27a - See Chapter 3.2.12.4 
27b ≥3 Immunofluorescence staining - 
 
28a 3 Representative western blot - 
28b 3 Western blot quantification -
28c - See Chapter 3.2.12.4 
 
29a ≥3 Immunofluorescence staining - 
29b 2 Expression pattern - 
29c 2 Immunofluorescence staining - 
29d 2 Immunofluorescence staining - 
 
30a - See Chapter 3.2.12.4
30b ≥3 Immunofluorescence staining - 
 
31 - See Chapter 3.2.12.4 
 
32 - See Chapter 3.2.12.4 
 
33a ≥3 Immunofluorescence staining - 
33b ≥3 Immunofluorescence staining -
 
34 - See Chapter 3.2.12.4 
 
35a ≥3 Immunofluorescence staining - 
35b 1 Immunofluorescence staining - 
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Figure Exp. 
# 
Conditions Testing 
36a - Schema - 
36b 12 Beta-oxidation  
CE 
RCR 
SRC 
One-tailed, unpaired Welch’s test: 
t(11.48)=2.092, P=0.0297; 
t(16.83)=5.028, P<0.0001; 
t(15.86)=5.228, P<0.0001 
36c 9 Complex I  
CE 
RCR 
SRC 
One-tailed, unpaired Welch’s test: 
t(6.352)=0.8558, P=0.2116; 
t(8.527)=0.8953, P=0.1976; 
t(10.87)=1.382, P=0.0973 
36d 9 Complex II  
CE 
RCR 
SRC 
One-tailed, unpaired Welch’s test: 
t(11.21)=0.1861, P=0.4279; 
t(7.615)=0.6322, P=0.2729; 
t(9.102)=1.072, P=0.1556 
 
37a ≥3 Immunofluorescence staining - 
37b 4 Representative western blot; 
Western blot quantification: 
PC vs GC vs A; 
PC mito (5) vs GC mito (5) 
PC mito (5) vs A mito (5) 
GC mito (5) vs A mito (5) 
- 
One-way Friedman test, Dunn’s post hoc: 
F(3)=10.0, P=0.0008; 
P=0.0047; 
P=0.3415; 
P=0.3415 
37c 8 Representative experiment - 
37d 8 Quantification: 
PC vs GC vs A; 
PC mito (7) vs GC mito (5) 
PC mito (7) vs A mito (7) 
GC mito (5) vs A mito (7) 
One-way ANOVA, Tukey’s post hoc: 
F(2, 16)=8.881, P=0.0025; 
t(16)=5.944, P=0.0018; 
t(16)=3.108, P=0.1020; 
t(16)=3.106, P=0.1023 
 
38a ≥3 Immunofluorescence staining - 
38b 6 Representative western blot; 
Western blot quantification: 
 
WT vs WT/FL vs FL; 
WT (4) vs WT/FL (6) 
WT (4) vs FL (8) 
WT/FL (6) vs FL (8) 
- 
One-way REML with Geisser-Greenhouse 
correction, Holm-Sidak’s post hoc: 
 
F(1.023, 6.14)=382.7, P<0.0001; 
t(5)=11.4, P<0.0001; 
t(5)=115.0, P<0.0001; 
t(7)=13.74, P<0.0001 
38c 6 Representative experiment - 
38d 6 Quantification: 
WT vs WT/FL vs FL; 
WT (5) vs WT/FL (6) 
WT (5) vs FL (7) 
WT/FL (6) vs FL (7) 
One-way ANOVA, Tukey’s post hoc: 
F(2, 15)=33.99, P<0.0001; 
t(15)=2.073, P=0.3344; 
t(15)=10.64, P<0.0001; 
t(15)=8.947, P<0.0001 
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Figure Exp. 
# 
Conditions Testing 
39a ≥3 Immunofluorescence staining - 
39b 2 Electron microscopy - 
39c 1 Quantification (mitochondria): 
PC (160) vs GC (134) vs A (120); 
PC (160) vs GC (134) 
PC (160) vs A (120) 
GC (134) vs A (120) 
One-way Kruskal-Wallis, Dunn’s post hoc: 
F(3, 414)=243.8, P<0.0001; 
P<0.0001; 
P<0.0001; 
P<0.0001 
PC (10) vs GC (74) vs A (16); cells - 
 
40a 2 Immunofluorescence staining - 
40b 3 Representative western blot; 
Western blot quantification: 
WT (4) vs +/− (4) vs ko (4) 
WT (4) vs +/− (4) 
WT (4) vs ko (4) 
+/− (4) vs ko (4) 
- 
RM one-way ANOVA, Tukey’s post hoc: 
F(2,6)=460.7, P<0.0001 
t(6)=25.72, P<0.0001; 
t(6)=42.63, P<0.0001; 
t(6)=16.91, P<0.0001 
40c 2 Quantification (PC cells): 
WT (12) vs +/− (8) vs ko (14); 
WT (12) vs +/− (8) 
WT (12) vs ko (14) 
+/− (8) vs ko (14) 
One-way ANOVA, Tukey’s post hoc: 
F(2, 31)=37.45, P<0.0001; 
t(31)=5.254, P=0.0022; 
t(31)=12.23, P<0.0001; 
t(31)=5.444, P=0.0016 
WT (207) vs +/− (189) vs ko (306);   
PC mitochondria 
- 
Quantification (A cells): 
WT (12) vs +/− (10) vs ko (11); 
One-way ANOVA, Tukey’s post hoc: 
F(2, 30)=2.567, P=0.0935; 
WT (135) vs +/− (105) vs ko (119);   
A mitochondria 
- 
 
41a ≥5 Expression pattern - 
41b 2 Immunofluorescence staining - 
41c 2 Immunofluorescence staining - 
 
42a ≥5 Expression pattern -
42b 2 Immunofluorescence staining - 
42c 2 Immunofluorescence staining - 
 
43a-b - 
≥3 
3 
1 
Immunofluorescence staining: 
mouse 
rat 
human 
- 
 
44a ≥3 Immunofluorescence staining - 
44b 3 Immunofluorescence staining - 
44c ≥3 Immunofluorescence staining - 
44d 3 Immunofluorescence staining - 
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Figure Exp. 
# 
Conditions Testing 
45a 2 Immunofluorescence staining - 
45b 2 Immunofluorescence staining - 
45c 2 Immunofluorescence staining - 
46a 1 Immunofluorescence staining - 
46b 1 Immunofluorescence staining - 
 
47 ≥3 Immunofluorescence staining - 
 
48a 1 Immunofluorescence staining - 
48b 1 Immunofluorescence staining - 
48c 1 Immunofluorescence staining - 
48d 1 Immunofluorescence staining -
 
49-51 - Schemata - 
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1C 
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Acot7 Acyl-CoA thioesterase 7 
Acox1 Peroxisomal acyl-coenzyme 
A oxidase 1 
Acsbg Acyl-CoA synthetase 
bubblegum family member 2 
Acsl Long-chain fatty acid-CoA 
ligase 
Acsm5 Acyl-CoA synthetase 
medium-chain family 
member 5 
Acss1/3 Acyl-CoA synthetase short-
chain family member 1/3 
Adck1 AarF domain-containing 
protein kinase 1 
Ak3/4 Adenylate kinase 3/4 
ANT1/2 Adenine nucleotide 
translocator 1/2 
Asns Asparagine synthetase 
Ass Argininosuccinate synthase 
ATP5a Mitochondrial ATP synthase 
subunit alpha 
Atp5po Mitochondrial ATP synthase 
subunit O 
Bcl2 Apoptosis regulator Bcl-2 
Calb Calbindin 
Cat Catalase 
ChAT Choline O-acetyltransferase 
CHCHD2 Coiled-coil-helix-coiled-coil-
helix domain-containing 
protein 2 
Coq8a/b Mitochondrial atypical 
kinase COQ8A/B 
Cox4i1 Cytochrome c oxidase 
subunit 4 isoform 1 
Cpt1a/2 Carnitine O-
palmitoyltransferase 1/2 
CS Mitochondrial citrate 
synthase 
CypD Cyclophilin D/F 
Dao D-amino-acid oxidase 
Drp1 Dynamin-1-like protein 
EAAT2/4 Excitatory amino acid 
transporter 2/4 
Echs1 Mitochondrial enoyl-CoA 
hydratase 
Eci2 Mitochondrial enoyl-CoA 
delta isomerase 2 
Eci2 Mitochondrial enoyl-CoA 
delta isomerase 2 
Emre Mitochondrial essential MCU 
regulator 
Emx1 Empty spiracles homeobox 
protein 1 
F0F1ATPase Complex V or mitochondrial 
ATP synthase 
Fh Fumarase 
Fis1 Mitochondrial fission 1 
protein 
FUS RNA-binding protein FUS/TLS 
(Fused in 
Sarcoma/Translocated in 
Sarcoma) 
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Gfap Glial fibrillary acidic protein 
Ggc1p Mitochondrial GTP/GDP 
carrier 
Gldc Glycine dehydrogenase
Glo1/2 Glyoxalase 1/2 
Gls/2 Glutaminase, kidney/liver 
isoform 
Glut1/3 Glucose transporter type 1/3
Got2 Glutamate oxaloacetate 
transaminase 2 
Gpt2 Alanine aminotransferase 2 
Gs Glutamine synthetase 
Hk1/2 Hexokinase 1/2 
Hsd17b10 3-hydroxyacyl-CoA 
dehydrogenase type-2 
Idh2/3 Mitochondrial isocitrate 
dehydrogenase 
Ldha/b L-lactate dehydrogenase A/B 
chain 
Ldhd Mitochondrial D-lactate 
dehydrogenase 
MaoB Monoamine oxidase type B 
MAP2 Microtubule-associated 
protein 2 
Mavs Mitochondrial antiviral-
signaling protein 
MCT1-4 Monocarboxylate 
transporter 1-4 
Mcu Mitochondrial calcium 
uniporter 
McuB Mitochondrial calcium 
uniporter regulatory subunit 
MCUb 
McuR1 Mitochondrial calcium 
uniporter regulator 1 
Mdh Malate dehydrogenase 
Me2/3 Malic enzyme 2/3 
Mff Mitochondrial fission factor 
Mfn1/2 Mitofusin-1/2 
mGluR1β Metabotropic glutamate 
receptor 1 
MIC60 MICOS complex subunit 
MIC60 
Micu1-3 Mitochondrial calcium 
uptake protein 1-3 
Mim1 Mitochondrial import 
protein 1 
Mos1 Drosophila mauritiana 
transposon Mos1 
MPC1/2 Mitochondrial pyruvate 
carrier 1/2 
Mpv17l2 Mitochondrial inner 
membrane protein like 2 
Mut Mitochondrial 
methylmalonyl-CoA mutase 
NCLX Mitochondrial 
sodium/calcium exchanger 
protein 
Ndufs1 Mitochondrial NADH-
ubiquinone oxidoreductase 
75 kDa subunit 
Nipsnap1 4-nitrophenylphosphatase 
domain and non-neuronal 
SNAP25-like protein 
homolog 1 
Nme3 Nucleoside diphosphate 
kinase 3 
Nnt NAD(P) transhydrogenase 
Num1 Nuclear migration protein 
NUM1 
Oat Mitochondrial ornithine 
aminotransferase 
Ociad1/2 Ovarian carcinoma 
immunoreactive antigen 
domain–containing protein 
1/2 
OMP25 Mitochondrial outer 
membrane protein 25 
Opa1 Optic atrophy protein 1 
homolog 
ORP5/8 Oxysterol-binding protein-
related protein 5/8 
PCC Propionyl-CoA carboxylase
Pck1/2 Phosphoenolpyruvate 
carboxykinase 1/2 
Pdk1-4 Mitochondrial [pyruvate 
dehydrogenase (acetyl-
transferring)] kinase isozyme 
1-4 
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Pdp1/2 Mitochondrial [pyruvate 
dehydrogenase [acetyl-
transferring]]-phosphatase 1 
Pex11β Peroxisomal membrane 
protein 11B 
Pex11β Peroxisomal membrane 
protein 11B 
Pex14 Peroxisomal membrane 
protein PEX14 
Pex34 Peroxisomal membrane 
protein PEX34 
Pfk1 6-phosphofructo-1-kinase
Pfkfb3 6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase 3 
PLCβ3/4 1-phosphatidylinositol 4,5-
bisphosphate 
phosphodiesterase beta-3/4 
Plin5 Perilipin 5 
POLG DNA polymerase subunit 
gamma-1 
Pptc7 Protein phosphatase PTC7 
homolog 
PS45 Presenilin 1 G384A mutant 
Pvalb, PV Parvalbumin 
Pycr Mitochondrial pyrroline-5-
carboxylate reductase 
Rab7 Ras-related protein Rab 7 
RanGAP1 Ran GTPase-activating 
protein 1 
Rmdn3 Regulator of microtubule 
dynamics protein 3; 
Rpl10a 60S ribosomal protein L10a 
Rpl22 60S ribosomal protein L22 
Sfxn3-5 Sideroflexin 3-5 
Slc25a18 Glutamate/H(+) symporter 2 
Slc25a20 Mitochondrial 
carnitine/acylcarnitine 
carrier protein 
Slc25a22 Mitochondrial glutamate 
carrier 1 
Slc25a38 Mitochondrial glycine 
transporter 
Slc6a9 Sodium-/chloride-dependent 
glycine transporter 1 
SNAP25 Synaptosomal-associated 
protein 25 
Snph Syntaphilin 
SOD1 Superoxide dismutase [Cu-
Zn] 
Sucla2 Mitochondrial succinate-CoA 
ligase [ADP-forming] subunit 
beta 
Suclg1 Mitochondrial succinate--
CoA ligase [ADP/GDP-
forming] subunit alpha 
Suclg2 Mitochondrial succinate-CoA 
ligase [GDP-forming] subunit 
beta 
TDP-43 TAR DNA-binding protein 43 
TFAM Mitochondrial transcription 
factor A 
Tom22 Mitochondrial import 
receptor subunit TOM22 
homolog 
Tomm20 Mitochondrial import 
receptor subunit TOM20 
homolog 
VAPB Vesicle-associated 
membrane protein-
associated protein B/C 
VDAC Voltage-dependent anion-
selective channel 
Yme1L1 ATP-dependent zinc 
metalloprotease YME1L1 
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